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Nitric oxide (NO) is known to be a potent inhibitor of platelet activation and adhesion. NO 
released by macrophages or other inflammatory cells also serves as a natural antimicrobial 
agent in the immune system.  Therefore, polymeric materials that are capable of stable and 
long-term NO release should exhibit similar antithrombotic and antimicrobial properties. 
 
In this dissertation, novel polymeric materials that can release NO at physiological relevant 
levels for extended time periods were examined and evaluated for their potential
 
 xxviii 
 biomedical applications. S-Nitroso-N-acetylpenicillamine (SNAP), the NO donor 
compound, exhibits unprecedented shelf stability when incorporated into low water uptake 
polymer CarboSil 20 80A, a tri-copolymer of polyurethane, poly(dimethylsiloxane) and 
polycarbonate.  Solid-state analysis demonstrated that SNAP can partially dissolve in 
CarboSil polymer (ca. 3.4-4.0 wt%) and the SNAP molecules exceeding the solubility limit 
crystalize via hydrogen bonding within the polymer phase to form a stable polymer-crystal 
composite material.  The slow dissolution of the crystals ultimately contributes to the long-
term NO release upon solution contact (Chapter 2).  The unique NO release mechanism 
also directly correlates with the polymer surface area that is exposed to the aqueous 
solution, suggesting that a water rich layer in the outermost surfaces of the polymer 
material is the likely site where most of the NO is liberated from the soluble SNAP within 
the polymer (Chapter 3).  An optimized solvent impregnation process was also developed 
to transform off-the-shelf medical devices, such as intravascular (IV) catheters, to NO 
releasing catheters (Chapter 4).  For example, dip-coated CarboSil IV catheter tubing can 
be impregnated with up to 15 wt% SNAP loading in methanol/methyl ethyl ketone (30/70 
v/v) within 2 h.  Both SNAP-doped and SNAP-impregnated CarboSil catheters exhibit 
significantly less bacterial biofilm formation in vitro and reduced clotting in vivo when 
compared to the controls. 
 
Further, dual-functional antibacterial biomaterial surfaces that combine the physical 
modification (e.g., topographical texture) and chemical modification (e.g., NO release) 
were developed, with the aim of achieving a synergistic and/or additive effect on the 
inhibition of bacterial adhesion. Textured CarboSil surfaces bearing ordered pillar 
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topographies (400/400/600, 500/500/600 and 700/700/300 nm) were fabricated via a soft 
lithography two-stage replication process.  The NO release concept was introduced either 
by spin-coating SNAP-doped CarboSil sub-layer in the middle of the polymer film 
(Chapter 5) or by impregnating SNAP into the bulk of the polymer via solvent 
impregnation (Chapter 6).  The antibacterial results demonstrated that the dual functional 
polymer surfaces provide a synergistic effect in reducing bacteria adhesion of S. 
epidermidis and P. aeruginosa.  
 
Overall, the stable and long-term delivery of NO from biomedical polymers provides an 
attractive approach to improve the hemocompatibility and antibacterial properties of a wide 




CHAPTER 1  
Recent Advances in Thromboresistant and Antimicrobial 
Polymers for Biomedical Applications: Just Say Yes to Nitric 
Oxide (NO) 
Wo, Y.; Brisbois, E.J.; Robert, R.H., Meyerhoff, M.E., Biomater. Sci., 2016; 4: 1161-83. 
(Highlighted on Front Cover) * 
 
1.1 Challenges for Current Implantable Medical Devices 
 
Blood-contacting biomaterials are an integral part of various biomedical devices, ranging 
from simple catheters to intravascular grafts to extracorporeal circuits and membrane 
oxygenators, that offer lifesaving treatments to thousands of patients every day.  The 
incorporation of these blood-contacting materials is usually complicated by foreign body 
response that is initiated by the coagulation cascade1 (see Figure 1.1 ). 
                                                
* This introduction chapter is primarily comprised of a review article published in Biomaterials Science, 
written mostly by this Ph.D. candidate, with valuable edits, insights, suggestions and proofreading by Dr. 





Figure 1.1. Simplified schematic of the blood-coagulation cascade, where both intrinsic 
(surface contact) and extrinsic (tissue factors) pathways converge and ultimately form 
thrombus (modified from review by Sefton et al.2).  
 
Exposure of blood to foreign materials will cause plasma proteins, such as Factor XII and 
Factor XI, to be activated and adhere to the polymer surface.  The activated protein will 
interact with platelet surface membrane receptor GPIIb/IIIa, that can bind with fibrinogen, 
von Willebrand Factors (vWF), fibronectin, and vitronectin, which ultimately leads to 
platelet conformational changes, subsequent release of intracellular agents (e.g., Factor V, 
VIII and Ca2+, etc.), and initiates platelet activation and aggregation (intrinsic pathway).2,3  
Further, surgical procedures that utilize these devices have the potential to injure the vessel 
wall, disrupt blood homeostasis and release tissue factor, also causing platelet activation 
and concomitant conformational changes as well (extrinsic pathway).1–6  Both pathways 
converge and trigger the coagulation cascade as the activated platelets bind with fibrinogen 
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and other clotting factors.  Fibrinogen forms insoluble fibrin, which traps red blood cells 
and ultimately forms a thrombus within a matter of hours7,8 (see Figure 1.2). 
 
 
Figure 1.2. Simplified representation of the processes that lead to thrombus formation on 
the surfaces of blood contacting biomedical devices. 
 
In addition to thrombus formation, bacterial infection is also often associated with the use 
of many biomedical devices.  The rise of hospital-acquired infections, also known as 
nosocomial infections, is a growing concern in healthcare industry.  It was reported that an 
estimated 1.7 million patients suffered from healthcare-associated infections (HAI) in the 
U.S. hospitals in 2002 and the number of HAI deaths was 98,987 patients, including 30,665 
resulting from bloodstream infections.9–15  Device-related infections are the result of 
bacteria adhesion to the biomaterial surface.  After planktonic bacteria initially colonize 
onto the surfaces of polymeric devices, cells start to grow into colonies, and then hydrated 
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matrices of extracellular polymeric substances (EPS) are formed, also known as biofilms, 
16–18  (see Figure 1.3).   
 
Figure 1.3. Representative processes involved in biofilm formation and bacteria 
dispersion. 
 
The EPS holds the bacterial cells together in a mass and firmly attaches the cells to the 
underlying surface.  Ultimately, a mature biofilm will periodically release bacteria cells 
from the biofilm colony into the surrounding medium.  Of note, the EPS is both a physical 
and a chemical barrier to antibiotics and significantly retards their rate of penetration that 
makes conventional antibiotic treatment for such infections ineffective.  Further, the EPS 
can possibly foster antibiotic-resistant bacterial gene mutations.19  Ideally, all biomedical 
devices should be able to prevent bacterial colonization on their surfaces, especially within 
the first 6 h of blood exposure, which is identified to be the most susceptible and most 
“decisive period” for the success of a long-term implant.20  Thrombus and bacteria biofilm 
formation cause device failure, which in many cases can only be solved by device removal 
and replacement.  Besides patients suffering, the increased healthcare costs associated with 
these infections has also created a significant economic burden.20  
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The clinical problems of thrombus and infection described above have triggered substantial 
interest among scientists to develop new and more effective ways to create antithrombotic 
and antibacterial polymeric surfaces for biomedical devices, especially those in direct 
contact with blood (e.g., intravascular catheters, vascular grafts, etc.). 
 
1.2 Current Strategies for Prevention of Thrombosis 
1.2.1 Actively releasing anticoagulants to block the innate coagulation cascade 
In a clinical setting, in order to prevent surface-induced thrombosis during 
cardiopulmonary bypass, hemodialysis, and angioplasty, anticoagulants are routinely 
administered, the most commonly used one being heparin.2,21  However, systemic heparin 
administration can lead to hemorrhage and thrombocytopenia.  Localized release of heparin 
with concentrations that are not tolerable at the systemic level may be applied with minimal 
side-effects.22,23  To date, several approaches have been pursued to achieve localized 
heparin activity at the surface of implanted devices including the creation of heparin-
releasing polymer surfaces via ionic bonding,22,24–26 physical dispersion27–30 and solution 
swelling,22,31,32 as well as heparin-immobilized polymer surfaces.33–36  For example, 
Gutowska et al.22 described a novel thermosensitive heparin-releasing poly(N-
isopropylacrylamide) (poly(NiPAAm)) coating for prevention of surface-induced 
thrombosis on polyurethane catheters.  Poly(NiPAAm) has a lower critical solution 
temperature (LCST) in aqueous solution, around 32 °C, which enables it to swell when 
immersed in a heparin solution at low temperature (e.g., room temperature, RT) and uptake 
this polyanionic drug.  When the temperature is higher than LCST, the swollen coating will 
collapse dramatically and release heparin.  Both the heparin impregnated and control PU 
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catheters were inserted into saphenous veins in a canine model for 1.5 h, and the heparin-
releasing PU catheter surfaces demonstrated a significant reduction of thrombus formation 
after contact with the venous blood.  This was demonstrated by SEM images of the 
explanted catheters when compared to the appropriate controls.  Heparin typically has low 
solubility in organic solvents, but this swelling method introduced the possibility of 
solution absorption in water and loading of a relatively large amount of the drug into the 
swollen polymer chains.  This method also offers flexibility for the amount and type of 
anticoagulant drugs that can be loaded into various thermosensitive coatings.22  However, 
the heparin release kinetics for this system are relatively fast, with the release rates of 1 
µg/cm2 per h for up to 6 h.  Therefore, the potential application of this material is limited 
to preventing thrombosis formation in short-term applications, such as for angiography 
catheters, etc. 
 
Heparin has also been covalently linked to the surface of vascular grafts via end-point 
immobilization and this approach has been commercialized for expanded 
polytetrafluoroethylene (ePTFE) and Dacron grafts.37–39  The key to the success of heparin-
immobilized polymers depends on the covalently bound heparin remaining flexible enough 
to bind antithrombin III in order to prevent fibrin formation and the ultimate blood clot.3  
The literature on immobilization of heparin is vast and has been reviewed extensively 
elsewhere.37,40  However, due to their very short half-life,41 heparinized polymer surfaces 
still suffer a great challenge when it comes to long-term in vivo applications.  Other 
anticoagulants such as thrombomodulin,36 direct thrombin inhibitors (e.g., hirudin42 and 
argatroban43), or antiplatelet drugs (e.g.: prostacyclin (PGI2))36,41,42 have also been 
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immobilized onto polymer surfaces to increase their hemocompatibility, with varying 
degrees of success.  
 
1.2.2 Chemical modification of the polymer surface to reduce protein adsorption 
It is widely known that the first step that initiates activation of the coagulation cascade is 
protein adsorption (especially fibrinogen and von Willebrand factor; see Figure 2) to the 
surface of a blood contacting medical device.  This knowledge has led to many years of 
research in developing approaches to modify polymer surfaces that focus on reducing such 
non-specific protein adsorption.  Some examples include immobilizing a layer of blood-
compatible hydrogels on the device surfaces, such as poly(vinyl alcohol) (PVA), 
polyacrylamide (PAAm), poly(N-vinyl pyrrolidone) (PNVP), poly(hydroxyethyl 
methacrylate) (PHEMA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG),  
poly(ethylene glycol) monomethyl ether (PEGME), and cellulose.3,22,44  Hydrogels are 
water-swollen polymeric networks containing chemical or physical cross-links and were 
first used initially as soft contact lenses in the late 1950s.45  Due to their hydrophilicity and 
excellent water retention properties, they have the natural tendency to prevent cell and 
protein adhesion and are considered to be very biocompatible and desirable in biomedical 
applications.  For example, immobilization of PEG (-CH2CH2O-) is a widely used method 
to modify traditional polymer surfaces employed in the medical field, such as plasticized 
poly(vinyl chloride) (PVC) and polyethylene (PE), etc.46–49  PEG is a non-toxic water-
soluble polymer approved by the U.S. Food and Drug Administration (FDA) for internal 
consumption.50  Lakshmi et al.46 were among the first to graft PEG 4000 onto medical 
grade PVC sheets and conducted thrombogenicity studies to evaluate platelet adhesion 
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using platelet rich plasma (PRP) and whole blood clotting time with fresh rabbit blood.  
The scanning electron microscope (SEM) images clearly indicated more platelet adhesion 
to the bare PVC sheet than the PEG-grafted ones.  The PEG grafting also extended the 
whole blood clotting time from 20 min to more than 70 min as determined by the hemolysis 
assay. Balakrishnan et al.47 later demonstrated success using bulk modification of PVC 
resin with PEG 600 that yielded greatly reduced solid/water interfacial free energy and 
platelet adhesion in in vitro PRP studies.  This study expanded the anti-fouling chemistry 
from surface modification on a finished product to bulk synthesis.  However, studies 
conducted by Sefton and coworkers, who used PEG immobilized PVA hydrogel coated PE 
tubing in an ex vivo canine arteriovenous (AV) shunt, reported that neither the PEG grafted 
or control PVA tubing could maintain circulating platelet levels after 4 d.49  Heparin and 
hydrogel modified surfaces are the most commonly studied approaches for achieving 
thromboresistant surfaces.  For further breadth, readers are guided to reviews that highlight 
additional approaches developed thus far, such as endothelial cell coated-surfaces, 
albumin-coated surfaces, pyrolytic carbon-coated surface, phosphorylcholine surfaces, 
elastin-inspired surfaces, etc.3,42,51–53 
 
1.3 Current Strategies for Creating Antibacterial Surfaces 
1.3.1 Surfaces that resist bacteria and reduce initial attachment 
Bacteria attachment to device surfaces is the first step required for biofilm formation.  
Therefore, using biomaterial surfaces that resist bacteria attachment is an intuitive solution 
to this problem.54  Super-hydrophobic polymer surfaces, such as very smooth silicone, 
polyurethane, polytetrafluoroethylene (PTFE), poly(vinyl chloride) (PVC), and 
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polyethylene (PE), that have water contact angles larger than 150°, low surface energy,55,56 
as well as unique water repellent57 and self-cleaning abilities,56 are known to have 
resistance to microbial cell adhesion during short-term applications.58  Hydrophilic surface 
modifications, such as the PEG modified surfaces discussed above, have also been widely 
characterized in the literature and have demonstrated excellent anti-adhesive properties for 
bacteria cells and proteins.44  However, the susceptibility of PEG to oxidative damage, 
especially in the presence of O2, transition metal ions or certain enzymes in vivo, has 
limited its long-term application in complex media.59,60  Some studies have demonstrated 
that polymer surfaces with segmented block co-polymers (hard and soft domains) that 
result in phase-separated structures also exhibit less bacterial adhesion and cell 
attachment.61–63  Overall, however, passive surfaces without functional active agents may 
not be ideal for long-term applications because these surfaces may eventually become 
contaminated due to defects during preparation or deterioration of the coating when in 
contact with physiological fluids.3,4,64 
 
1.3.2 Surfaces that disperse or detach biofilms  
Biofilm dispersal is a promising area of research that focuses on how to inhibit biofilm 
formation using dispersal agents, which induce biofilm bacteria to detach and return to 
their planktonic form.  Several studies have found that bacteria naturally produce biofilm 
dispersal agents when the community senses a quorum, signaling the detachment process.54  
These agents include D-amino acids,65 cis-2-decenoic acid (C2DA),16,18,54 peptides and 
various enzymes (e.g., dispersin B), etc.54,66  However, most mechanisms of action of these 
compounds are still unclear, which hinders further development and application in this 
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field.  Many researchers have studied the effects of these dispersal agents in vitro, by 
adding the agents directly to pre-formed biofilm in petri dishes or bioreactors.67  Jennings 
et al. attempted to load C2DA into chitosan sponges for localized delivery by initially 
immersing the sponges into 1 mL of 100 mg/mL C2DA in 10 % enthanol.68  The release 
of C2DA was determined by HPLC and its release lasted 5 d (200-1000 µg/mL) with a 
burst of C2DA release on day 1.  The anti-biofilm efficiency of the C2DA loaded chitosan 
sponge was tested against clinical isolates of methicillin-resistant Staphylococcus aureus 
(MRSA) and the results showed that C2DA at a concentration (in the sponge) at or above 
500 µg/mL can inhibit bacterial growth.  Current research in this field is aimed at 
developing vehicles for the controlled and sustained release of such biofilm dispersal 
agents.54 
 
1.3.3 Surfaces that have bactericidal functionalities 
The most common mechanism of creating functional antibacterial surfaces is through a 
bactericidal effect, which includes employing a vast collection of approaches involving 
quaternary ammonium compounds (QACs)64,69–71 and other polycations (e.g., 
organometallic dendrimers72 and chlorhexidine73), metal ions (e.g., silver,74,75 copper,76 
titanium,77 etc.), locally released antibiotics (e.g., gentamicin66,78,79) or bactericidal agents 
(e.g., bacteriophages,54,80,81 protein synthesis inhibitors,66  antibacterial enzymes such as 
lysozyme,64,82 antibacterial peptides,83–85 natural biomolecules such as chitosan86–88 and 
herbal extracts (e.g., flavanones and chalcones),89 etc.), and inducing oxidative stress.72,90  
In general, the mechanisms of bactericidal surfaces are: 1) contact-based bactericidal 
activity (e.g., QAC, etc.) which affects the ion-exchange processes and cause general 
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perturbations that destabilize the cytoplasmic membranes of bacteria, resulting in leakage 
of the intracellular fluid; and 2) release-based bactericidal (e.g., metal ions, antibiotics, 
etc.), which damage the bacterial cell membrane as well as disrupt the function of bacterial 
enzymes, DNA, proteins and cell membranes.64  A problem, however, with many 
bactericidal surfaces is the attachment of dead microorganisms remaining on the 
antibacterial coatings, which can trigger immune response and inflammation, as well as 
block a given coating’s active functional group.  
 
In recent years, in order to achieve improved antibacterial and anti-fouling efficacy, many 
researchers have developed polymeric surfaces that combine more than one of the 
antibacterial functionalities mentioned above; for example, creating a surface that not only 
can attach and kill bacteria but also be able to release any adhered dead bacteria debris.  
Toward this goal, many pH,59,82,91 thermo,92 or electrical voltage93-responsive polymers, 
that can be controllably extended or collapsed or altered in their charge carrying properties 
have been developed.  They are often termed “stimuli-responsive smart antibacterial 
surfaces”.  Jiang and coworkers developed a cationic poly(N,N-dimethyl-N-
(ethoxycarbonylmethyl)-N-[2’-(methacryloyloxy)ethyl]-ammonium bromide) that has a 
quaternary ammonium group and was grafted onto a gold surface by surface-initiated atom 
transfer radical polymerization.59  The cationic surface can kill 99.9% of E. coli bacteria 
when exposed to a suspension of 1010 cells/mL for 1 h, and then it hydrolyzes into a 
nonfouling zwitterionic surface and releases 98 % of the bacterial residue after 8 d at 37 °C 
and pH 10.0.  This is only a one-time transition between cationic and zwitterionic surface; 
therefore, in order to achieve a fully reversible “kill and release” functional surface, a 
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surface with morpholinone derivatives that can be switched repeatedly between two 
equilibrium states was developed by the same authors.91  In neutral or basic aqueous phase, 
the surface will release dead bacteria and at the same time resist bacteria adhesion.  
However, under acidic conditions (e.g., in acetic acid for 20 h), the surface will regenerate 
bacteria-killing function by reforming the quaternary ammonium functional group.  
 
Of note, there are some limitations of this method of using pH change to alter antimicrobial 
properties of a surface.  These include: 1) this surface can kill bacteria attached on the 
surface while it is dry, since a wet version of this surface is generally resistant to bacterial 
attachment, suggesting this method mainly works for applications that prevent airborne 
bacteria; and 2) the requirement of changing environmental pH to achieve surface 
functionality may be difficult in situ with certain biomedical applications (e.g., blood 
contacting devices).  Most recently, Chen and coworker developed an on-demand 
switchable and repeatable antibacterial surface.  They used a silicone nanowire grafted pH-
responsive poly (methacrylic acid) (SiN-PMAA) for loading a natural antibacterial agent 
(i.e.., lysozyme enzyme), enabling killing of bacteria and releasing dead bacteria debris 
when alternating the environmental pH between 4, 7 or 10, respectively.  The SiN-PMAA 
surface exhibits a high capacity for binding lysozyme at acidic pH, but can release the 
majority of the adsorbed lysozyme that serves as biocide to kill bacteria attached to the 
surface or suspended in solution at neutral pH, and then release the dead bacteria to provide 
a self-cleaning process when the environment pH is increased to a basic value.  This 
dynamic reservoir concept may serve as the foundation for engineering multifunctional 
surfaces that could find many practical applications (such as biocatalysis and biosensing) 
 
 13 
in both biomedical and biotechnology fields.  However, achieving the needed changes in 
pH within blood, which is a relatively strong buffer, will be more challenging.  
 
Lastly, bacterial interference is a different concept that uses active bacteria (either probiotic 
bacteria54,94,95 or bacteria with less virulence96–98) to inhibit the targeted bacteria by 
competing for common resources in the same environment.  This approach can be 
leveraged to prevent infections from exogenous sources.  Trautner et al. reported a 
prospective clinical trial of using nonpathogenic bacteria colonized on urinary catheters in 
patients who require indwelling catheter drainage, to examine their effect in preventing 
bacteriuria commonly present in patients with indwelling urinary tract catheters.98  
Commercial urinary catheters were incubated in broth of Escherichia coli (E. coli) HU2117, 
a genetic strain that can cause persistent colonization without symptomatic infection,99 for 
48 h before insertion into patients for 28 d.  The patients’ urine samples were collected at 
various time points until E. coli HU2117 was no longer detected.  Ten (83 %) out of 12 
subjects were successfully colonized with E. coli HU2117 for 14 d or more (range, 15-165 
d) after inoculation by insertion of the catheter.  One patient had urinary tract infection 
(UTI) symptoms caused by Pseudomonas but none of the patients experienced UTI 
attributable to the colonization of E. coli HU2117.  The overall rate of symptomatic UTI 
for this study was 0.15 cases per 100 patient-days of colonization, compared to the reported 
rate of 2.72 cases per 100 patient-days, which suggested that this organism may have a 
protective function in patients who used the E. coli colonized catheters.100  However, a 
larger study group is needed to test the safety and efficacy of E. coli HU2117 coated 




1.4 Creating Dual-Functionality Hemocompatible Surfaces 
The ultimate truly hemocompatible polymer for blood-contacting biomedical devices 
should have both antithrombotic and antibacterial functionalities.  Many dual-functional 
materials have been investigated, including zwitterion-based surfaces, submicron-
patterned surfaces, and surfaces with multiple functional moieties, etc.  
 
Zwitterionic polymers are polymers with equimolar number of homogeneously distributed 
anionic and cationic groups on their polymer chains, that form a hydration layer on the 
surface of the material through electrostatic interaction and therefore resists plasma protein 
and bacterial cell adhesion.64,101,102  An alternative strategy towards creating 
hemocompatible surfaces is to change the polymer’s surface topography, thereby 
mediating subsequent biological responses.  Creating a submicron-textured surface can 
dramatically reduce the accessible contact area for platelets or bacteria to interact with the 
surface, thereby minimizing the opportunities for bacteria and platelet adsorption.103–105  
Polymers that combine multiple functional groups on one surface have also been tested, 
such as combining a synthetic heparin-mimetic polymer or hydrophilic polymer brushes 
(e.g., PEG) with antibacterial quaternary compounds (QAC) or Ag nanoparticles.106–108   
 
Despite some successes in the research laboratory with the methods reported above, newer 
approaches to reduce the possibility of thrombus and/or infection on indwelling device 
surfaces are still in great demand within the medical community.  Therefore, the main focus 
of the remaining content of this review is the utilization of polymer-based NO delivery to 
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prepare dual functioning antithrombotic and antibacterial surfaces for biomedical 
applications. 
 
1.5 Nitric Oxide (NO) to the Rescue 
Nitric oxide (NO), a diatomic free radical, was identified as the endothelium-derived 
relaxation factor (EDRF) in the Nobel Prize-winning discovery by Ignarro, Furchgott, and 
Murad in 1987.20,109–114  Many researchers have later unveiled NO’s various physiological 
functions in the human body, including preventing platelet activation and adhesion, 
inhibiting bacterial proliferation and biofilm formation, enhancing endothelization, 
signaling in the immune system’s response, and promoting angiogenesis and the wound 
healing process.113,115–118  
 
The human body synthesizes a large quantity of bio-regulatory NO from the substrate L-
arginine via three distinct isoforms of nitric oxide synthase (NOS), including endothelial 
NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS).119–121  The NO produced 
by eNOS contributes to the thromboresistant properties of the endothelial lining of blood 
vessels by inhibiting platelet activation.  The activation of platelets is mediated by NO 
through the soluble guanylate cyclase (sGC) pathway.  NO binds to the heme iron moiety 
of sGC and subsequently increases intracellular concentrations of cyclic guanosine 
monophosphate (cGMP).122,123  In addition, the cGMP increases cyclic adenosine 
monophosphate (cAMP) levels indirectly through phosphodiesterase III, which will also 
decrease the intracellular calcium concentration.  The NO activated sGC ultimately results 
in reduced intracellular calcium, inhibition of platelet phosphoinositide 3-kinase (PI3), and 
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reduced affinity as well as number of surface membrane fibrinogen binding sites on 
platelets (GPIIb/IIIa).118,122–127  It has also been suggested that many NO-related species 
are essential for NO’s potent antimicrobial effects.  First, NO can react with superoxide 
(O2-)128 and form peroxynitrite (OONO-), which is a lethal oxidizing agent and can induce 
oxidative stress, nitrosate amino acids and thereby alter protein functionality, oxidize and 
break DNA strands, and cause cell membrane damage to the bacteria it comes in contact 
with via lipid peroxidation.20,128–130  A second possible route reported for NO mediated 
cytotoxicity relies upon the formation of S-nitrosothiols (RSNO) in which after oxidation 
of NO to N2O3 the N2O3 can react with sulfhydryl groups on cysteine residues of membrane 
proteins to create RSNO structures that alter protein functionality, leading to cell stasis or 
cell death.109  Indeed, NO released or generated from polymer matrices has been shown to 
have similar antiplatelet and antimicrobial effects, as further described in detail below.  
 
Some surgery interventions or trauma that destroys the endothelial lining, as well as certain 
vascular diseases, will lead to an increased level of superoxide anions and that react with 
NO and reduce its bioavailablity.120,131  Reduced NO levels are associated with many health 
complications and/or diseases, such as high blood pressure, deep vein thrombosis, intimal 
hypertension, restenosis, endothelial dysfunction, and prolonged wound healing times in 
diabetic patients, etc.1,132,133  There are three main strategies for increasing NO 
bioavailability: 1) by participating in physical exercise and controlling certain dietary 
components (e.g., nitrate-rich diet);133,134 2) by administrating drugs that alter the 
enzymatic production of NO through nitric oxide synthases (NOSs) and increase the 
biosynthesis of NO endogenously;118  and  3) by using modified polymeric materials that 
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can actively deliver NO exogenously to the sites of interest.3,110,111  Various NO-related 
drugs have been used in the clinical settings for many years: nitroglycerin (converted to 
NO by enzymes) for chest pain, sodium nitroprusside for controlling blood pressure, and 
molsidomine for pulmonary hypertension.132  This has triggered substantial interest in 
developing polymers that can be functionalized as an artificial endothelium-like surface to 
therapeutically deliver NO locally at the polymer/blood interface.   
 
Since NO is highly active in vivo (with a short-half life on the order of seconds due to its 
rapid reaction with oxyhemoglobin, oxygen, and thiols, etc.), many NO donors have been 
synthesized and used for achieving the goal of prolonged and controlled NO delivery.  
Some examples include organic nitrates or nitrate esters (e.g., nitroglycerin or glyceryl 
trinitrate (GTN) and pentaerythrityl tetranitrate (PETN)), metal-NO complexes (e.g., 
sodium nitroprusside), nitrite, N-diazeniumdialates (NONOate), and S-nitrosothiols 
(RSNO),135–141 (see Figure 1.4).  Nitroglycerin, the most commonly used organic nitrate 
for clinically treating hypertension and angina pain, is known to release 1 mole equivalent 
of NO upon bioactivation by mitochondrial aldehyde dehydrogenase (mtALDH).112  
However, patients often develop nitrate tolerance (tachyphylaxis) after prolonged use 
because the reactive oxygen species generated by nitroglycerin can oxidize the thiol group 
of the mtALDH and result in enzyme dysfunction.112,142–144  This low bioavailability limits 




Figure 1.4. Structures of commonly studied NO donors in biomedical applications, a) 
sodium nitroprusside; b) potassium nitrosylpentachlororuthenate; c) nitroglycerin: d) 
pentaerythrityl tetranitrate; e) diazeniumdiolated N-(6-aminohexyl)aminopropane; f) 
diazeniumdiolated N,N'-dibutylhexamethylenediamine;  g) S-nitrosoglutathione; h) S-
nitroso-N-acetylpenicillamine. 
 
Metal NO complexes (metal nitrosyls) represent another class of NO donors used in 
biological testing.  Many different metal NO complexes have been reported, including 
manganese,109,137 iron145 and ruthenium-NO109,112,137 complexes, with sodium nitroprusside 
(Na2[Fe(CN)5NO], SNP) being the most common.  SNP is often used as a potent 
vasodilator in hypertensive emergencies,145  and releases NO in the presence of reducing 
agents (e.g., thiol-containing compounds such as cysteine or glutathione) or by illumination 
with near-infrared or visible light.112,121,145  However, cellular toxicity concerns due to the 
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release of cyanide and cytotoxic peroxynitrite as byproducts have made metal nitrosyl 
complexes less attractive as medicinally used NO donors.112,141   
 
Reduction of nitrite can generate NO via both enzymatic (nitrite reductase, xanthine 
oxidoreductase, etc.) and non-enzymatic (gastrointestinal acid, ascorbate, myoglobin, etc.) 
pathways.133  Recently, it was demonstrated that nitrite can also be used to generate NO 
via electrochemical reduction at an electrode surface with either Cu(I) ion generated from 
oxidation of Cu0 146,147 or via the use of Cu(II)-ligand complexes that mimic the active site 
of nitrite reductase (e.g.,  Cu(II)-tri(2-pyridylmethyl)amine, Cu(II)TPMA).148   
 
Many researchers over the past two decades have focused on using N-diazeniumdiolates 
(NONOates) and S-nitrosothiols (RSNOs) as leading candidates for controlled NO delivery 
due to their relatively high stability, their ability to spontaneously release NO under 
physiological conditions (e.g., no enzyme required) in a predictable manner, and their 
higher bioavailability in vivo.3,121,136  Furthermore, the tissue and metabolite independent 
release also avoids the build-up of tolerance over time, which makes these agents more 
suitable for biomedical applications.  
 
N-Diazeniumdiolates (1-amino-substituted diazen-1-ium-1,2-diolate) are a class of NO 
donor molecules formed by reactions between primary or secondary amines with NO under 
high pressure (e.g., 5 atm) in the presence of base (either an unreacted amine substrate or 
an added metal alkoxide base) at low temperatures.1,137  These species are able to generate 
two mole equivalents of NO per mole of donor, via a proton-driven reaction (hydrolysis), 
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in the physiological environment such as when the compound is exposed to blood or tissue 
fluids (see Figure 1.5).  NONOates can also release NO via thermal, photochemical or 
enzymatically (e.g., esterase) reactions.137,149 
 
Figure 1.5.  N-Diazeniumdiolates (NONOates) formation and decomposition. 
 
The half-lives of the synthesized NONOates strongly depend on the structure of the amine 
precursors and hydrogen bonding stabilization from additional amines within the molecule.  
It has also been reported that hydroxyl groups within the donor molecule, or the matrix it 
is within, can also contribute to the hydrogen bonding with the diazeniumdiolates.150,151  
For example, half-lives can range from the shortest reported t1/2 of 1.8 s for the 
diazeniumdiolated amino acid proline (PROLI/NO) to t1/2 of 20 h for diethylenetriamine 
(DETA/NO).136,137  One drawback of the diazeniumdiolate compounds is that they may 
potentially form carcinogenic nitrosamines.152,153  Batchelor et al. synthesized more 
lipophilic NONOates for use in reducing the NO donor leaching into blood from polymers 
that had been doped with such NO donors.154  Since the NO release process produces a 
lipophilic amine byproduct that increases the pH of organic phase, many additive 
compounds (such as tetraphenylborate or other borate derivatives154) have been included 
within  the organic polymeric phase to serve as counter ions for organic ammonium cations 
(when amines form after NO release and proton is extracted into the polymer to create the 
ammonium species) and thereby partly prevent a pH increase within the organic polymer 
phase.  This can greatly prolong the NO release lifetime from such NO donors when 
incorporated into biomedical polymers.  Unfortunately, the borate additives are not ideal 
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because of their inability to extend the NO release to more than a few days and their 
cytotoxicity toward endothelial cells.155,156  Therefore, Handa et al.155,156 as well as Cai et 
al.157 studied various poly(lactic-co-glycolic acid) (PLGA) additives with different 
hydrolysis rates as a means to slowly produce protons within the organic polymer phase 
that can continue to drive NO release reaction from NONOates.  PLGA is a biocompatible 
and biodegradable polymer, with tunable mechanical properties and wide range of erosion 
times.  Further, it is already approved for use by the FDA for the development of devices 
for controlled delivery of small molecule drugs, proteins and other macromolecules.158  
These studies demonstrated that the presence of PLGAs in the base polymer containing 
diazeniumdiolate species can extend NO release under physiological conditions for up to 
at least 2 weeks.   
 
S-Nitrosothiols (RSNO) represent an endogenous class of NO donors and natural 
transporters of NO within tissues and blood.121,159  Such molecules include S-
nitrosoalbumin (SNO-Alb), S-nitrosohemoglobin (SNO-Hb), S-nitrosocysteine (SNO-
Cys) and S-nitrosoglutathione (GSNO).160  RSNOs can be synthesized via the thiol 
nitrosation reaction (such as nitrous acid and alkyl nitrite, etc. in an acidic environment).141  
Owing to the natural occurrence of RSNOs in vivo, these molecules pose a relatively low 
risk of toxicity to cells/tissues in comparison to NONOates.  The transnitrosation reaction 
transfers the NO+ functional group from an RSNO species to another existing free thiol, 




RSNOs have characteristic UV-Vis spectra.  In general, they appear green for tertiary 
RSNOs (such as S-nitroso-N-acetylpenicillamine, SNAP) or pink for primary and 
secondary RSNOs (such as SNO-Cys, S-nitroso-N-acetylcysteine (SNAC) and GSNO).  
There are two primary bands in the UV-Vis spectra.  The strong band in the UV region is 
between 330 and 350 nm (ε~103 M-1 cm-1), which is attributed by the n0 è π* 
transition.141,162–164  A weak band in the visible region is between 550 to 600 nm (ε~20 M-
1 cm-1), which is attributed to the nN è π* transition.141  It is known that RSNOs can release 
NO via multiple pathways.164–169  Thermal or photo-initiated decomposition will lead to 
homolytic cleavage of the S-N bond, and form thiyl and NO radicals, where thiyl radical 
(RS) will react with another RSNO and generate disulfide (RSSR) and another NO radical.  
Metal ions (such as copper or ferrous ions)170,171 or organoselenium compounds can 
catalyze RSNO decomposition.115,172–174  It is reported that Cu+ (generated from reduction 
of Cu2+ by trace amounts of thiol) can react with RSNO and form the corresponding thiolate 
and Cu2+, which then react to regenerate Cu+ and a disulfide to continue the catalytic 
cascade.  RSNOs can also react with ascorbate to generate NO via two pathways.  In one, 
ascorbate (at low concentration) acts as a reducing agent to generate Cu+ from trace copper 
ion impurities in solution, or at high concentration ascorbate can act as a nucleophile, 
attacking the nitroso group to generate NO, a thiolate and dehydroascorbate.8,175,176  Further, 
certain enzymes such as copper-containing superoxide dismutase (CuZn-SOD)141,177 or the 
selenium-containing enzyme glutathione peroxidase (GPx)141,172,174 can also convert 
RSNO to NO in the presence of a reducing agent, such as glutathione (GSH) (see Figure 





Figure 1.6.  S-Nitrosothiol (RSNO) formation and decomposition. 
 
GSNO and SNAP are two commonly used RSNOs that have been intensively studied in a 
variety of biomedical applications.  GSNO is present in blood endogenously, which makes 
it innately more biocompatible and attractive for many applications, such as promoting 
wound healing process in mice or rats.178–181  The precursor for SNAP synthesis is N-
acetylpenicillamine (NAP), whose ultimate hydrolysis product, penicillamine, is already a 
FDA approved chelator for treating heavy metal poisoning, such as Wilson’s disease.182–
185  SNAP is reportedly one of the most stable NO donors available, due to its 
intermolecular hydrogen bonding,163,186 and has already been shown to be a very promising 
candidate for fabricating long-term NO releasing polymeric materials.162,163,187  Lipophilic 
analogs of SNAP (such as N-substituted derivatives of SNAPs) have also been developed 
by addition of bulky side-chains to N-acetylpenicillamine and preventing Cu+ catalysis 
through steric hindrance.188,189  Other lipophilic RSNOs (e.g., S-nitroso-tert-dodecyl 
mercaptan (SNTDM), log P = 5.3)190 (note:  P = partition coefficient of a molecule between 
octanol and water) with a higher Log P value than SNAP (log P = 0.4)163 have been 
synthesized for reducing the NO donor leaching from the hydrophobic polymer phase.   
 
1.6 Polymer-Based Strategies for NO Delivery 
For the past two decades, many research groups have focused on developing techniques to 
deliver NO locally, continuously and efficiently from polymeric devices where blood 
clotting and/or bacteria infection are major complications.  To improve the NO payload 
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and stability, achieve targeted NO delivery through multi-functionalization and elongate 
NO releasing lifetime, many different scaffolds have been used as NO-releasing or NO-
generating vehicles.  These include micelles,139,191,192 microbubbles,193 proteins,194–198 
liposomes,127,199 inorganic nanoparticles (such as silica,71,200–204 gold,205,206 
microparticles,199,207 zeolites,208,209), metal-organic frameworks (MOFs),210–213 
dendrimers,72,214,215 xerogels,216–218 electrospun fibers,89,101,219 natural polymers 
(chitosan,86–88,220–222 gelatin,223 etc.), and other organic polymers (polymethacrylate,224 
polyester,225,226 polydimethylsiloxane (PDMS),227 polysaccharides,228,229 
hydrogel,179,180,230,231 PVA,49,232,233 polyurethanes,162,163,234,235 and PVC155).  The 
approaches and benefits of different NO-delivery materials have been highlighted in 
numerous reviews.1,112,121,132,136–139,236  Here, an overview of the most promising polymer-
based NO delivery strategies are discussed, including covalently bound NO donors 
within/on a polymer matrix, physically dispersed NO donors within a polymer matrix, and 
catalytically generated NO from various RSNO reservoirs in the body (see Figure 1.7), and 





Figure 1.7. Three different strategies to fabricate of polymer surfaces that release or 
generate NO, including physical dispersion of NO donor into polymeric matrix, covalently 
bound NO donor functionalities onto polymer backbone, or NO generation from 
endogenous RSNO species in blood by metal catalysts embedded in or covalently bound 
to the surface of the polymer. 
 
1.6.1 Covalently bound NO releasing polymers 
N-Diazeniumdiolates are one of the most studied NO donors, and many polymers with 
secondary amine groups have been chemically modified to create the NONOate 
moiety.110,111,137  Meyerhoff and coworkers were among the first to link these NO donors 
to particle fillers (such as fumed silica particles237) or to the polymer backbone of polymers 
such as PVC,34,238 polyurethane (PU),34,111,234 and silicone rubber (SR).239  Zhang et al. 
synthesized NO-releasing fumed silica (FS) particles (0.2-0.3 µm) by tethering alkylamines 
onto the surface of the FS particles using amine-containing silylation reagents (coupling 
efficiency 50-70 %), and then converted them to corresponding NONOate groups with 
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final NO loading of ca. 0.6 µmol/mg of particle.237  The half-lives of the particles are 
significantly longer than the solution phase NO donor analogs, owing to the fact that a large 
quantity of amines present at the particle surface can increase the local pH, which then 
reduces the NO release rate.  Of note, when local pH decreases significantly, it results in 
partial release of the stored NO due to the proton-driven NO release mechanism.  
Therefore, some methods utilize additional acid-generating compounds to facilitate 
continual release of the entire NO payload. 
 
Keefer and coworkers were one of the earliest groups to covalently attach a 
diazeniumdiolate species to the backbone of poly(ethylenimine) (PEI) to form 
PEI/NONOate, which later was used to provide a flexible NO release coating for PTFE 
vascular grafts.240  The NO release from the sample was at a relatively constant rate (0.5 
pmol min -1 mg -1) for 5 weeks in PBS buffer at 37 °C.  In subsequent studies, Saavedra et 
al. prepared methoxymethyl-protected diazeniumdiolated piperazine PVC;238 however, the 
NO release rate was slow due to the fact that the NO could only be released from the 
NONOate group after the hydrolysis of the methoxymethyl protecting group.34  In addition, 
this PVC film can concurrently release toxic methanol and formaldehyde as byproducts of 
the methoxymethyl-protecting group, which is undesirable for use as materials in 
biomedical applications.  Zhang et al. later incorporated diazeniumdiolated functionalities 
into more biocompatible silicone rubber.239  Briefly, the diaminoalkyltrimethoxysilane 
crosslinking agent (DACA) was reacted with the terminal hydroxyl groups of the PDMS, 
and then the aminated PDMS macromolecules were cross-linked to each other 
(condensation-curing) in the presence of ambient moisture before forming the NONOates 
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species at the amine sites (via reaction of the polymer with NO(g) at high pressure).  
Likewise, N-diazeniumdiolated NO donors have been covalently linked to polyester,241 
polymethacrylate,224 polyurethane (PU),35,111,234,235 PVA233 and other hydrogels242 as well.  
The synthetic methods are somewhat similar to that described above, with the exception of 
one type of PU containing  a diamine chain extender, where sodium salts (NaX, where X 
is an anion) are incorporated into the reaction mixture during the NO addition process to 
facilitate the formation of anionic diazeniumdiolates.111 
 
Dendrimers are another class of popular NO delivery vehicles due to their ability to store 
a large reservoir of NO, have tunable sizes, and to be multi-functionalized for targeted 
delivery.215,243  Stasko et al. were the first to modify generation 3 and 5 polypropylenimine 
dendrimers at their exterior with different amine functionalities that were then converted 
to diazeniumdiolated dendrimers via reaction with NO(g) at high pressure.  The secondary 
amine/NONOates yield the highest storage capacity for NO, with up to 5.6 µmol NO/mg 
of polymer, and a NO release duration of >16 h under physiological conditions.243 
 
Frost et al. was the first to modify fumed silica particles (7-10 nm in diameter) with an 
RSNO functionality,200,201 such as S-nitrosocysteine-FS (SNO-Cys-FS), S-nitroso-N-
acetylcysteine-FS (SNAC-FS) and S-nitroso-N-acetylpenicillamine-FS (SNAP-FS).  This 
was accomplished, by tethering the thiol containing amino acids or N-acetylpenicillamine 
thiolactone onto aminopropyl-FS.  In these efforts, a total NO loading of up to 1.38 ± 0.29 
x 10-7 mol NO/mg particles was achieved.  The SNAC-FS and SNAP-FS particles can be 
blended into polyurethane (PU) or trilayer silicone rubber (SR) matrices to create films that 
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release NO at different rates by tuning the chemical identity, water uptake, or thickness of 
the PU polymer.201  However, the SR films containing SNAC-FS or SNAP-FS in the 
middle layer do not release NO upon exposure to copper ions or ascorbate in PBS solution 
because the very high hydrophobicity of the SR blocks the contact between the buffer and 
the RSNOs.200  However, such films are able to release NO at levels proportional to the 
intensity of visible light that is allowed to shine on the polymer, providing the first 
hydrophobic materials that have an external on/off trigger that precisely controls the rate 
of NO release via a photodecomposition reaction.  The authors determined that 590 nm 
light is primarily responsible for the release of NO from the SNAP-FS-SR films.  Evidence 
suggested that 67 % of the photoinitiated NO was accounted for by the longer wavelength 
(590 nm) and 33 % by shorter wavelengths (centered around 340 nm).  SNAP has also been 
covalently attached to PDMS,227 gelatin223 and a macrocycle (e.g., cyclam).244  The ability 
to generate programmable sequences of NO flux from these light-sensitive materials can 
offer precise spatial and temporal control of the NO release and potentially provides a 
platform to systematically study, at a fundamental level, the in vivo physiological response 
to implanted devices.227  Of note, SNAP-cyclam is capable of releasing physiological 
relevant levels of NO for up to 3 months in vitro when blended into poly(L-lactic acid) thin 
films and irradiated by a 385 nm LED, and this represents the longest NO release from 
SNAP-based polymer films reported to date.244 
 
RSNOs have also been used to form functionalized dendrimers214 or hyperbranched 
polymers (e.g., hyperbranched polyamidoamine (HPAMAM) or hyperbranched 
polyethers241) to achieve a high NO payload.  Stasko et al. functionalized generation 4 
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polyamidoamine (PAMAM) dendrimers with N-acetylpenicillamine or N-acetylcysteine 
and both macromolecular scaffolds have an NO storage of ca. 2 µmol NO/mg polymer 
after the required nitrosation raction.214  
 
Another category of NO delivering materials with large NO storage capabilities are xerogel 
films.  Riccio et al. designed thiol-modified xerogels derived from 3-
mercaptopropyltrimethoxysilane (MPTMS) and methyltrimethoxysilane (MTMS).217  The 
subsequent thiol nitrosation generates xerogels with NO loadings up to 1.31 ± 0.07 µmol 
NO/mg, and films of these materials are capable of releasing NO for up to 2 weeks under 
physiological conditions.  Similar to N-diazeniumdiolates, many other polymer 
modification studies have been conducted using S-nitrosothiols (RSNOs) as well, including 
those utilizing PDMS,227 PVA hydrogel,180 polyester and poly(methylmethacrylate),225 as 
the base polymer materials.  
 
Lastly, several biodegradable polymers, such as citrate-based226 or saccharide-based 
polymers (e.g., dextran228,245 and chitosan87,88,221) provide very attractive scaffolds for NO 
delivery because of their natural occurrence, biodegradability, tolerability to mammalian 
cells and accessibility for NO donor functionalization reactions.221,245,246  Reynolds and 
coworkers synthesized two S-nitrosated dextran thiomers (dextran-cystamine and dextran-
cysteine), with up to 0.205 ± 0.003 µmol/mg NO loading and the capability to release NO 
for 6 h in PBS buffer at 37 °C.  It has been further demonstrated that these dextran-based 
materials are susceptible to enzymatic degradation by dextranase, and the degradation of 
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dextran derivatives is slower and partial when compared to the unmodified dextran because 
of the chemical modification of the dextran backbone.245 
 
1.6.2 Physical encapsulation-based NO releasing polymers  
Physical encapsulation methods for preparing NO releasing polymers are based on 
embedding the NO donor within a polymer matrix physically without chemical bonding. 
This provides a much less complicated method to prepare NO release polymers than 
covalent attaching NO donors to particle fillers or the polymer backbones.  This approach 
is a more attractive strategy for future commercialization if stable long-term NO release 
can be achieved by dispersing the NO donor within a polymer matrix.   Toward this goal, 
polymer193 or phospholipid247 shelled microbubbles have been developed in recent years 
to create a hydrophobic microenvironment for NO transportation and therapeutic delivery.  
Paradossi and co-workers prepared NO-loaded PVA-shelled microbubbles (4.6 µm ± 0.4 
µm diameter and 0.4 µm shell thickness) for treating acute vascular disease, such as 
thrombosis.193  The microbubbles were loaded with NO by exposing to gas phase NO at 
1.5 bar for 2 h.  The NO encapsulation is about 1% of the NO present in the reaction vessel 
during the loading procedure, with the final content being 3.6 µmol/mg microbubbles.  The 
NO release measured by the Griess assay showed that ca. 90% of the NO is released during 
a 50 min period in phosphate buffer saline solution.  Ideally, the NO delivery should be 
controlled and selective bursts at a specific time and place, but the release can also be 
spontaneous and nonspecific.193  Unfortunately, the in vitro stability of such NO-loaded 




Gas storage in porous materials, such as zeolites, is also another attractive method for 
medicinal applications.  Wheatley et al. have used cobalt-exchanged zeolite-A to absorb 
and store NO (1.2-1.3 µmol NO/mg zeolite).  The NO release was triggered by contacting 
with water at physiological temperature and pH, replacing the gaseous NO with cobalt-
water interactions.  These NO-zeolite samples were also blended with powdered PTFE or 
PDMS to increase their mechanical stability and then pressed as disks for in vitro testing.  
The t½ values of NO release from zeolite polymer disks was significantly increased (from 
340 s for zeolite powder to 509 s for PTFE disk and 3076 s for PDMS disk).208  The results 
obtained in a platelet aggregometry assay also suggested that the NO-zeolites greatly 
inhibits platelet aggregation in vitro. 
 
Liposomes are also a popular choice to protect and deliver gaseous NO.  McPherson and 
coworkers prepared liposomes encapsulated with NO and argon gas (NO/Ar-ELIP) by a 
pressured-freeze and thawing method.  They used these capsules for attenuating intimal 
hyperplasia and reducing arterial wall thickness.199  Other researchers have conducted 
further studies to encapsulate NO donors within pH127 or thermo-sensitive248 liposomes to 
achieve controlled release.  In short, when N-diazeniumdiolates are encapsulated within 
liposomes, pH or temperature fluctuations change the proton influx through the biolayer 
membrane and subsequently induce a significant NO release.  Koehler et al. have also 
encapsulated SNAP within liposome vesicles and then doped the resulting vesicles within 




Biodegradable poly(ethylene oxide-co-lactic acid) (PELA)250 and poly(lactic-co-glycolic 
acid) (PLGA)207,220,250 have also been shown to be suitable vehicles for encapsulating NO 
donors to prolong the NO release.  Yoo and coworkers developed PLGA (5050DLG5E) 
nanoparticles (NO/PPNPs) with diazeniumdiolated polyethylenimine (PEI) for long term 
NO release for antimicrobial applications.220  The average size of the NO/PPNPs was 162 
± 19 nm as confirmed by scanning electron microscopy (SEM), with a NO release capacity 
of 1.4 µmol NO/mg polymer.  The incorporation of PEI/NONOate into hydrophobic PLGA 
nanoparticle matrix successfully restricts the spontaneous degradation of the NONOate 
group and extends the NO release lifetime from 12 h to over 6 d.220  More recently, Lautner 
et al. demonstrated the encapsulation of SNAP into PLGA (RG 503H and RG 504) 
microspheres (20-125 µm in diameter) using a solid-oil-in water (S/O/W) method251  and 
achieved up to 4 weeks of controlled release of SNAP from PLGA RG 504, which then 
generates localized NO in the presence of copper (II) and ascorbate.207  
 
Mowery et al.34 prepared diazeniumdiolated N,N-dimethyl-1,6-hexanediamine (DMHD) or 
linear PEI and dispersed them into plasticized PVC or PU.  Unfortunately, NO donor 
leaching was observed by HPLC and this raises potential concerns regarding toxicity if 
nitrosamine formation occurs, and such nitrosamines are also leached into the surrounding 
aqueous environment. Bachelor et al. 154 synthesized more lipophilic 
dialkylhexamethylenediamine-based NONOates with different alkyl groups (from methyl 
to didodecyl) which can enhance the retention of potential byproducts within the 




Seabra et al. incorporated GSNO and SNAC into Synperonic F-127 gel using a ‘cold 
method’252 and formed a hydrogel that contained 0.3 mol of GSNO or 0.6 mol of SNAC 
per gram of hydrogel.252  Kinetic studies showed that SNAC releases NO thermally 3.6 
times faster than GSNO (11 ± 0.4 min -1 vs. 3.1 ± 0.8 min -1); however, approximately 50% 
of both NO donors had decomposed after only 3 h.232  Kim et al. developed NO-releasing 
films by dispersing GSNO into biopolymer chitosan, where 75% GSNO remains after 
storing at room temperature for 4 weeks.  The 20 wt% GSNO/chitosan film released NO 
over 48 h in PBS buffer at 37 °C.222  Recently, Brisbois et al. discovered that SNAP is 
exceptionally stable when doped within several low water uptake biomedical grade 
polymers, such as Elast-eon E2As and CarboSil, and can release NO for up to 3 weeks at 
physiological conditions.156,162  Wo et al. later demonstrated that the SNAP in CarboSil 
mainly exists in crystalline form when the SNAP concentration exceeds its solubility in the 
polymer.  Ultimately, a slow crystal dissolution process leads to its long-term NO release 
under physiological conditions.163  Additionally, this crystal-polymer composite is very 
stable during storage for at least 8 months, not only because of the hydrophobicity of the 
CarboSil polymer that limits water diffusion primarily to only the polymer surface, but also 
because the crystalline SNAP is stabilized by intermolecular hydrogen bonds.163,253 
 
In order to apply NO release to any pre-made or off the shelf biomedical devices, Colletta 
et al.19 developed a simple solvent impregnation method to load SNAP into commercially 
available silicone Foley urinary tract catheters at room temperature.  This impregnation 
process takes place under very mild conditions, which is beneficial because, like many NO 
donors, SNAP or its analogs are sensitive to high temperatures used during industrial 
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catheter extrusion processes.  In this approach, SNAP or a SNAP analog is dissolved in an 
organic solvent that can swell the polymer to a great extent without dissolving it, and as 
the polymer uptakes the solvent, the NO donors are loaded into the polymers.  After drying 
to remove the solvent, the resulting polymer contains a stabilized form of the SNAP or 
analog of SNAP.  As an initial example, commercial silicone Foley catheters (i.d. of 0.30 
cm and o.d. of 0.59 cm) were swelled in a SNAP solution prepared in tetrahydrofuran 
(THF) (125 mg/mL) for 24 h, resulting in SNAP impregnation of 5.43 ± 0.15 wt% SNAP 
in the final dried catheter.  This level of SNAP loading enabled the catheters to achieve 
stable NO release above physiological levels for > 4 weeks.19 
 
1.6.3 Catalysis-based NO generating polymers 
Instead of incorporating NO donors or NO functionalities into polymers, many efforts have 
been devoted to generate NO from endogenous RNSOs or infusion of RSNO solutions 
through thiol transnitrosations,161,254 and subsequent catalytic reactions using immobilized 
copper or selenium-based species (e.g., copper nanoparticles,255 copper(II)-cyclen,171,256 
copper-complexes,257,258 copper-containing metal-organic frameworks (MOFs),210–213 and 
organoselenium species115,172–174).  Meyerhoff and coworkers were the first to covalently 
attach copper(II)-cyclen onto commercial biomedical grade polyurethane, which can 
generate physiological levels of NO (1-2 x 10-10 mol cm-2 min-1) when in contact with 
endogenous RSNO and RSH species, such as 10 µM GSNO/GSH in PBS buffer containing 
3 µM EDTA.171  This polymer has also been used as an outer coating at the distal end of 
an amperometric NO sensor that can generate electrochemical response toward the RSNO 
species in whole blood.171  However, it was reported that 50 % of copper(II) ion leached 
 
 35 
out after soaking in GSNO/GSH containing PBS buffer at RT for 7 d, which may limit the 
use of such polymers for long-term applications and generate cytotoxicity concerns.   
 
Reynolds and coworkers are developing many MOF-NO generating catalysts with 
accessible catalytic sites and that have resistance to degradation, including Cu3(BTC)2 
(BTC: 1,3,5-benzenetricarboxylate), Cu(II)1,3,5-benzene-tris-triazole (CuBTTri) and 
Cu(II)1,3,5-tricarboxylate (CuBTC).211–213  It has been reported that CuBTC can be 
extruded within Tecoflex SG80A polyurethane into single lumen tubing while maintaining 
the catalyst structure and functionality.  The in vitro NO release generated from 
endogenous RSNO species ranges from 1 h to 16 h with tunable dosage, depending on the 
specific RSNO levels present in the soaking solution.211 
 
As previously mentioned, Meyerhoff and coworkers have also demonstrated an 
electrochemical NO generation via a Cu+ ion mediated reduction reaction of inorganic 
nitrite.  The Cu+ ion is generated from oxidation of a copper wire146,147 or the reduction of 
copper(II)-tri(2-pyridylmethyl)amine (Cu(II)TPMA) complex.148  The electrochemically 
generated NO can be modulated by changing the potentials applied to the electrodes and 
can achieve fluxes between 0.5 and 3.5 x 10-10 mol cm-2 min-1 (for catheter applications), 
which is in the range of physiological relevant levels of NO released by the endothelial 
cells.  This approach has been utilized to develop a new generation of multi-lumen catheters 
in which one lumen is dedicated to generating NO electrochemically to reduce thrombus 




1.7 Applications of NO Releasing/Generating Polymers for Preparing Antithrombotic 
and Antibacterial Biomedical Devices 
1.7.1 Inhibition of thrombosis formation 
In a healthy vasculature, endothelial NOS (eNOS) in the endothelial cells that line the inner 
wall of blood vessels produce NO with a surface flux of 0.5 – 4.0 x 10-10 mol cm-2 min-1 to 
prevent platelet activation and thereby control the balance between thrombosis and 
hemorrhage.120  However, many procedures (such as placing stents, grafts, catheters, or 
other biomedical devices) disrupt the endothelial cells lining and destroy the delicate 
balance of vascular homeostasis.133  The tissue factor release and protein absorption trigger 
the coagulation cascade and the lack of NO production leads to platelet activation, 
aggregation, and ultimately thrombus formation.  Therefore, NO and its unique 
antiplatelet/antithrombotic activity represents a very promising approach to prevent 
thrombus associated complications in many biomedical applications. 
 
Mowery et al. reported that PVC- or PU-based polymer films, prepared with NO releasing 
diazeniumdiolate functionality via either dispersion or covalent bonding of NO donors, can 
exhibit significant improvements in biocompatibility during in vitro platelet adhesion tests 
using platelet-rich plasma (PRP).34  Wu et al. prepared PVC films (with borate additives 
and di(2-ethylhexyl) ester (DOS)) mixed with 0.5, 1.0, 2.0, 4.0 wt% of diazeniumdiolated 
N,N’-dibutyl-1,6-hexanediamine (DBHD/N2O2) to determine the effect on platelet 
adhesion at the surface of polymeric films with various NO flux levels.260  A lactate 
dehydrogenase (LDH) assay was used to determine the amount of platelets adhered onto 
the polymer surface.  LDH, which is normally stored within intact platelet, is released into 
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the bulk solution when the platelets are lysed by surfactant and is a very useful for 
indication of the amount of cells adhered.260  Fewer platelets adhered on the polymer 
surfaces with higher NO flux levels, and NO successfully reduced the amount of platelets 
adhered on the polymer surfaces from 14.0 ± 2.1 x 105 cells/cm2 on the controls to 2.96 ± 
0.18 x 105 cells/cm2 on the surfaces with highest NO release of 7.05 x 10 -10 mol cm-2 min-
1. 
 
Thrombosis is also an important risk factor in any blood exposure to synthetic materials, 
such as grafts, stents, intravascular sensors, catheters, extracorporeal circuits (ECC) or 
hemodialysis membranes.120,121,261,262   Efforts to use NO release polymers for these 
applications are summarized below based on the type of biomedical device.  
 
1.7.1.1 Intravascular grafts 
Keefer and coworkers were the first to test the antithrombotic and antiplatelet activity of 
NO released from a polymer matrix in animal models.240  Diazeniumdiolated cross-linked 
PEI coated PTFE vascular grafts were inserted into silicone rubber shunts that were placed 
between baboons’ femoral and artery veins for 1 h.  The autologous baboon platelets were 
labeled with indium-111-oxine before the start of experiment.  The number of platelets 
adhered on the graft surface at the end of experiment was accessed by measuring the 
radioactivity intensity using a gamma scintillation camera.  The NO-releasing grafts were 
found to be substantially less thrombogenic than the controls, suggesting considerable 
promise for this approach to improve the performance of vascular graft after 
implantation.240  The West116 and Wang115 groups both reported that NO 
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releasing/generating grafts encourage endothelialization/endothelial cell proliferation, 
which can alleviate the complications of thrombosis and intimal hyperplasia (IH) that cause 
the failure of small diameter vascular grafts without the use of systemic anticoagulants.  
 
1.7.1.2 Intravascular sensors 
Monitoring the levels of chemical species in blood (such as blood gases (PO2, pH, and 
PCO2), electrolytes (K+, Na+ Ca2+), glucose, lactate, etc.) can provide invaluable 
information for diagnosis and treatment of hospitalized patients.263  Currently, however, 
measurements are done in vitro with point-of-care devices intermittently, leaving large 
gaps of information between blood draws.259,264  Therefore, developing intravascular 
sensors that can monitor key chemical species in real time in critically ill patients is an 
important avenue of research.265   However, adhesion of platelets, and eventual thrombus 
formation on the surface of the sensors can occur within a few hours after blood contact, 
and such processes can not only isolate the chemical sensing area from the bulk of the 
blood and lead to false analytical results but also increase the risk of emboli or stroke.8,266  
Many researchers have attempted to address this problem by incorporating continuous NO 
release/generation into the sensor design to prevent adhesion of metabolically active 
platelets from adhering to the sensor surface.  To increase the biocompatibility of 
intravascular oxygen sensors, Marxer et al. developed an amperometric sol-gel derived 
oxygen sensor that consists of a platinum electrode coated with a diazeniumdiolate and 
polyurethane containing xerogel film.267  The coating released NO at a flux up to 4.32 x 
10-10 mol cm-2 min-1 for the first 12 h and effectively reduced platelet adhesion in the in 
vitro biocompatibility testing when immersed in platelet rich plasma for 1 h at 37 °C.  
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Instead of directly coating the electrodes with NO release polymers, many catheter-style 
intravascular oxygen sensors have been developed for testing in vivo with NO released or 
generated through the polymeric material of the catheters.  So far, several different NO 
delivery approaches have been reported for such intravascular oxygen sensors, including 
coating the catheter surface with NONOates,268,269 covalently attaching NONOates to 
catheter polymer surface,270 catalytically generating NO in situ from endogenous RSNOs 
using embedded copper particles8,271 and electrochemically modulating NO generation 
from nitrite.259  For example, Schoenfisch et al. coated outer surfaces of SR catheters with 
2 wt% (Z)-1-[N-methyl-N-[6-(N-methylammoniohexyl)amino]] diazeniumdiolate 
(MAHMA/N2O2) and demonstrated that the NO release from the catheter lasted more than 
20 h in PBS at 37 oC.  One control (coated only with MAHMA) and one NO release catheter 
(coated with MAHMA/N2O2) were implanted within the carotid or left femoral arteries in 
a canine model for 12-23 h.  The electrochemical response of the NO-releasing O2 sensor 
more closely represented the real arterial blood gas value measured by a benchtop blood-
gas analyzer than the control sensor, which had a significant discrepancy starting from the 
first few hours after the implantation.  SEM images also confirmed that a much greater 
number of platelets adhered and aggregated on the surfaces of the control sensors compared 
to the NO releasing sensors.  In a separate study, Ren et al. recently demonstrated the use 
of a dual lumen catheter configuration to combine an amperometric oxygen sensor (in one 
lumen) with the electrochemical NO generation in the other lumen using Cu(II)TPMA as 




Figure 1.8. Simplified schematic of dual-lumen catheter-type oxygen sensor with 
electrochemical NO generation from nitrite solution via Cu(II)TPMA (figure not drawn to 
scale). 
 
Applying different potentials on the electrodes can modulate the rate of NO generation, 
which offers a steady, controllable, and physiologically relevant flux of NO, compared to 
the chemically-based NO generation.  The performance of the sensor was evaluated in 
rabbit veins and pig arteries for 7 and 21 h, respectively.  The sensors in the arteries were 
challenged with a wider range of oxygen levels by changing the pig’s fraction of inspired 
oxygen between 100 % and 21 %.259  In both cases, the sensors with electrochemical NO 
generation provided very accurate oxygen responses, while control sensors deviated from 
 
 41 
the real values by 30-40 % after 5 h of implantation because the local oxygen was 
consumed by the activated platelets and other cells trapped in the thrombus formed on the 
surface of the control sensors.  Similar to oxygen sensors, NO releasing intravascular 
glucose,272–276  pH,276,277 and CO2276,278 sensors using diazeniumdiolated NO donors have 
also been tested, demonstrating much improved electrochemical responses over the 
corresponding control sensors.  
 
1.7.1.3 Extracorporeal circulations (ECCs) 
Extracorporeal circuits are used for several different types of medical procedures, such as 
hemodialysis, cardiac bypass surgery, and extracorporeal membrane oxygenation 
(ECMO).  The latter is employed to keep newborn babies alive for weeks at a time, if their 
lungs are not fully developed.  The need for systemic anticoagulation in each of these 
extracorporeal procedures can be problematic, particularly in patients that have heparin 
induced thrombocytopenia (HIT).  Due to the large surfaces area that is in contact with 
blood in extracorporeal circulation (ECC), the loss of platelet count and platelet 
functionality are significant,162 and many researchers have developed NO 
releasing43,155,156,162,237,239,279,280 or NO generating255 polymeric ECC tubing to prevent 
platelet activation and consumption during this process (see Table 1.1). 
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Table 1.1. Summary of NO releasing and NO generating coatings reported to increase the hemocompatibility of extracorporeal circuits 
(ECC). 
Summary ECC coating material 
NO donor, 
additives, etc. 
NO level (x 10 -10 
mol min-1 cm2) 
Platelet count after 4 h 






Tygon tubings with 




ca. 85 ± 15 % (NO) 
vs. 58 ± 5 % (PU) 
237 
Silicone rubber tubings 
N-diazeniumdiolated 
PDMS 
>4.0 at 23 °C; 
>10.0 at 37 °C 
86 ± 24 % (NO) 









79 ± 7 % (NO) 
vs. 58 ± 7 % (PVC/DOS) 
279 





79 ± 11 % (NO) 
vs. 54 ± 6 % (PVC/DOS) 
155 





97 ± 10 % (NO) 
vs. 58 ± 3 % (E2As) 
156 





ca. 90 % (NO/argatroban) 
vs. 58 ± 3 % (E2As) 
43 
Tygon tubings with 
Elasteon-E2As coating 
SNAP 2 
100 ± 7 % (NO) 
vs. 60 ± 6 % (E2As) 
162 
NO generation 
Tygon tubings with Tecophilic 
SP-60D-60 coating containing 
10 wt% Cu0 nanoparticle 
endogenous RSNO 
and/or infused SNAP 
>10 (in presence of 
1	µM GSNO, 30	µM 
GSH, 
5	µM EDTA)	
ca. 90% (10 wt% Cu0 and SNAP) 
vs. 75 % (10 wt% Cu0 only) 




Tygon tubings with Tecoflex 
SG 80A, Tecophilic SP-60D-60, 
PVC/DOS coating 
N/A N/A 
44 ± 4 % (SG 80A) 
vs. 41 ± 5 % (SP-60D-60) 




Zhang et al. prepared PVC tubing with PU coating containing 20 wt% diazeniumdiolated 
FS particle fillers237 and SR tubing with covalently attached to DACA/N2O2239 as NO 
releasing polymer tubing circuits for 4 h ECC experiments in a rabbit model.  Both types 
of NO release tubing exhibited less overall platelet adhesion and thrombus surface 
coverage compared to the controls.  However, it still remains a challenge to achieve long-
term NO release at physiologically relevant conditions, stable storage capability at room 
temperatures and high NO donor loading.  Handa et al. recently prepared ECC tubing 
composed of 25 wt% DBHD/N2O2 and 10 wt% PLGA (5050DLG7E) additives in 2:1 
PVC/DOS polymer matrix and achieved up to 14 d of NO release between 7-18 x 10-10 mol 
cm-2 min-1 at 37 °C.155  This circuit tubing successfully preserved the platelet count during  
4 h of experiments, with 79 ± 11 % vs. 54 ± 6 % for the NO release circuits compared to 
PVC/DOS controls.  In a subsequent study by the same authors, four different biomedical 
grade polymers were evaluated for their inherent hemocompatibility in 4 h ECC 
experiments in rabbits.156  The type of polymer material can ultimately influence their 
efficiency as NO releasing coatings.  E2As polymer was found to be the most 
biocompatible material amongst the four tested.  E2As coated ECC tubing can preserve 56% 
of baseline platelet after 4 h versus 48, 40 and 47 % for PVC/DOS, Tecophilic SP-60D-60 
and Tecoflex SG 80A, respectively.  Major et al. later used E2As polyurethane with 
DBHD/N2O2 and a direct thrombin inhibitor argatroban (AG) as an ECC coating to better 
mimic the vascular endothelium.  The results showed that the combined AG/DBHD 
polymer coatings can better prevent thrombus formation after 4 h of blood exposure 




In addition to diazeniumdiolates, RSNOs has also been used to create NO releasing 
coatings for ECC applications.  Brisbois et al.162 were the first to discover that SNAP-
doped E2As polymer films exhibit unprecedented shelf-life stability, with 82 % of the 
initial SNAP remaining after 2 months storage at 37 °C.  The 10 wt% SNAP/E2As films 
can release NO for up to 20 d at levels above the physiological NO flux range.  In the ECC 
experiments with rabbits, the inner walls of PVC ECC circuits were coated with the 
SNAP/E2As polymer.  Such coated tubing successfully preserved the platelet count during 
the 4 h of experiments (at 100 ± 7% % vs. 60 ± 6 % for controls), with 33 % less thrombus 
formation on the tubings’ inner surfaces.  
 
Another related approach to increase the biocompatibility of ECC tubing is to generate NO 
catalytically using infused RSNOs.255  Hydrophilic SP-60D-60 polyurethane polymer 
containing 10 wt% Cu0 nanoparticles (NP) (80 nm) coated on the inner walls of ECC circuit 
tubing were tested in the rabbit thrombogenicity model.  Experiments were conducted with 
and without intravenous SNAP infusion (0.1182 µmol/kg/min) over a 4 h period.  The Cu0 
NP embedded ECC circuit with SNAP infusion yields considerably less thrombus (0.4 ± 
0.2 pixel/cm2) on the surface of the chamber after 4 h, as compared to the Cu0 NP circuit 
without SNAP infusion (3.2 ± 0.2 pixel/cm2) or the control circuit without Cu0 NP (4.9 ± 
0.5 pixel/cm2).  Of note, since the endogenous RSNO levels are low (e.g., 1-10 µmol/L for 
SNO-albumin),281 this approach requires consistent supply of infused RSNOs to provide 




1.7.2 Prevention bacterial infection or biofilm formation 
Nitric oxide (NO) has antimicrobial activity against a growing list of microorganisms, 
including bacteria, fungi, parasites, viruses, and yeast.20,112,121,128,178,282,283  However, for 
medical device applications, the focus has thus far been on its antibacterial/antibiofilm 
properties, especially for the bacteria that most commonly cause CRBSIs (catheter related 
bloodstream infections), such as Staphylococcus epidermidis (S. epidermidis), 
Staphylococcus aureus (S. aureus), and Pseudomonas aeruginosa (P. aeruginosa).66,104  It 
has been clearly demonstrated that NO releasing/generating polymers can have strong 
bactericidal effects,19,147,148,163,202,228,284,285 even for bacteria that are able to metabolize and 
deactivate NO, such as P. aeruginosa, that possesses NO reductase enzyme that converts 
NO to nitrous oxide (N2O) and ultimately nitrogen (N2).87,202,220  Of note, NO possesses 
broad-spectrum antibacterial activity against both gram-positive and gram-negative 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).220,282  Moreover, 
the dose of NO required to kill bacteria (e.g., 200 ppm of gaseous NO) 282,283,286 does not 
show any cytotoxic effects in human dermal fibroblasts when exposed for 48 h.217,221   In 
addition to its bactericidal activity at high dosage, low levels of NO (picomolar to 
nanomolar range in solution phase)287 also serve as a key mediator that minimize 
planktonic bacteria adhesion and colonization, as well as disperse mature biofilm and 
release the bacteria trapped in the EPS film back to their planktonic state.287–289  It has been 
proposed that exposure to low doses of NO restore the sensitivity of biofilm and dispersed 
bacteria towards several types of antibiotics, greatly increasing their efficacy.287  
Overcoming bacteria colonization on the surfaces of biomedical devices through 
continuous NO release represents an innovative and highly desirable approach to reduce 
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risk of infections, which can ultimately increase device functionality and success rates, 
reduce morbidity and mortality, and improve patient outcomes..  
 
Frost et al. successfully develop a S-nitroso-N-acetyl-D-penicillamine functionalized 
polymer matrix (e.g., PDMS,227 cyclam244 and gelatin223) that can release NO via light-
initiated SNAP decomposition.  SNAP modified purified gelatin can release NO up to 1 x 
10-8 µmol mg-1 s-1 under a 527 nm wavelength light-emitting diode (LED,) and it also 
shows continuous and light intensity-responsive NO release over 24 h, with a total payload 
of 0.06 µmol NO mg-1.223  The antibacterial activity of SNAP/gelatin was tested against S. 
aureus (3 x 105 CFU/mL) and it demonstrated the ability to create a zone of inhibition of 
1.2 ± 0.7 mm and 0.75 ± 0.3 mm, when exposed to the 4.5 V and 3 V LED light, 
respectively, over 24 h.  Schoenfisch and coworkers have evaluated the antibacterial 
characteristics of NO releasing sol-gel coatings290 and xerogel films217 which are capable 
of releasing NO for 5 and 14 d, respectively, against a 108 colony forming units (CFU)/mL 
saline suspension of P. aeruginosa for up to 4 h.  NO successfully reduced bacterial cell 
coverage on these surfaces by up to 40 %.  Recently, Reynolds and coworkers developed 
a water-soluble NO-releasing polysaccharide derivative that can release 100 % of its NO 
storage capacity (49.5 ± 5.0 µmol/g) over 24 h.228  The bactericidal activity of this species 
was evaluated against E. coli, Acinetobacter baumannii (A. baumannii) and S. aureus and 
the reported data demonstrated an 8-log unit reduction in viable bacteria cell counts for all 
three types of bacteria after 24 h of incubation.  The absence of CFU counts after 72 h 
corroborated that there was no bacterial growth recovery after exposure to NO.  This is the 
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first time a water-soluble antibacterial agent has reached an industrially relevant level of 
antimicrobial activity.228  
 
Further, it is also well known that bacteria in mature biofilms are much harder to eradicate 
than when they are in planktonic stage.  Meyerhoff and coworkers have conducted many 
experiments where the antibacterial properties of NO releasing polymer were evaluated 
against mature biofilm, developed in CDC bioreactors prior to contacting with NO.146,148   
Electrochemical NO generating catheters using inner copper wire working electrode and 
inorganic nitrite salt solution can generate NO through the walls of the catheters with a flux 
> 1.0 x 10-10 mol cm-2 min-1 for more than 60 h.147  First, the catheters were mounted in a 
drip-flow bioreactor, which is a standardized model that allows growth of high biomass-
biofilm of E. coli at the air liquid interface when incubated with in LB (Luria Bertani) broth 
for 2 d and 4 d without the NO turned on.  After allowing biofilm to form on catheter 
surfaces, the electrochemical NO release was “turned on” for only 3 h at the end of the 
experiments.  The short period of NO release was effective at dispersing and killing the E. 
coli biofilm, and could lower the number of live bacteria adhered on the catheter surfaces 
by > 99.9%.  In a separate study, Backlund et al.215 synthesized diazeniumdiolated 
PAMAM dendrimers with different alkyl chain modifications and examined their 
antibacterial properties against 24 h old Streptococcus mutans biofilm (S. mutans) at pH 
7.4 and 6.4.  The bactericidal action of the NO releasing dendrimers was reported to 
increase with alkyl chain length of the dendrimer and lower pH.  In another experiment 
conducted by Schoenfisch and coworkers, a Center for Disease Control (CDC) bioreactor, 
that mimics bacterial growth under different sheer force conditions, was used to grow P. 
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aeruginosa biofilms over a 48 h period.  The biofilms were then exposed to a water-soluble 
NO releasing chitosan oligosaccharide (0.17-0.46 µmol NO/mL) for 24 h.  The presence 
of the NO release elicited a 5-log unit reduction in viable bacterial counts with a minimal 
bactericidal concentration (MBC) of the dendrimer preparation as low as 400 µg/mL.221   
 
Continuous NO release during bacterial proliferation has also been proven to prevent 
biofilm formation.  Cai et al. fabricated NO releasing silicone rubber films containing 
DBHD/N2O2 along with PLGA (RG 502H) additives that can release NO for 10 d at 
physiological conditions.   pH sensitive dyes were incorporated in the films to help 
visualize the pH change within the polymeric matrix due to slow hydrolysis of the PLGA 
that promotes the extended NO release.157  Both the NO release and control films were 
incubated in a CDC bioreactor for 7 d at 37 °C and the number of live bacteria on the 
surfaces of the silicone rubber was assessed.  The NO release films exhibited substantial 
antibiofilm properties against both gram-positive S. aureus (98.4 % reduction) and gram-
negative E. coli (99.9% reduction) when compared to controls.157  In subsequent studies, 
Colletta et al.19 and Ketchum et al.190 used the solvent impregnation method previously 
described above (see Section 1.6.2) to load silicone-based tubing with NO donors (SNAP 
and lipophilic SNAP derivatives, respectively) and demonstrated that they have 
antibacterial effects toward several microorganisms (e.g., Staphylococcus epidermis, 
Proteus mirabilis or S. aureus).  These results offer a new strategy to reduce bacterial 




In addition to in vitro experiments, NO releasing polymers (e.g., catheters) have also 
exhibited both antithrombotic and antibacterial properties in vivo.  Brisbois et al. conducted 
experiments where both SNAP-doped E2As catheter and control E2As catheters were 
implanted in sheep jugular veins for 7 d.187  At the end of the 7 d period, the catheters were 
carefully explanted and both the clot area as well as the number of live bacteria adhered on 
the catheter surfaces were assessed.  The 10 wt% SNAP/E2As catheters exhibited enhanced 
hemocompatibility (70% less thrombus formation) and bactericidal activity (90% 
reduction of bacteria adhesion) when compared to the controls.  
 
Nitric oxide releasing polymers have also provided a potential strategy for use as active 
wound healing dressings, capable of reducing bacterial infections at wound sites and 
accelerating the wound healing process for incisional and excisional wounds,180,220,222 burn 
wounds,291 and diabetic wounds.233  While normal fibroblasts do not synthesize NO, it has 
been demonstrated that fibroblasts isolated from the regular wound can release NO.292  The 
iNOS is synthesized in the early phase of wound healing by inflammatory cells, such as 
macrophages, monocytes, and other immune lineage cells.120,121,293  The NO released 
through iNOS enhances angiogenesis, regulates collagen formation, cell proliferation and 
wound contractions.112,293  Studies using induced NOS (iNOS) knock out mice showed 
diminished collagen deposition, with the restoration of normal collagen deposits upon 
exposure to SNAP, indicating the important relationship between NO production and 
wound healing.294  Therefore, elevating the local NO concentration at a wound site by an 




Yoo and coworkers developed PEI/NONOate nanoparticles (NPs) capable of prolonged 
NO release, which were then used to treat MRSA-infected excisional wounds (5 mm 
diameter, full thickness) in mice.220  MRSA was inoculated in the wound for 1 d to develop 
infection and then the wounds were treated with the NO releasing NPs or control NPs over 
6 d.  The photographs of the wounds taken at day 0, 1, 4 and 7 clearly showed an accelerated 
wound healing process for mice treated with NPs, with wound area reduced to 25% at the 
end of 7 d.  The untreated wounds showed a thicker scab with no reduction in the wound 
area.  In a subsequent study, GSNO-doped chitosan films, which exert strong antimicrobial 
activity against a broad spectrum of bacteria, were evaluated as a wound healing dressing 
on full thickness excisional wounds (1.5 m x 1.5 cm) in a rat model for 15 d.222  Comparing 
the NO-treated and untreated wounds, those treated with the GSNO/Chitosan dressing were 
almost completely healed at the end of the 15 d, with less bacterial burden and decreased 
inflammatory cell infiltration, but enhanced re-epithelialization.121,222  Brisbois et al. tested 
the antibacterial efficacy of DBHD/N2O2 and PLGA (5050DLG1A) doped biomedical 
grade PU films as a dressing for burn wounds (10 cm2 and partial thickness) in a mouse 
model.291 Burn wounds are quite common, but difficult to treat and often lead to 
infections.112  The burn wounds in mice were inoculated by A. baumannii for 24 h prior to 
application of the NO and control wound dressings.  After 24 h of treatment, the wound 
area skin tissue was harvested and assessed for number of viable bacteria adhered at the 
wound sites.  A 4-log unit bacterial reduction was observed for the NO treated wounds 




1.8 Summary  
As detailed above, there are many approaches that have been examined to improve the 
biocompatibility and antimicrobial activity of biomedical polymers/devices.  Most of the 
conventional approaches, (e.g., creating heparin-releasing surfaces, bacteria-resistant or 
biocide-releasing surfaces, etc.), can only improve either the hemocompatibility or the 
antibacterial properties of the devices.  However, NO release or generating polymers have 
demonstrated very positive effects in terms of preventing both platelet activation and 
thrombus formation as well as exhibiting significant antimicrobial activity toward 
infection/biofilm formation without bacterial resistance.  Although this review mainly 
focused on the use of NO release polymers for antithrombotic and antibacterial 
applications, these polymers also have many other potential applications for use on skin, 
bones, connective tissue, gastroenterology, or studying NO-induced cellular 
responses.112,178,295,296   
 
Recently, considerable effort has been devoted to develop combination therapy and hybrid 
drugs that combine NO release functionality with other active agents for increased 
efficacies, including anticoagulants,35,127 direct thrombin inhibitors,36,43 antimicrobial 
metal ions,216 quaternary ammonium compounds,71 PEG,116 antibiotics,297 and non-
steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.141  The remaining 
challenge for NO delivery polymers in order to be used in clinical settings lies in the 
development of more stable NO donors and polymer scaffolds and delivering the desired 
amount NO in a controlled spatial and temporal manner.  In many cases, long-term NO 
release is desired, especially for using NO-releasing, blood compatible polymeric materials 
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for preparing intravascular grafts, stents, catheters, and other vascular access devices.  
Further research should focus on the dose-dependent biological responses to different NO 
concentrations and aim towards developing clinically relevant NO delivery materials for 
that purpose, that can ultimately expedite the translation of these materials from the 
laboratory to clinical use.  Overall, both in vitro and in vivo (animals) studies of some of 
the NO releasing/generating polymers developed to date have clearly demonstrated the 
immense potential of this approach to improve the hemocompatibility/antimicrobial 
activity of a variety of biomedical devices that are required to improve patient care.  
Hopefully, the first commercial devices that employ this strategy will soon become 
available for routine use within hospitals. 
 
1.9 Statement of Research 
As previously described in this chapter, since SNAP is soluble in water, it is often 
covalently attached to filler particles which are then filled into polymer matrix in order to 
reduce leaching when the polymer is in contact with physiological solutions.  Yet in recent 
studies, SNAP was found to be exceptionally stable when doped into low water uptake 
biomedical polymers, such as Elast-eon E2As. However, the reason for this enhanced 
stability still remains unclear.  Therefore, the first goal of this dissertation work is to further 
examine different SNAP-incorporated polymeric materials and conduct solid-state analysis 
to understand the origin of the high stability of SNAP-doped polymers.  The purpose of 
developing NO releasing polymers is to mimic the antithrombotic and antimicrobial 
functions of NO released by the endothelial cells, macrophage and other cells. Hence, it is 
very essential to develop materials that can release NO in a similar flux range.  Therefore, 
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the second purpose of this research is to understand the various factors that control the NO 
release rates from these new composite biomaterials.  Furthermore, this thesis introduces 
the concept of a simple solvent impregnation process to incorporate SNAP into pre-made 
polymeric devices.  The successful adaptation of this technology may facilitate the process 
of developing commercial biomedical devices that can employ this NO release technique 
to prevent thrombus formation and bacterial biofilm infection.  This dissertation also 
includes results from a research collaboration with Dr. Lichong Xu and Dr. Christopher A. 
Siedlecki‘s laboratory at Penn State University Medical Center with the aim to develop 
dual-functional antibacterial biomaterial surfaces.  It should be noted that this dissertation 
is prepared using a multiple manuscript/publication format, and hence the introduction 
sections in each of the chapters may be somewhat repetitive.  
 
Chapter 1 summarizes and reviews in detail the research efforts to date in designing and 
creating antithrombotic and antimicrobial biomaterials for potential biomedical 
applications, with an emphasis on the use of NO releasing/generating polymeric materials.  
This portion of the chapter was published in RSC Biomaterials Sciences and was 
highlighted on the cover of the journal. (Y. Wo, E. J. Brisbois, R. H. Bartlett, M. E. 
Meyerhoff, RSC Biomaterials Sciences, 2016, 4, 1161-1183). 
 
Chapter 2 reports on fundamental solid-state studies that examine the origin of the high 
stability of SNAP-doped CarboSil 20 80A polymer-crystal composites and their potential 
in reducing bacterial biofilm formation in vitro and reducing thrombus formation in vivo. 
This work was published in ACS Applied Materials & Interfaces (Y. Wo, Z. Li, E. J. 
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Brisbois, A. Colletta, J. Wu, T. C. Major, C. Xi, R. H. Bartlett, A. J. Matzger, M. E. 
Meyerhoff, ACS Applied Materials & Interfaces, 2015, 7 (40), 22218-22227). 
 
Chapter 3 focuses on examining the NO release mechanism from SNAP-doped CarboSil 
polymer with respect to SNAP concentration, water-contacting polymer surface area and 
polymer thickness.  This chapter also includes a kinetics study of SNAP decomposition in 
various solution phases.  Finally, it demonstrates the antibacterial properties of SNAP-
doped CarboSil catheters are solely from the effect of NO released from the catheter 
surface.  This work has been submitted to Composite Part B: Bio-inspired Nano-
engineered Materials.  
 
Chapter 4 introduces the solvent impregnation approach to prepare SNAP-impregnated 
CarboSil 20 80A catheters.  This chapter details the optimization of the impregnation 
process and reports on the solid-state analysis of the new material.  It also includes the 
results and discussions regarding the in vitro anti-biofilm experiments and in vivo testing 
in an animal model.  This work has been submitted to ACS Biomaterials Science & 
Engineering. 
 
Chapter 5 summarizes our collaborative studies with Penn State Medical School to design 
and spin-coat a dual-functional antibacterial surface that combines the physical 
modification of material surface with submicron textures (e.g, pillars) and the chemical 
modification of the material by incorporating NO release functionality.  We have 
demonstrated there is synergy between NO release and surface textures against 
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Staphylococcus epidermidis bacterial adhesion.  The work presented in this chapter has 
been accepted for publication in Acta Biomaterialia.  
 
Chapter 6 describes the use of the solvent impregnation technique reported in Chapter 4 to 
create SNAP-impregnated NO releasing CarboSil biomaterial surface that also has surface 
texturing.  This approach provides a more efficient and cost-effective approach to create 
dual-functionality biomaterials in which the antibacterial properties of the resulting 
materials increase with impregnated SNAP concentration.  Statistical analysis of the 
bacterial adhesion suggests that either NO release and surface texturing has a significant 
effect in reducing bacterial adhesion alone. However, there is synergy when the NO release 
approach is combined with surface texturing against Staphylococcus epidermidis and 
Pseudomonas aeruginosa, not Staphylococcus aureus and Escherichia coli.  This work will 
be submitted to Biomaterials Science.  
 
Chapter 7 summarizes the major findings/conclusion from this dissertation research and 
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CHAPTER 2  
Origin of Long-Term Storage Stability and Nitric Oxide 
Release Behavior of CarboSil Polymer Doped with S-Nitroso-
N-acetyl-D-penicillamine 
 
Wo, Y.; Li, Z.; Brisbois, E.J.; Colletta, A.; Wu, J.; Major, T.C.; Xi, C.; Bartlett, R.H.; 
Matzger, A.J.; Meyerhoff, M.E. ACS Appl. Mater. Interfaces 2015; 7 (40): 22218-27 * 
 
2.1 Introduction 
Blood-contacting biomedical devices ranging from simple catheters to complex 
extracorporeal life support systems 1 are central for everyday medical care.  For example, 
the use of intravascular catheters, which enables direct vascular access, is crucial for patient 
diagnosis and treatment.  However, despite substantial efforts to better understand 
blood/surface interactions, complications like pulmonary embolism, stroke and deep vein 
thrombosis are still associated with the use of indwelling blood-contacting medical 
devices.2  In a clinical setting, a systemic anticoagulation agent, such as heparin is often
                                                
* The principal experiments of this chapter were conducted by Yaqi Wo, with the help of Dr. Zi Li in 
conducting the solid-state PXRD measurements, Dr. Jianfeng Wu in carrying out the microbiology 
experiments, and Mr. Terry C. Major in helping perform the animal testing. 
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 given to patients in order to reduce the risk of surface induced thrombus formation.3  
However, heparin treatment should be conducted with extreme care, as an inadvertent 
overdose of heparin can lead to hemorrhage and thrombocytopenia.4  Although heparin 
preferentially binds to antithrombin (ATIII), preventing fibrin formation and hindering the
development of the hemostatic plug, platelet activation and reduced platelet count is 
inevitable when foreign surfaces are in contact with blood for a prolonged period.  
Moreover, biofilm-associated infections are a significant cause of morbidity and death. 
Staphylococcus aureus (S. aureus) is the most prevalent cause of the high incidence of 
nosocomial bloodstream infections, specifically, biofilm-associated infections on 
indwelled biomedical devices.5,6  S. aureus biofilms form embedded matrixes which resist 
both antimicrobials and host defense, thus leading to chronic infections.7  Therefore, new 
approaches to reduce the possibilities of these complications and to create truly 
nonthrombogenic and antimicrobial prosthetic surfaces are still in needed within the 
medical community.2  
 
Nitric oxide (NO), the endothelium-derived relaxing factor, is a gaseous signaling molecule 
that has been extensively studied over the past two decades for its role in inhibiting platelet 
activation and adhesion, preventing bacterial growth, reducing smooth cell proliferation 
and regulating complex biological processes, etc.8–31  The ubiquity and apparent chemical 
simplicity of NO have made it a promising therapeutic agent.  The production of NO can 
be accomplished through either enzymatic or nonenzymatic pathways.11,32  Nitric oxide 
can be either synthesized enzymatically by nitric oxide synthase (NOS) that catalyze the 
conversion of L-arginine to L-citrulline, or it can be formed nonenzymatically from the 
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reduction of nitrite11 or nitrosothiols.  The flux of NO released from a healthy endothelium 
lining, which constitutes the inner walls of all blood vessels, has been estimated to be 
between 0.5 and 4.0 x 10-10 mol cm-2 min-1.3,10,33,34  Therefore, a potential approach to 
increase the hemocompatibility of blood-contacting devices is to develop polymeric 
materials or coatings with sustained NO release at this physiological flux level.  Indeed, it 
has been demonstrated that surfaces capable of releasing NO at these levels can 
significantly reduce thrombus formation on the surface of implantable chemical sensors,35 
intravascular catheters,14,15 as well as extracorporeal circuits (ECC).3,10,33  
 
Since NO is highly reactive under physiological conditions and has a very short half-life 
in vivo,10,36 a wide range of NO donors, such as S-nitrosothiols (RSNO) and N-
diazeniumdiolates (NONOate), have been used to prepare NO releasing polymeric 
matrixes.  Such NO donors have been incorporated into various polymers, including 
polyethylene glycol,37 Pluronic F127 hydrogel,12 polyurethanes,38 poly(dimethylsiloxane) 
(PDMS),9 xerogel39 and poly(vinyl chloride),23 and these materials can provide continuous 
and localized NO delivery to specific sites of interest.  S-Nitrosoglutathione (GSNO), S-
nitrosohemoglobin (SNO-Hb) and other endogenous RSNOs are considered NO donors in 
vivo.   However, in recent years, researchers have studied synthetic RSNOs, such as S-
nitroso-N-acetylpenicillamine (SNAP).9,10,18  SNAP is a synthetic tertiary RSNO and it is 
more stable than most endogenous primary RSNOs due to the steric hindrance of the sulfur 
atom.40,41  SNAP, like other RSNOs, can decompose and release NO via thermal 
decomposition, metal ion catalysis (e.g., Cu+) and photolysis when the light energy 
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corresponds with the SNAP absorption bands at 340 nm and/or 590 nm (see equation 2.1 
for overall reaction).10,42 
2 SNAP à 2 NO + NAP disulfide                                                                                    [2.1] 
Previous work by our group has suggested that SNAP is stable when doped within low 
water uptake polymers, such as Elast-eon E2As, a siloxane-base polyurethane elastomer.10  
Doping SNAP into the E2As polymer using a solvent evaporation method produced a 
homogeneous and transparent film, which exhibits relatively high stability during shelf-
life studies (82% of the initial SNAP remains after 2 months of dry storage at 37 °C).10  
However, the details of the NO release mechanism from SNAP within the polymer phase 
and the reason SNAP is so stable in certain polymer materials still remains unclear.  
 
In this study, three different SNAP-doped biomedical grade polymers, including CarboSil 
20 80A (a thermoplastic silicone-polycarbonate-urethane with a mix of soft segments of 
poly(dimethylsiloxane) and polycarbonate as well as a hard segment of methylene diphenyl 
isocyanate (MDI)), Elast-eon 5-325 (a copolymer of mixed soft segments of 
poly(dimethylsiloxane) and poly(hexamethylene oxide) as well as the MDI hard segment), 
and silicone rubber (poly(dimethylsiloxane)) are investigated and further evaluated for 
their ability to store SNAP for extended periods at 37 °C.  CarboSil 20 80A possesses the 
innate biocompatibility and biostability of conventional silicone elastomers but has the 
processing capability and toughness of thermoplastic polycarbonate-urethanes.  Therefore, 
the SNAP/CarboSil system is further examined for its NO releasing properties, and 
leaching of SNAP as well as concomitant NAP and NAP disulfide (NAP dimers) with time 
from the polymer phase into the PBS soaking buffer.  Raman spectroscopy and powder X-
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ray diffraction are utilized to conduct in-situ solid-state analysis of SNAP/CarboSil system 
to better understand the origin of the high stability and long-term NO release properties of 
this new composite material.  Further, catheters fabricated with SNAP-doped CarboSil 
polymer are evaluated for their efficacy in reducing microbial biofilm formation after 7 d 
of exposure to flowing media containing S. aureus, the common bacteria that causes 
intravascular infections within a drip-flow bioreactor.  Finally, these NO release catheters 
are also investigated for their potential as antithrombotic devices via 7 h implantation 
within the veins of rabbits. 
 
2.2 Experimental Section 
2.2.1 Materials 
N-Acetyl-D-penicillamine (NAP), sodium nitrite, L-cysteine, sodium chloride, potassium 
chloride, sodium phosphate dibasic, potassium phosphate monobasic, copper (II) chloride, 
ethylenediaminetetraacetic acid (EDTA), tetrahydrofuran (THF) and N,N-
dimethylacetamide (DMAc) were purchased from Sigma-Aldrich (St. Louis, MO).  N-
Acetyl-D,L-penicillamine disulfide (NAP disulfide) was purchased from Enzo Life 
Science, Inc. (New York, NY).  Methanol, hydrochloric acid, sulfuric acid, Luria Bertani 
(LB) broth and LB agar were obtained from Fisher Scientific (Hampton, NH).  CarboSil 
20 80A was obtained from DSM Biomedical Inc. (Berkeley, CA).  Elast-eon 5-325 (E5-
325) was from AorTech International plc (Scoresby, Victoria, Australia).  Dow Corning 
RTV 3140 silicone rubber (SR) was a product of Ellsworth Adhesives (Germantown, WI).  
An Agilent ZORBAX rapid resolution high definition (RRHD) Eclipse Plus C18 column 
(2.1 x 50mm, 1.8 µm particle size) was purchased from Altmann Analytik GmbH & Co.KG 
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(Munich, Germany).  All aqueous solutions were prepared with 18.2 MΩ-deionized water 
using a Milli-Q filter from EMD Millipore (Billerica, MA).  Phosphate buffered saline 
(PBS), pH 7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, and 
100 µM EDTA was used for all in vitro experiments.  S. aureus ATCC 25923 was obtained 
from the American Type Culture Collection (ATCC) (Manassas, VA). 
 
2.2.2 SNAP Synthesis 
SNAP was synthesized as previously reported.1,2  In brief, an equimolar ratio of NAP and 
sodium nitrite was added to a 1:3 mixture of water and methanol containing 2 M H2SO4 
and 2 M HCl.  The reaction vessel was cooled in an ice bath for 5 h and the green SNAP 
crystals precipitated.  The crystals were collected by vacuum filtration, washed by iced DI 
water and allowed to air dry for 24 h before being storage at -20 °C.  The entire synthesis 
process was performed in the absence of ambient light.  
 
2.2.3 Polymer Film Fabrication 
Polymer films containing different wt% SNAP (1-15 wt%) were prepared by solvent 
evaporation, based on a modified version of the previously reported method.2  Briefly, 3 
different biomedical grade polymers (CarboSil 20 80A, Elast-eon 5-325 and Dow Corning 
RTV silicone rubber) were dissolved in THF to prepare the casting solution.  For the 10 
wt% SNAP films, 200 mg of CarboSil and E5-325 were dissolved in 3 mL of THF and SR 
was dissolved in 1 mL THF.  Then, 22.5mg of SNAP was added and dissolved into the 
polymer solution.  After 5 min of stirring, the solutions were cast in Teflon rings (d=2.5 
cm) on a Teflon surface, and the films were allowed to dry overnight under ambient 
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conditions.  Small film disks (d=0.7 cm) were cut from the parent films and weighed 
individually.  These disks were then dip coated twice in non-SNAP containing topcoat 
solution; i.e. the CarboSil topcoat solution (200 mg polymer in 4 mL THF), the E5-325 
topcoat solution (200 mg polymer in 4 mL) or the SR topcoat solution (800 mg polymer in 
4 mL THF), respectively.  The SNAP-doped polymer films that were subjected to Raman 
spectroscopy and powder X-ray diffraction (PXRD) studies were not coated with any 
topcoats in order to more easily study the chemical properties of the SNAP-doped CarboSil 
matrix directly.  All films were dried under vacuum for additional 48 h to remove any 
residual THF before storage at -20 °C.  All SNAP-doped films and SNAP containing 
solutions were protected from ambient light during preparation.  The thickness of the 
SNAP-doped film layer was ca. 250 µm and the thickness of the two topcoat layers was ca. 
45 µm, as measured with a Mitutoyo micrometer. 
 
2.2.4 Preparation of SNAP-doped CarboSil Catheters 
The SNAP/CarboSil solution was prepared by dissolving SNAP (450 mg) and CarboSil 
(1800 mg) in THF (18 mL).  The CarboSil control solution consisted of CarboSil (2250 
mg) in THF (18 mL).  The topcoat solution was prepared with SR (1600 mg) in THF (8 
mL).  For the 20 wt% SNAP-doped CarboSil catheters, layers of SNAP/CarboSil were 
coated onto the stainless-steel mandrels (McMaster-Carr, IL).  as the active coats and dried 
overnight before removal.  Then, the SNAP/CarboSil catheters were then dipcoated in the 
SR topcoat solution (which coats both the inside and outside surfaces).  The topcoats were 
prepared with two-minute intervals in between.  For the CarboSil control catheters, 
coatings were applied in similar methods using non-SNAP containing CarboSil polymer 
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solution and the SR top-coating solution.  For the dripflow biofilm experiments (in vitro), 
the final catheters had an i.d. of 2.0 mm and an o.d. of 4.0 mm (SR : CB : SR = 7:30:7).  
However, because of the size limit of rabbit vein, catheters with 1.1 mm i.d. and 2.2 mm 
o.d. (SR : CB : SR = 3:10:3) were fabricated for the in vivo experiments.  
 
2.2.5 Polymer Water Uptake 
Control films (without SNAP) made from the 3 different biomedical grade polymers 
(CarboSil, E5-325 and SR) were cast as described above.  The weight of each film was 
recorded before immersing them in 1 mL DI water for 48 h at 37 °C and after taking them 
out and wiping the surface dry.  The polymer water uptake was calculated and represented 
as weight percent: wt% = (Wafter – Wbefore)/(Wbefore) x 100, where Wbefore and Wafter are the 
weights of the same film before and after soaking.2 
 
2.2.6 Shelf-life Storage Stability Study 
To simulate the harsh environments that could potentially occur during actual storage and 
shipping, 10 wt% SNAP-doped CarboSil/E5-325/SR films were prepared and stored in 
amber vials with desiccant at 37 °C.  After various time points over an 8-month period, the 
total NO release of the films were measured by the NOA to determine the wt% of SNAP 
remaining in the film, as compared to the initial amount of SNAP.  Films were cut into 
smaller pieces and immersed in a clear glass vial containing 50 mM CuCl2 and 10 mM L-
Cysteine, which led to the rapid catalytic decomposition of SNAP and the release of NO.  
Meanwhile, a 100 W halogen floodlight (GE model 17986), a broad-spectrum light source, 
was placed 20 cm away from the sample vessel and utilized to further enhance the NO 
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release rate via a photoinitiated decomposition process.  The corresponding NO release 
measured by a Sievers chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, 
CO).  The total moles of NO released was integrated and used to calculate the amount of 
SNAP remaining in the films.  
 
2.2.7 Ethylene Oxide (EtO) Sterilization 
Ten wt% SNAP-doped CarboSil/E5-325/SR films were prepared and sent to the University 
of Michigan hospital sterilization facility for ethylene oxide treatment, which is a 
standardized procedure for many devices used in clinical applications.  Briefly, the films 
went through 1 h of preconditioning and humidification process, followed by 2-3 h of EtO 
gas exposure, both performed at a high temperature (54 °C) and high humidity environment 
(40-80 %).  After the 1-2 h of EtO gas evacuation (54 °C), the films were subjected to 12 
h of air washes (54 °C).  The amount of SNAP remaining in the films was determined as 
described above.   
 
2.2.8 UV-Vis 
All UV-Vis spectra were recorded in the wavelength range of 250 nm - 650 nm with a UV-
Vis spectrophotometer (Lambda 35, Perkin-Elmer, MA) at room temperature.  The molar 
absorptivity of SNAP in PBS at 340 nm was determined as εSNAP= 1075 M-1 cm-1.  The 
characteristic absorbance at 340 and 590 nm correlated to the π à π* and nN à π* 




2.2.9 Cumulative SNAP, NAP, and NAP disulfide leaching from SNAP-doped CarboSil 
polymer films immersed in PBS 
Ten wt% SNAP-doped CarboSil films with no topcoat, 2 layers of CarboSil topcoats, and 
2 layers of SR topcoats, respectively, were fabricated (see the Supporting Information) and 
placed in individual vials containing 1 mL 10 mM PBS, pH 7.4, with 100 µM EDTA to 
minimize trace metal catalyzed decomposition of SNAP.  All films were incubated in the 
dark at 37 °C at all times.  After various time points, aliquots (15 µL) of the individual 
soaking solutions were analyzed by liquid chromatography-tandem mass spectrometry 
(6520 Accurate-Mass Q-TOF LC/MS, Agilent Technologies, CA) for quantification of 
SNAP, NAP, and NAP disulfide present in the soaking solution.  The studies were 
conducted using a reversed-phase column (ZORBAX RRHD Eclipse Plus C18, 1.8 µm, 
2.1 x 50 mm).  The gradient was obtained with eluent A (water with 0.1% formic acid) and 
eluent B (95% acetonitrile, 0.1% formic acid).  After sample injection (15 µL), a linear 
change of eluent mixtures from 100% A to 0% A over 10 min was carried out with a flow 
rate of 0.4 mL/min.  The mass spectrometer used electrospray ionization in the negative 
ion mode, and the detected species were [M-H]-.  All films were placed in fresh PBS buffer 
immediately after each measurement while the previous soaking solutions were analyzed.  
The results were compared between films with different topcoats.  The amount of total 
SNAP ([SNAP]total) that had diffused into the PBS after time t was calculated as follows 
(equation 2.2):  
[SNAP]total = [SNAP]t + [NAP]t + 2 x [NAP disulfide]t                                                 [2.2]   
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The amount of total SNAP leached into the buffer was compared with the initial amount 
SNAP in the polymer film. 
 
2.2.10 Cumulative NO release from SNAP-doped CarboSil films/catheters 
Nitric oxide release from the polymer films or catheters was measured using a Sievers 
chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  For example, a 10 
wt% SNAP-doped CarboSil film with 2 SR topcoats was placed in the sample vial 
containing 4 mL of 10 mM PBS, pH 7.4, with 100 µM EDTA at 37 °C to mimic the 
physiological conditions.  Nitric oxide was continuously generated and immediately 
purged and swept into the chemiluminescence detection chamber by N2 sweeping gas and 
bubbler.  All films were placed in fresh PBS buffer during NO release measurements and 
incubated at 37 °C in the absence of ambient light after each measurement.  Cumulative 
NO release ([NO]total) of a given SNAP-doped CarboSil film after various time points was 
determined by the sum of the NO release amount in fresh PBS measured by NOA 
([NO]NOA) and total amount of SNAP ([SNAP]total) leached into previous soaking solutions 
(equation 2.3):  
[NO]total = [NO]NOA + [SNAP]total                                                                                   [2.3] 
Cumulative NO release ([NO]total) was also compared with the initial amount SNAP in the 
polymer film.   
 
2.2.11 Polarized Optical Microscopy 
Five wt% SNAP-doped CarboSil films and a blank CarboSil film, both without topcoats, 
were prepared as described above.  Optical images were captured by a Leica DMLP 
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polarization microscope equipped with an N Plan 20× objective under crossed polarizers 
in combination with a quarter-wave plate, and were then taken with a SPOT Flex Mosaic 
15.2 camera using SPOT 5.2 Software from Diagnostic Instruments, Inc.   
 
2.2.12 Raman spectroscopy characterization 
Raman spectra were collected by using a Renishaw inVia Raman microscope equipped 
with a Leica microscope, a RenCam CCD detector and a 633 nm laser employing an 1800 
lines/nm grating and a 50 µm slit.  Spectra were obtained using the WiRE 3.4 software 
package.  Calibration was performed using a silicon standard in static mode.  Full spectra 
of blank CarboSil (without SNAP), pure SNAP crystals and 15 wt% SNAP-doped CarboSil 
were collected through an Olympus SLMPlan 20× objective in extended scan mode in the 
range of 100-4000 cm-1 and further analyzed by ACD/SpecManager Version 12.01 
software from Advanced Chemistry Development, Inc.  For Raman mapping 
characterization, SNAP-doped CarboSil samples were cut into thin strips and laid down on 
the stage with the cross section facing upward.  Raman cross-section mapping data were 
obtained by using an Olympus SLMPlan 100× objective in combination with an automatic 
Renishaw MS20 encoded stage in static scan mode.  The exposure time was 40 s with a 
static scan centered at 720 cm-1.  The mapping data were analyzed using the Wire 3.4 
software package component direct classical least-squares (DCLS) analysis routines with 
the full spectra of blank CarboSil and pure SNAP crystals as references. 
 
Raman mapping characterization in the low wavenumber regions, where SNAP and 
polymer peaks can be distinguished readily, was conducted on a randomly selected 32 µm 
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× 24 µm rectangular regions of the SNAP-doped CarboSil film cross section, with 1 µm 
steps in both the x and y dimensions to create a fine grid.  Raman spectra of all steps were 
compared with the orthorhombic SNAP spectrum using direct classical least squares 
(DCLS) analysis.7 
 
2.2.13 Powder X-ray diffraction (PXRD) measurements 
Powder X-ray diffraction (PXRD) patterns of SNAP-doped (1-15 wt%) and blank CarboSil 
films (without topcoats) were collected at room temperature using a Rigaku R-Axis Spider 
diffractometer with an image plate detector and graphite monochromated Cu-Ka radiation 
(l = 1.54187 ) at 40 kV and 44 mA.  Synthesized SNAP crystals were finely ground to 
eliminate preferred orientation, whereas blank CarboSil and SNAP-doped CarboSil 
samples were cut into cubes with dimensions of approximately 250 µm.  All samples were 
mounted on a CryoLoopTM using heavy mineral oil, and images were collected for 15 min 
with a 0.3 mm collimator.  The w-axis was oscillated between 120° and 180° at 1°/secs, 
the f-axis was rotated at 10°/secs, and the c-axis was fixed at 45°.  The obtained images 
were integrated from 2.5 to 70° with a 0.1° step size in AreaMax 2.0 software from Rigaku.  
All powder patterns were processed using Jade 9 XRD Pattern Processing, Identification 
& Quantification analysis software from Materials Data, Inc.  The simulated powder 
patterns of monoclinic and orthorhombic SNAP crystals were calculated in Mercury 3.3 
from the CCDC and were compared with the experimental SNAP powder pattern in Jade 
9.  Linear least squares regression for quantitation of peak area ratios versus doped-SNAP 
weight percentage was performed in MATLAB. PXRD measurements of 5 wt% and 15 
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wt% SNAP/CarboSil film (both freshly made and 10 d old under ambient environment at 
RT) were taken and compared.  
 
2.2.14 In vitro characterization of SNAP-doped CarboSil catheters against microbial 
biofilm 
A drip-flow biofilm reactor system (Biosurface Technologies Corp., Bozeman, MT),15 
which mimics the catheter environment and bacteria growth condition (at air-liquid 
interface) in vivo 8,9, was used to test the antibiofilm properties of SNAP/CarboSil catheters 
against biofilm formed by Staphylococcus aureus ATCC 25923.  The catheters were 
secured in the center of the bottom surface.  The biofilm chambers were first inoculated 
with 10 mL of bacteria culture (diluted with overnight culture, ~1 x 106 CFU/mL) for 1 h 
to allow bacterial cell adhere on the catheter surfaces.  Then the biofilm chambers were 
supplemented with continuous sterile nutrient medium (10% Luria Broth) at the flow rate 
of 100 mL/h (controlled by a peristaltic pump) for 7 days at 37 °C.  Finally, the catheters 
were aseptically removed and each catheter was cut into two 1 cm pieces, which was used 
for plate counting and imaging, respectively.  For plate counting, the catheter segment was 
homogenized (OMNI TH, Omni International, kenesaw, GA) for 30 s in 2 mL of 10 mM 
sterile PBS (pH 7.4) in order to disintegrate the biofilm to single cell suspension, which 
was later diluted by 10-fold each time and plated onto LB agar plates.  For imaging, the 
catheter segment was stained with fluorescent dyes by using Live/Dead BacLight Bacterial 
Vaiability kit (Invitrogen, Carlsbad, CA) for 20 min in the dark, exactly per the kit’s 
instructions.  Fluorescent images were acquired with an inverted fluorescence microscope 
(Olympus IX71, Center Valley, PA) equipped with Fluorescence Illumination System (X-
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Cite 120, EXFO) and filters for SYTO-9 (excitation = 488 nm/emission  = 520 nm) and 
Propidium Iodide (excitation = 535 nm/emission = 617 nm).  Images were obtained using 
an oil immersed 60× objective lens, in which red indicates dead bacteria while green 
indicates live ones. 
 
2.2.15 In vivo characterization of SNAP-doped CarboSil catheters in the veins of rabbits 
All animal handling and surgical procedures employed in this research were approved by 
the University Committee on the Use and Care of Animals in accordance with university 
and federal regulations.  A total of 3 New Zealand white rabbits (Covance, Battle Creek, 
MI) were used in this study.  All rabbits (2.5-3.5 kg) were initially anesthetized with 
intramuscular injections of 5 mg/kg xylazine injectable (AnaSed® Lloyd Laboratories 
Shenandoah, Iowa) and 30 mg/kg ketamine hydrochloride (Hospira, Inc. Lake Forest, IL).  
Maintenance anesthesia was administered via isoflurane gas inhalation at rate of 1.5-3% 
by mechanical ventilation via a tracheotomy and using an A.D.S 2000 Ventilator (Engler 
Engineering Corp. Hialeah, FL).  Peek inspiratory pressure was set to 15 cm of H2O) and 
the ventilator flow rate was 8 L/min.  To facilitate the maintenance of blood pressure 
stability, IV fluids of Lactated Ringer’s were given at a rate of 10 mL/kg/h.  In order to 
monitor blood pressure and to collect intermittent blood samples for analysis during the 
experiment, the rabbit’s right carotid artery was cannulated using a 16-gauge IV 
angiocatheter (Jelco®, Johnson & Johnson, Cincinnati, OH).  The blood pressure and 
derived heart rate were monitored by a Series 7000 monitor (Marquette Electronics 
Milwaukee, WI) while the animal body temperature was monitored with a rectal probe and 
maintained at 40 °C using a water-jacketed heating blanket.  Sample blood gas analysis 
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(arterial blood pH, PCO2, PO2, total hemoglobin and methemoglobin) was conducted using 
an ABL 825 blood-gas analyzer and an OSM3 Hemoximeter (Radiometer Copenhagen, 
DK).  Prior to the placement of catheters, the rabbit left and right external jugular veins 
were isolated.  Five cm lengths of the catheters (one SNAP and one control) were inserted 
into the veins.  The animals were not treated with anticoagulant systemically during the 
experiments. 
 
During the experiment, the mean arterial pressure (MAP) of the rabbit was maintained at 
38 ± 2 mmHg for 7 h by continuous IV fluid maintenance.  The heart rate average was 228 
± 4 beats/min and no significant change was noted for the duration of experiments.  The 
blood gas was measured once every hour and the results were all within the normal ranges. 
 
After 7 h of catheter implantation, all animals were first given (400 U/kg) sodium heparin 
(APP Pharmaceuticals, LLC Schaumburg, IL) systemically to prevent thrombosis during 
necropsy and were then euthanized with a dose of Fatal Plus (130 mg/kg sodium 
pentobarbital) (Vortech Pharmaceuticals, Dearborn, MI).  The jugular veins were clamped 
and the catheters were carefully removed from the vein, leaving the thrombus intact on the 
catheter surface.  After rinsing the catheter with saline, any residual thrombus was 
photographed and quantitated using Image J imaging software provided by the National 
Institutes of Health (Bethesda, MD).   
 
Rabbit whole blood samples were collected in non-anticoagulated 1 cc syringes for 
activated clotting times (ACT) analysis at the beginning of the experiments.  The whole 
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blood samples were also collected by 1 cc heparinized syringes (40 U/mL of sodium 
heparin) for blood gas analysis every hour for 7 h. 
 
2.2.16 Statistical analysis 
All experiments were conducted in triplicate.  Data are all expressed as mean ± SEM 
(standard error of the mean).  Comparison of means using student’s t-test was utilized to 
analyze the statistical differences between SNAP-doped catheters and control catheters.  
Values of p < 0.05 were considered statistically significant for all tests. 
 
2.3 Results and Discussion 
2.3.1 Preliminary shelf-life study of various SNAP-doped biomedical grade polymer films 
Three biomedical grade polymers (CarboSil, E5-325, and SR) with low water uptake (see 
Table 2.1) were chosen as matrixes for incorporating SNAP.  Ten wt% SNAP-doped 
polymer films were prepared to evaluate their shelf-life during dry storage.  To simulate 
the actual storage and/or shipping environments, the SNAP-doped SR, E5-325, and 
CarboSil films were stored in the dark with desiccant at 37 °C over a period of 8 months.  
The amount of SNAP remaining in different polymer films was determined at various time 
points to find the best polymer matrix for maintaining SNAP functionality during storage.  
The SNAP remaining in the film was decomposed through both the Cu (I) mediated 
catalytic decomposition pathway and the photoinitiated decomposition pathway by the 
broad-spectrum 100 W halogen light source.  The corresponding NO release measured by 
the NOA was integrated to determine the total amount of SNAP present in the polymer.  
The results indicate that SNAP is the most stable in the CarboSil polymer matrix, with 88.5 
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± 4.3% of the initial SNAP remaining after 8 months, compared to 86.8 ± 4.9% in SR and 
68.3 ± 3.2% in E5-325 (see Figure. 2.1).  Though the conventional silicone elastomer also 
exhibits equivalent stability, its lack of processability together with the prolonged polymer 
curing process (for cross-linking to occur) makes CarboSil a more promising material in 
terms of NO release properties.   
Table 2.1. The water uptakes of 3 biomedical grade polymer films.  Blank polymer films 
were soaked in DI water for 48 hours at 37 °C. Water uptake was calculated in the 
percentage representation, wt % = (Wafter – Wbefore)/(Wbefore) x 100, where Wbefore and Wafter 





Figure 2.1. Shelf-life study of 10 wt% SNAP-doped CarboSil, SR, and E5-325 films stored 
dry (with desiccant) in the dark at 37 °C.  The SNAP remaining in the films after various 




2.3.2 Ethylene oxide (EtO) sterilization of various SNAP-doped biomedical grade polymer 
films 
Ethylene oxide sterilization is a routine procedure for sterilizing clinical appliances inside 
hospitals, during which the devices are subjected to high temperature and high humidity 
level.43,44  Ten wt% of SNAP-doped SR, E5-325 and CarboSil were sterilized in order to 
evaluate the SNAP stability in these materials when undergoing ETO sterilization.  The 
results parallel the shelf-life studies, indicating that SNAP is most stable within the 
CarboSil polymer matrix.  Indeed, the CarboSil films maintain 91.8 ± 3.2% of the initial 
SNAP after ETO sterilization, compared to 82.7 ± 3.8% for the E5-325 films and 78.7 ± 
3.1% for the SR films (see Table 2.2).  These data suggest that the SNAP-doped CarboSil 
polymer matrix is the most attractive of all formulations as a NO release material for 
fundamental studies and eventually for potential biomedical applications. 
Table 2.2. Stability of 10 wt% SNAP-doped CarboSil, SR and E5-325 films after ethylene 
oxide sterilization process.  The SNAP remaining in the films after the sterilization were 




2.3.3 Cumulative leaching and NO release of SNAP-doped CarboSil films 
Although SNAP is reported to be slightly hydrophobic and should preferentially stay 
within the polymer phase,45  some SNAP is likely to diffuse from the polymer to the 
soaking solution.  Thus, in vitro studies were conducted with SNAP-doped CarboSil films 
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to examine the effects of different topcoat polymers by analyzing the amount of total SNAP 
leached into the PBS during soaking.  Ten wt% SNAP-doped CarboSil films with no 
topcoat, 2 layers of CarboSil topcoat, and 2 layers of SR topcoat were soaked in 1 mL of 
PBS at 37 °C.  Although SNAP can absorb light in the UV range (see Figure 2.2 ),37,42 it is 
not practical to quantify its decomposition species (e.g., NAP and NAP disulfide) by UV-
Vis.37,46   
 
Figure 2.2. The UV-Vis spectrum of 1mM SNAP dissolved in PBS buffer.  The molar 
absorptivity of SNAP in PBS at 340 nm is εSNAP= 1075 M-1 cm-1. 
 
Therefore, the concentrations of SNAP, NAP and NAP disulfide in PBS solution buffers 
at each time point were monitored by LC-MS.  Standard solutions of NAP, NAP disulfide 
and SNAP (1, 5, 10, 20, 40 and 60 µM) were prepared and analyzed for the individual 




Figure 2.3. The calibration curves of peak area vs analytes concentration. 1, 5, 10, 20, 40 
and 60 µM standard solutions of SNAP, NAP and NAP disulfide were prepared using 
Miili-Q Millipore purified water (18.2 MΩ) and analyzed by LC-MS.  Data are mean ± 
SEM (n=3). 
 
The elution times of NAP, NAP disulfide and SNAP from the C18 column are determined 
to be 3.45, 4.25, and 4.5 min, respectively, which correspond with the increasing log P 
values of three molecules (-0.07, 0.01, and 0.40, respectively).  The log P values were 
calculated using Marvin Sketch software, where a higher value means greater lipophilicity 
and hence a longer retention time.  Ten wt% SNAP films initially contain ca. 450 nmol of 
SNAP per mg of polymer.  When SNAP films are in contact with the soaking solutions, 
water starts to diffuse into the polymer outer surface; SNAP begins to leach into the soaking 
buffer; and at the same time, SNAP (both from the PBS buffer and within the polymer) 
starts to release NO and form the NAP disulfide byproduct.  The detection of NAP thiolate 
ion in the soaking solutions can be from two possible sources.  It is known that, for solid 
RSNO samples, contamination of thiols is likely and such thiols can react with the trace 
amount of Cu (II) in solution and form Cu (I) (equation. 2.4).  Then, Cu (I), acting as a 
catalyst, can react with RSNOs (e.g., SNAP), and form RS- (e.g., NAP thiolate) and Cu (II) 
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(equationo 2.5).47,48  Alternatively, it is conceivable that small amounts of thiolate can be 
generated by hydrolysis of RSNOs (equation 2.6).48 
Cu2+ + RS- à Cu+ + ½ RSSR                                                                                        [2.4] 
Cu+ + RSNO à  Cu2+ + RS- + NO                                                                                [2.5] 
RSNO + 2 OH- à RS- + NO2- + H2O                                                                            [2.6] 
As shown in Figure 2.4A, 47% of the initial SNAP (210 nmol/mg polymer) diffuses out of 
the CarboSil films without any topcoat over the period of 22 d, compared to 35% for the 
films with CarboSil topcoat and only 19% for the films with SR topcoat.  For each type of 
film, the rate of SNAP leaching is the fastest in the first few hours, and then significantly 
lower amounts of SNAP continue to diffuse into the PBS over sequential days.  The SR 
topcoat, which is a cross-linked polymer, can reduce the amount of SNAP diffusion into 
the soaking solution better than the non-cross-linked CarboSil topcoat.  Similar leaching 
patterns are observed for the NAP and NAP disulfide species from the films with different 
topcoats (Figure 2.4B and 2.4C).  NAP is a widely used chelating and detoxifying agent 
for treatment of heavy metal poisoning (e.g., mercury, cadmium, and arsenic, etc.).49–54  
Indeed, it hastens the excretion of poisons out of human body without inducing toxic 
effects, and it represents a protective measure against free radical induced organ injury.53  
Therefore, it is reasonable to believe that small amounts NAP and/or the dimer of NAP 
(NAP disulfide) emitted from the polymer into the contacting buffer or blood would not 




Figure 2.4.  Cumulative leaching of SNAP (A), NAP (B), and NAP disulfide (C) into 1 
mL of PBS (soaking buffer) from 10 wt% SNAP-doped CarboSil films with different 
coating conditions: without topcoats, CarboSil topcoats and SR topcoats, over the period 
of 22 days, at 37 °C in the dark.  Data are mean ± SEM (n=3). 
 
The 10 wt% SNAP-doped CarboSil film with SR topcoats releases NO above 0.5 x 10-10 
mol cm-2 min-1, the lower end of endothelial NO flux levels, for more than 3 weeks under 
physiological conditions (see Figure 2.5A).  A large burst of NO release was observed by 
the NOA (via chemiluminescence) on day 0 that correlates with the rapid SNAP leaching 
into the PBS buffer in the first few hours.  The cumulative amount of SNAP that releases 
NO was calculated based on the NOA measurements and compared to the initial amount 
doped within the film.  The total NO release from polymer films can originate from the 
SNAP decomposing and releasing NO inside the polymer phase as well as from SNAP 
(C) 
(A)  (B)  
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molecules that diffuse out of the polymer into the PBS buffer.  Assuming that the NAP and 
NAP disulfide detected in the buffer are reaction products of the original SNAP leached 
from the polymer, the total amount of SNAP that leaches out after time t should be 
[SNAP]total = [SNAP]t + [NAP]t + 2 x [NAP disulfide]t.  Since the films were placed into 
fresh PBS during NOA measurements, the NO release detected by the NOA can be only 
attributed to the SNAP decomposing and releasing NO from inside the polymer phase 
([NO]NOA) (assuming the amount of SNAP leaching during the measurement was 
negligible).  Therefore, the total NO release ([NO]total) from the polymer film is [NO]total = 
[NO]NOA + [SNAP]total, which was compared with the initial SNAP in the CarboSil film.  
As shown in Figure 2.5B, the total moles of SNAP ([SNAP]total) leached out over 22 d, the 
time period of the leaching experiment, is approximately 38.5% of the total NO released 
([NO]total) and, therefore, more than 60% of the total NO is, in fact, released from the 
polymer phase.  This suggests that the leaching process is much slower than the rate of NO 
release from the polymers, so it is likely that, after the first day, NO release from within 
the polymer  (primarily in the water rich regions near the outer surfaces of the polymers) 
is the primary source of NO emission.  The ability of the SNAP/CarboSil polymer system 
to deliver localized NO continuously and sufficiently to sites of interest makes it a very 




Figure 2.5. (A) NO flux from 10 wt% SNAP-doped CarboSil films with SR topcoats in 
PBS at 37 °C for 22 days.  Data are mean ± SEM (n=3).  (B) Comparison of total NO 
release and total SNAP leaching (sum of SNAP, NAP, and disulfide species) from the 10 
wt% SNAP-doped CarboSil films with SR coatings soaking in PBS at 37 °C.  The 
cumulative/total NO release comes from the thermal decomposition of the SNAP in 
polymer phase as well as the SNAP leached into the buffer.  The SNAP leached in PBS 
accounts for 38.5 % of the total NO release.  Data are mean ± SEM (n=3).  
 
2.3.4 Solid-state analysis of SNAP-doped CarboSil polymer systems 
To better understand the fundamental reasons for which SNAP is so stable in CarboSil and 
is able to release NO for 3 weeks, a series of solid phase characterization has been 
conducted.  Films of 5 wt% SNAP-doped CarboSil and blank CarboSil were viewed under 
a polarized optical microscope.  Distinguished crystalline patterns were found in the 
SNAP/CarboSil film in comparison with the blank film (see Figure 2.6). 
   




Figure 2.6. Optical image of (a) blank CarboSil and (b) 5 wt% SNAP-doped CarboSil film 
surface taken under crossed polarizers in combination with a quarter-wave plate.  The 5 
wt% film clearly shows patterns which suggest the presence of crystalline structures. The 
scale bars are both 100 µm. 
 
Therefore, it is hypothesized that SNAP crystallized in the polymer matrix during the 
solvent evaporation process, as opposed to all dissolving in the polymer and forming a 
homogeneous matrix as previously suggested.10  We further compared the Raman spectra 
of SNAP crystals, blank CarboSil film and 15 wt% SNAP/CarboSil film.  The spectrum of 
15 wt% SNAP/CarboSil (Figure 2.7.) showed characteristic peaks of both CarboSil and 






Figure 2.7. Raman spectra comparison of SNAP powder (black), blank CarboSil (blue) 
and 15 wt% SNAP-doped CarboSil (red).  The existence of SNAP crystals in SNAP-doped 
CarboSil is verified by the characteristic peaks of crystalline SNAP between 500-600 cm-
1 (see inset). 
 
In order to identify the form of crystalline SNAP detected in the Raman spectroscopy 
characterization, powder X-ray diffraction (PXRD) analysis of the synthesized SNAP 
crystals was conducted, and the results agree with the patterns of the orthorhombic SNAP 





Figure 2.8. The PXRD patterns comparison for grounded SNAP powder, simulated 
orthorhombic SNAP powder10 and simulated monoclinic11,12  SNAP powder suggests that 
the SNAP crystal synthesized is orthorhombic.  The consistent difference in peak positions 
of powdered SNAP and simulated orthorhombic SNAP patterns (2θ values of powdered 
SNAP peaks are always slightly smaller than those of the simulated pattern) can be 
attributed to the difference in operating temperature.  Powdered SNAP samples were tested 
at room temperature while the simulated patterns were based on single crystal XRD 
patterns taken at low temperature (-100 °F). 
 
It has been suggested that, in orthorhombic SNAP, one SNAP molecule can form 4 
intermolecular hydrogen bonds with 4 surrounding SNAP molecules (Figure 2.9).55 
 





Figure 2.9. (A) The orthorhombic SNAP crystal structure shown in 3D representation, 
suggesting that one SNAP molecule can form 4 intermolecular hydrogen bonds with 4 
surrounding SNAP.  (B) The elaboration of the number and position of the hydrogen bonds 
of one SNAP molecule in 2D schematic.  
 
The PXRD results of SNAP-doped CarboSil films (1-15 wt%) indicate that the 
characteristic film diffraction patterns are convolutions of blank Carbosil and the 
crystalline SNAP powder patterns (see Figure 2.10). 






























Figure 2.10. Representative PXRD patterns of SNAP powder, blank CarboSil and SNAP-
doped CarboSil film samples of different weight percentages (1-15 wt%) were tested.  
Sample peaks were able to be clearly distinguished when the wt% SNAP doping is no less 
than 4 wt%. 
 
The results also suggest that as the amount of doped SNAP increases (for films with greater 
than 4 wt% SNAP), the intensity of orthorhombic SNAP peaks in the obtained PXRD 
pattern is enhanced, indicating a greater percentage of crystalline SNAP within the polymer 
films.  However, SNAP peaks could barely be detected in PXRD patterns for samples with 
< 4 wt% doped SNAP, indicating an apparent threshold for formation of the crystalline 
form of SNAP within CarboSil.  Since all SNAP-doped CarboSil films (including those 
with <4 wt%) have a light green color, it is speculated that SNAP partially dissolves in the 
polymer, forming a polymer solution, and any excess SNAP beyond the polymer solubility 
limit crystallizes in the orthorhombic form during the THF evaporation and embeds in the 
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polymer.  This explanation is in agreement with the Raman spectroscopy and PXRD results 
that orthorhombic SNAP crystals are detected only when the SNAP concentration exceeds 
the solubility of SNAP in the CarboSil polymer.  To calculate the SNAP solubility in the 
CarboSil polymer, a linear least-squares regression was conducted using three main PXRD 
peaks.  Based on the following assumptions that (1) crystalline SNAP is uniformly 
distributed in CarboSil and that (2) the preferred orientation of SNAP crystals in CarboSil 
could be eliminated by cutting samples into cubes and rotating the samples during PXRD 
characterization, the ratio of peak areas (at a chosen 2q angle) of a specific SNAP PXRD 
peak over the total area of the obtained pattern would be proportional to the weight 
percentage of crystalline SNAP in the sample.  In fact, by using the area ratio as a 
quantitative representation, all the other factors that could influence the peak area (e.g., the 
volume of the sample irradiated by the X-ray source, the exposure time of sample under 
the X-ray, etc.) can be eliminated.  Here, we set the doped SNAP weight percentage as " 
and the ratio of the #$% orthorhombic SNAP peak area over the SNAP-doped CarboSil 







                                     [2.7] 
For a PXRD pattern of a sample with a unit volume and taken with a unit exposure time, 
H', H and I correspond to the area of the #$% peak in the orthorhombic SNAP pattern, the 
total area of all orthorhombic SNAP peaks, and the total area of blank CarboSil pattern, 
respectively.  The term "J is the SNAP solubility in SNAP-CarboSil solid solution system 
in the percentage representation.  As a result, for any SNAP-doped CarboSil sample, 
H'(" − "L) represents the area of the #$% orthorhombic SNAP peak in the pattern,	H " −
"J  represents the area of all signals from orthorhombic SNAP, and I(1 − ") represents 
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the area of all signals from CarboSil in this sample.  Since &' is a ratio of areas, which is 
independent of sample volume and exposure time, etc., the only factor that influences &' 
is the SNAP weight percentage " in the prepared CarboSil films. By substituting various " 
and &' at chosen 2q angles (three main SNAP peaks, 2q = 9.5, 14.5, 14.9), H', H, I and "J 
can be determined.  The H values calculated using three different SNAP peaks were 0.099, 
0.082 and 0.102, respectively, and the I  values were 12.996, 12.934 and 12.985, 
respectively.  As both values are within the error of tolerance, it suggests that the derived 
equation and the fitting model are successful quantitative representations of the doped 
polymer system. The calculated solubility is 3.6, 3.5 and 3.9 wt%, respectively (see Figure 





Figure 2.11.  Correlation of data obtained by powder X-ray diffraction for SNAP in 
CarboSil.  Linear regression lines were fitted using least squares approach.  The 3 most 
prominent orthorhombic SNAP peaks were chosen to do the fitting (2 theta = 9.5 (A), 14.5 
(B) and 14.9 (C)) and the calculated SNAP solubility in CarboSil polymer was 3.6 wt%, 
3.5 wt% and 3.9 wt%, respectively.  
 
Characterizing the stabilities of SNAP-doped CarboSil films using PXRD further verifies 
the dissolution hypothesis.  We compared the PXRD patterns of freshly prepared 5 and 15 
wt% SNAP-doped CarboSil samples as well as the samples stored under ambient light at 
room temperature for 10 d under the same conditions.  We hypothesize that the solubilized 
SNAP behaves as a solute, dissolving in the CarboSil polymer that acts as the solvent, and 
it is less stable at room temperature and decomposes faster than the crystalline SNAP.  As 





saturation, the crystalline SNAP is driven to gradually dissolve into the CarboSil polymer.  
For 5 wt% fresh samples, most of the SNAP added during preparation is dissolved in the 
polymer, which is labile and more likely to decompose via thermal decomposition.  
However, for the 15 wt% SNAP films, most of the SNAP in the film (ca. 11-12 wt%) is 
stabilized by the intermolecular hydrogen bonding.55 The percentage of SNAP remaining 
in the 5 and 15 wt% films after 10 d under ambient light is 19.8 and 83.2 wt% of the initial 
amount, respectively.  The attenuation of orthorhombic SNAP peaks in 5 wt% SNAP-
doped CarboSil films relative to the fresh samples is indeed much greater than that of the 
15 wt% samples (see Figure 2.12) where the SNAP peak changes are almost undetectable, 





Figure 2.12. PXRD pattern comparison between freshly prepared (blue spectra) and 10 d 
old (red spectra) of (a) 5 wt% and (b) 15 wt% SNAP-doped CarboSil films.  The crystal 
peaks intensity of 5 wt% films (19.8 wt% SNAP remained) decreased significantly while 
the 15 wt% one has minimal decrease in intensity (83.2 wt% SNAP remained) after storage 





Intermolecular hydrogen bonding in the SNAP crystals is one of the key reasons for the 
elevated stability of SNAP-doped CarboSil films during dry storage for 8 months.  In 
addition, as a tertiary nitrosothiol, the SNAP molecule itself is more stable with respect to 
the loss of NO than other primary and secondary RSNOs due to the steric hindrance effect 
imposed by the gem methyl group on the dimerization of the radicals that leads to the 
formation of the sulfur bridge10,40,41,45 and the hindered rotation of the RSNO 
linkage at room temperature.55  The literature also suggests that the acetamide group in 
SNAP plays a key role in increasing the SNO bond strength and reducing the NO 
liability.46  Moreover, it has also been reported that the viscosity of the polymer imposes 
an important cage effect on the SNO bond cleavage and radical pair formation.  
Specifically, the restricted mobility of soluble SNAP molecules in the CarboSil 
microenvironment may favor the recombination of the primary radicals rather than radicals 
escaping from the solvent cage.10,12,37  Therefore, doping SNAP into the polymer represents 
a viable option for storage and handling for long-term NO release applications.  Further 
studies comparing SNAP solubility in different polymer matrixes and examining the 
relationship between the SNAP crystallization/dissolution process and the stability of 
SNAP in certain polymers could be quite useful in designing additional NO release 
polymers with enhanced stability and long-term shelf life.   
 
Lastly, Raman mapping characterization using static scans was employed to determine the 
2D representation of the SNAP crystal distribution in 3 and 5 wt% SNAP-doped CarboSil 
films.  The green spots in Figure 2.13 represent regions where the orthorhombic SNAP 
peaks are detected and are found in large quantities only in the 5 wt% SNAP/CarboSil film 
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but not in 3 wt% films.  This finding correlates with the PXRD peak area fitting results that 
indicate the solubility of SNAP in polymer is ca. 3.4-4.0 wt%.  However, the exact grain 
sizes of the SNAP crystals could not yet be quantified by this method because the focal 
depth of the laser is likely to exceed the grain size of the crystal.  Thus, the green spots 
could represent crystals from both the surface and deeper within the polymer phase, which 
results in difficulty in distinguishing any individual crystal from overlaid crystals.  
 
 
Figure 2.13. Raman mapping results for fitting of (a) 3 wt% and (b) 5 wt% SNAP-doped 
Carbosil with pure orthorhombic SNAP spectrum as the reference under 100x objective.  
Green represents areas fitting the crystalline SNAP spectrum. 
 
2.3.5 In vitro antibiofilm experiments 
In order to generate NO release (at the higher end of the normal physiological flux level) 
for longer periods, 20 wt% SNAP-doped CarboSil catheters were prepared as described in 
the Experimental Section.  These devices can release physiological levels of NO for 28 d 





Because stable NO releasing devices can abate bacterial adhesion and colonization 
associated with catheterization, we examined the antibiofilm properties of catheter 
segments with S. aureus for 7 d in a drip-flow biofilm reactor at 37 °C.  The drip-flow 
bioreactor was chosen because it promotes the growth of the bacteria that grows at the air-
liquid interface, which mimics the condition of the surface of indwelling intravascular 
catheters.  Results for 7 d S. aureus biofilms shows a 5 logarithmic unit reduction in viable 
cell count on the surfaces of NO release catheters segments when compared to the control 
segments (see Figure 2.15A).  This finding is further corroborated by the fluorescent 
images (Figure 2.15B), which illustrates the live/dead bacteria as well as the bacterial 
 
 
Figure 2.14. Long-term (28d) NO release from the 20 wt% SNAP-doped CarboSil 
catheter for antibiofilm studies (o.d. 4mm).  NO release was measured in PBS via 




surface coverage on the surfaces of both catheters, respectively.  These results demonstrate 
that the SNAP/CarboSil catheter provides an approach that can potentially reduce/prevent 






Figure 2.15.  S. aureus biofilms developed on catheter segments in a drip-flow 
bioreactor for 7 d.  (A) Plate count of the number of viable bacteria adhered to the 
catheter surface.  (B) Representative fluorescence images with oil immersion 60X 






2.3.6 In vivo antithrombotic experiments in rabbits 
In order to demonstrate the potential benefits of using SNAP-doped CarboSil polymer as a 
thromboresistant material, acute 7 h rabbit experiments were conducted to study the effect 
of NO release from CarboSil catheters on the thrombus formation area.  The NO release 
from the SNAP/CarboSil catheter maintains an average flux of approximately 5.5 x 10-10 
mol cm-2 min-1 for 7 h at 37 °C (see Figure 2.16).   
 
One SNAP/CarboSil and one control catheter (non-SNAP) were placed into the external 
jugular veins of each rabbit for 7 h.  Owing to the very slow loss of SNAP from the catheter 
reservoir (given the composite nature of the material), the dose of SNAP leached from the 
catheters is significantly below the threshold that can induce the adverse reactions.10 
 
   
Figure 2.16 Representative NO surface flux profile from a section of the 
SNAP/CarboSil rabbit catheter for 7h (o.d. 2.2mm).  NO release was measured in PBS 





After 7 h of implantation, the catheters were carefully removed from the rabbit veins, 
leaving the thrombus formation intact on the surface.  To determine whether the NO release 
reduced the clotting on the catheter surface, digital images of the catheter surfaces were 
taken, and the two-dimensional (2D) representation of the thrombus area was quantitated 
using ImageJ software from the NIH.  As shown in Figure 2.17, the thrombus formation is 
significantly reduced for the SNAP/CarboSil catheters with NO release ability when 
compared to the controls (n = 3 rabbit experiments).  The SNAP/CarboSil catheters were 
also examined for NO release rates via chemiluminescence after explantation, and they still 
exhibit an average flux of 3.8 ± 0.2 mol cm-2 min-1.  This clearly demonstrates that the 
localized NO release from the catheter surface can significantly reduce platelet activation 







Figure 2.17. (a) Five cm of the catheters (left of the dash line) were inserted into 
the rabbit external jugular veins for 7 h.  Representative pictures of thrombus 
formation on the SNAP/CarboSil and control catheters after removal from veins.  
(b) Two-dimensional representation of clot area (cm2) on SNAP/CarboSil and 
control catheters in rabbit veins for 7 h, as quantitated using ImageJ software from 








In this study, we have shown that SNAP doped into the CarboSil 20 80A polymer forms a 
polymer-crystal composite during solvent evaporation and can locally release NO over a 
22 d period via thermal decomposition.  Utilizing a cross-linked silicone rubber topcoat 
can greatly reduce the amount of SNAP, NAP, and NAP disulfide leaching as measured by 
LC-MS.  The 10 wt% SNAP/CarboSil has excellent stability during the 8 month shelf-life 
study at 37 °C as well as during ethylene oxide sterilization, where 88.5% and 91.8% of 
the initial SNAP remain in the polymer, respectively.  These data suggest the practicality 
of sterilizing, storing and shipping biomedical devices made with or coated with this 
material.  Raman spectroscopy and PXRD characterization of SNAP-doped CarboSil films 
demonstrate that the solubility of SNAP in CarboSil is ca. 3.4-4.0 wt%.  However, when 
the SNAP doping wt% is higher than this solubility threshold, SNAP exists in an 
orthorhombic crystal form within the bulk of the polymer, in which intermolecular 
hydrogen bonds between SNAP molecules play a key role in maintaining the RSNO 
stability and functionality over a long period of time.  Solubilized SNAP in the polymer 
phase behaves like a solute in the solid solution polymer system and is less stable and 
decomposes faster than the crystalline SNAP.  When the solubilized SNAP in polymer 
decomposes/releases NO and the SNAP within the polymer phase is under saturation, the 
crystalline SNAP in the bulk of the polymer is driven to gradually dissolve into the polymer 
and further release NO.  The NO release process ceases after 22 d when all the SNAP 
crystals are depleted.  The catheters fabricated with this SNAP composite are shown to 
exhibit significant antibiofilm properties against S. aureus, and such catheters could 
eventually be used to reduce the rate of nosocomial catheter related bloodstream infections.  
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The SNAP/CarboSil catheters also greatly reduce thrombus formation during 7 h 
implantation within the veins of rabbits when compared to the corresponding control 
catheters.  Given its excellent stability and long-term NO release capability, the new 
SNAP-doped CarboSil composite system offers many new opportunities to improve the 
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CHAPTER 3  
Study of Crystal Formation and Nitric Oxide (NO) Release 
Mechanism from S-Nitroso-N-acetylpenicillamine (SNAP)-
Doped CarboSil Polymer Composites for Potential 
Antimicrobial Applications 
 
Wo, Y.; Li, Z.; Colletta, A.; Wu, J.; Xi, C.; Matzger, A.J.; Brisbois, E.J.; Bartlett, R.H.; 
Meyerhoff, M.E. “Development of S-Nitroso-N-acetylpenicillamine (SNAP)-Doped 
CarboSil Polymer Composites for Antimicrobial Biomedical Applications.” Composite 
Part B, Bio-Inspired special issue, Submitted. * 
 
3.1 Introduction 
Microorganisms commonly attach to living and nonliving surfaces, including those of a 
variety of indwelling medical devices.1  After the initial colonization on the abiotic surfaces, 
bacteria form extracellular polysaccharide substance (EPS), also known as biofilm, that 
creates a physical and chemical barrier for the bacteria, preventing conventional antibiotic
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 treatment or appropriate activation of the host defense system.2,3  Infection due to bacterial 
adhesion and biofilm formation represents a major complication associated with the long-
term use of indwelling biomedical devices, such as intravascular and urinary tract catheters. 
Intravascular catheters are utilized for management of hospitalized patients, where 
catheters are placed into the blood vessel for direct vascular access and used for infusion 
of fluids, drug administration, removal of blood samples, and patient monitoring, etc.  
Meanwhile urinary catheters serve an indispensable role in patient care, including 
preventing patient urine retention as well as providing a solution to chronic urinary 
incontinence.  However, external bacteria can access the blood vessel or urinary tract 
despite the routine antiseptic procedures used when implanting these devices, and both 
catheter-related bloodstream infections (CRBSIs) and catheter-associated urinary tract 
infections (CAUTIs) cause lengthy hospital stays, increased healthcare costs and high 
mortality rates.4–6  Current antimicrobial approaches for use with biomedical catheters 
include using catheters impregnated with antibiotics, employing antibiotic lock solutions, 
or utilizing catheters that possess a silver alloy coating that is capable of releasing Ag+ ions 
to prevent bacterial infection.7–10  Even though these antimicrobial catheters have been 
demonstrated in the laboratory to reduce bacterial adhesion and inhibit bacterial growth 
with some success,11–14 clinical results and efficiencies with such catheters have been less 
than satisfactory owing to the polysaccharide matrix that protects the bacteria and the 
increased level the microbial mutations (that prevents given antibiotic from proper 
functioning) within the biofilm.15,16  Therefore, efforts aimed at devising novel solutions 
to effectively prevent biofilm-induced infections associated with the long-term use of 




Nitric oxide (NO) was identified as the endothelium-derived relaxation factor (EDRF) by 
Ignarro, Furchgott, and Murad in 1987, and these scientists were awarded the Nobel Prize 
in Physiology or Medicine for their discovery in 1998.17,18  NO is an endogenous gas 
molecule synthesized from the amino acid L-arginine via three distinct isoforms of nitric 
oxide synthases (NOS): endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible 
NOS (iNOS).19–21  The NO released by the endothelium cells that line the inner wall of all 
blood vessels helps to prevent platelet activation/adhesion and serves to control blood 
pressure, and the rate of release into the blood stream is typically at a surface flux rate of 
0.5 - 4 x 10-10 mol cm-2 min-1.19,22–24  The human body also synthesizes greater amounts of 
NO from macrophages, upper airway epithelial cells, and other cells to serve as a potent 
antimicrobial agent to fight against bacterial infections in vivo.25,26  In this regard, NO has 
been reported to kill both gram-positive and gram-negative bacteria.27–32  It has also been 
reported that NO can modulate biofilm metabolism and make bacteria within biofilm more 
susceptible to antibiotics.33,34  
Because NO has a very short half-life, a wide variety of NO donors that are capable of 
releasing NO via different mechanisms/stimuli have been studied for therapeutic and 
targeted NO release.17,35–43  One very promising NO release compound is S-nitroso-N-
acetylpenicillamine (SNAP).  SNAP is a tertiary S-nitrosothiol species, which is much 
more stable in storage than primary S-nitrosothiols (e.g., S-nitrosoglutathione) and it is also 
considered very biocompatible because NAP and its ultimate degradation product, 
penicillamine, have been used as chelators to treat heavy metal poisoning, such as Wilson’s 
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disease in humans, for many years.44–48  Our group recently reported that SNAP is 
exceptionally stable when incorporated into CarboSil, a low water-uptake thermoplastic 
silicone-polycarbonate-urethane biomedical polymer.6  The low water uptake nature of 
CarboSil enables minimized SNAP leaching when in contact with solution.  Moreover, 
CarboSil itself has enhanced inherent biocompatibility over many previously studied 
polymer systems,35,49 such as poly(vinyl chloride)(PVC)-based materials.  Solid state x-ray 
diffraction studies demonstrated that SNAP can partially dissolve in the CarboSil 
polymeric matrix (solubility: ca. 3.4-4.0 wt%), while the proportion exceeding this 
solubility limit crystallizes in its orthorhombic form.  It was proposed that the hydrogen 
bonding between crystalline SNAP molecules contributes to its excellent shelf stability and 
slow dissolution of crystalline SNAP within the bulk of the CarboSil polymer determines 
the rate of NO release and ultimately leads to its long-term release under physiological 
conditions.6  However, more detailed studies are needed to further understand the 
polymer/crystal composite formation and the NO release mechanism from the SNAP-
doped CarboSil polymer matrix.  Herein, we report our effort to prepare S-nitroso-N-
acetylpenicillamine (SNAP)-doped CarboSil 20 80A polymer films and observe, in real 
time, the crystal formation process within the bulk of the polymer phase.  The NO release 
mechanism of this composite material when it is in contact with physiological solutions 
and its correlation with respect to film surface area and polymer thickness are also carefully 
examined.  SNAP/CarboSil catheters are also fabricated and evaluated for their long-term 
antimicrobial activity toward Pseudomonas aeruginosa (P. aeruginosa) and Proteus 




3.2 Experimental Section 
3.2.1 Materials 
N-Acetyl-D-penicillamine (NAP), sodium nitrite, L-cysteine, sodium chloride, potassium 
chloride, sodium phosphate dibasic, potassium phosphate monobasic, copper (II) chloride, 
ethylenediaminetetraacetic acid (EDTA), and tetrahydrofuran (THF) were purchased from 
Sigma-Aldrich (St. Louis, MO).  Methanol, hydrochloric acid, sulfuric acid, Luria Bertani 
(LB) broth and LB agar were obtained from Fisher Scientific (Hampton, NH).  CarboSil 
20 80A was obtained from DSM Biomedical Inc. (Berkeley, CA).  All aqueous solutions 
were prepared with 18.2 MΩ-deionized water using a Milli-Q filter from EMD Millipore 
(Billerica, MA).  Phosphate buffered saline (PBS), pH 7.4, containing 138 mM NaCl, 2.7 
mM KCl, 10 mM sodium phosphate, and 100 µM EDTA was used for all in vitro 
experiments. P. aeruginosa ATCC 27853 and P. mirabilis ATCC 29906 was obtained from 
the American Type Culture Collection (ATCC) (Manassas, VA). 
 
3.2.2 Study of SNAP decomposition reaction in solution 
SNAP was synthesized as previously reported.6,50 SNAP solutions (2 mM) in various 
solvents were prepared.  The solvents chosen in this experiment were PBS with EDTA 
(100 µM), PBS without EDTA, ethanol, THF and methanol-methyl ethyl ketone (30/70 
v/v) solvent mixture.  The decomposition experiments of SNAP in solution were conducted 
at 60 °C.  The concentration of SNAP in solution were monitored by UV-Vis absorbance 
spectroscopy at 380 nm (in order to avoid any absorbance overlapping with solvents) using 
an Agilent 8453 UV-visible spectrophotometer from Agilent Technologies.  Two hundred 
UV-Vis spectra were taken at 5 min intervals for each decomposition experiment.  The 
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absorbance data were fit into a first order reaction equation by KaleidaGraph 3.5 Synergy 
Software. 
 
3.2.3 Real-time monitoring of SNAP crystallization process in CarboSil 
An 8 wt% SNAP-CarboSil solution was prepared by dissolving 17.4 mg SNAP and 200 
mg CarboSil in 2 mL THF.  A clean glass cover slide was weighed.  Three drops of solution 
were then dispensed on the glass slide and the total weight was measured immediately, 
followed by weight measurements every 10 min.  Optical images of the sample were 
captured every 10 min by a Leica DMLP polarization microscope equipped with a N Plan 
2.5× objective under crossed polarizers in combination with a quarter-wave plate, and were 
then taken with a SPOT Flex Mosaic 15.2 camera using SPOT 5.2 Software from 
Diagnostic Instruments, Inc. 
 
3.2.4 Preparation of SNAP-doped CarboSil films 
Ten wt % SNAP was doped into CarboSil 20 80A polymer by solvent casting method using 
a Teflon plate.6  After curing fully, small disks (0.7 cm diameter and 260 µm thickness) 
were punched from the 10 wt% parent films.  To actively control the surface area of the 
films that are in contact with buffer during NO release measurements, SNAP/CarboSil 
films were separated into two groups and sputter coated with a 400 Å thick of gold film by 
gold sputtering (Denton Vacuum Inc., Desk II) for 120 s on either the front or the back side 




Figure 3.1. The images of 10 wt% SNAP-doped CarboSil film with no gold sputtering 
(left), front side gold sputtering (middle) and back side gold sputtering (right). 
 
Meanwhile, another set of the cured films (all with 0.7 cm in diameter), but with different 
wt% levels of SNAP within (5 wt% or 10 wt%) or different thicknesses (260 µm or 520 
µm thick) were also prepared for NO release measurements.  Films with the following 
configurations (5 wt% and 260 µm thick, 10 wt% and 260 µm thick, and 10 wt% and 520 
µm thick) were coated with plain CarboSil polymer topcoats by dip-coating (45 µm thick) 
to reduce SNAP leaching.  The NO release from all polymeric films was measured in PBS 
buffer at 37 °C using a nitric oxide analyzer (NOA) (General Electric Analytical 
Instruments, Boulder, CO) via chemiluminescence measurements.  The NO release profiles 
were recorded and compared between films with no gold coating, with only front side gold 
coating, and only back side gold coating, as well as between films with the same diameter 
but different SNAP concentration or thicknesses.  
 
3.2.5 Evaluation of the antimicrobial activities of NO release CarboSil catheters 
All SNAP catheters and control catheters were sterilized by ethylene oxide in the 
University of Michigan Central Sterile Processing Department 6 prior to testing.  In order 
to determine whether the bactericidal effect of SNAP-doped catheter is directly related to 
the nitric oxide that is being released, three control groups were used in the study.  These 
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included NAP-doped CarboSil catheters, plain CarboSil catheters, and a commercial 
silicone tubing.  This combination allowed us to evaluate the whether the precursor NAP 
or the polymer CarboSil itself has any effect on bacterial adhesion.  SNAP-doped, NAP-
doped or plain CarboSil catheters were fabricated by a dip-coating method using a stainless 
steel mandrel 6 and the final catheters had dimensions of 2 mm i.d. and 4 mm o.d. (see 
Figure 3.2).   
 
Figure 3.2. The images of SNAP-doped (top), NAP-doped (middle) and plain control 
CarboSil catheters, all with blank CarboSil topcoats. 
 
The NO release from SNAP-doped catheters with CarboSil topcoats was measured using 
the NOA, as described in Section 3.2.4.  All CarboSil catheter segments and commercial 
silicone tubing segments were mounted on coupon holders within a CDC bioreactor (see 
Figure 3.3) and the bioreactor was kept at 37 °C and supplemented with 10% Luria Bertani 




Figure 3.3. Schematic of the CDC bioreactor in which the different catheters were tested 
for bacterial biofilms formation. 51 
 
First, the media in the bioreactor in contact with the catheter/tubing segments was 
inoculated with overnight bacteria culture (~1 × 108 colony forming unit/mL) for 1 h 
without stirring.  Then the bacteria, P. aeruginosa ATCC 27853 or P. mirabilis ATCC 
29906, respectively (for two different studies), were cultured and grown onto surfaces of 
catheters for 14 d, with stirring.  Finally, all the catheter/tubing segments were removed 
from the bioreactor and cut into halves, and one half of each was homogenized in sterile 
PBS buffer, 10-folds serially diluted and then subjected to bacteria plate counting.  The 
other half of all the segments were used for fluorescence imaging of live bacteria on the 
surface of the tubing.  Briefly, control and SNAP impregnated catheter segments were 
stained with LIVE/DEAD BacLight Bacterial Viability kit (L7012, Invitrogen, Carlsbad, 
CA) according to the instructions, where green color indicates live bacteria and red color 
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indicates dead bacteria.  All fluorescence images were acquired with an inverted 
fluorescence microscope (Olympus IX71, Center Valley, PA) equipped with Fluorescence 
Illumination System (X-Cite 120, EXFO) and filters for SYTO-9 (excitation = 488 
nm/emission = 520 nm) and propidium iodide (excitation = 535 nm/emission = 617 nm).  
Images were obtained using an oil immersed 60× objective lens.   
 
3.2.6 Statistical analysis 
All experiments were conducted in triplicate.  Data reported herein are all expressed as 
mean ± SEM (standard error of the mean).  Comparison of means using student’s t test was 
utilized to analyze the statistical differences between SNAP-doped catheters and control 
catheters.  Values of p < 0.05 were considered statistically significant for all tests. 
 
3.3 Theory 
In solution, the decomposition of solubilized SNAP is a pseudo-first-order reaction 
proportional to the SNAP concentration, resulting in a relatively short half-life and rapid 
decomposition at room temperature. The stability of SNAP can be improved by doping 
SNAP into low water uptake polymers, such as CarboSil 20 80A, where SNAP will form 
crystals and embed within the polymer matrix.  The intermolecular interactions between 
SNAP molecules in the crystal lattice stabilize this NO donor, and leads to long-term NO 
release via slow crystal dissolution process into the solid polymer.  If this mechanism is 
correct, the NO release profile (such as NO release rates and longevity of the release) from 
SNAP-doped CarboSil polymer should be dictated by three factors: 1) the SNAP 
concentration in the polymer matrix; 2) the water-contacting polymer surface area exposed 
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to the test solution; and 3) the film thickness of the specific SNAP-doped CarboSil polymer 
formulation.  In theory, NO release rates are controlled by SNAP concentration in the 
polymer and the water-contacting polymer surface area.  The longevity of NO release, on 
the other hand, should be directly proportional to the SNAP loading/concentration and the 
film thickness of a specific SNAP-doped CarboSil polymeric material. 
 
3.4 Results and Discussion 
3.4.1 NO release mechanism 
It has been previously reported that SNAP is stable when doped into low-water uptake 
polymers such as CarboSil 20 80A,6 which is a polyurethane-based triblock copolymer.  
The elevated stability of SNAP in this polymer during storage has been previously ascribed 
to the strong intermolecular interactions between SNAP molecules that forms crystals in 
the bulk of the polymer phase when SNAP concentration exceeds its solubility limit in the 
polymer.  However, the process of how the polymer-crystal composites are formed during 
the casting and drying of the polymer phase as well as understanding what key parameters 
dictate the observed NO release rates from the polymer crystal composites still remains 
unclear. 
 
We hypothesize that the NO release profile of the certain SNAP-doped polymer films are 
related to several factors: the film surface area in contact with aqueous phase, the film 
thickness, and the SNAP concentration within the polymeric film (see Section 3.3 above).  
In this work, to better understand the properties of this new composite material we first 
compared the NO release rates between 10 wt% SNAP-doped CarboSil films (all with 0.7 
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cm diameter) with thicknesses of 260 and 520 µm in PBS buffer.  Of note, all the NO 
release data from CarboSil films were recorded until when the release rate was no longer 
above 0.5 x 10 -10 mol min -1 cm -2, which is the lower end of physiological NO release 
levels by the endothelial cells.19,22–24  As shown in Figure 3.4A, the results demonstrate 
that the NO release levels are not significantly different between the 10 wt% films with 
260 or 520 µm thickness, but the NO release lifetime is much longer for the films with 
twice the thickness.  The overall thickness of the films tested is very small compared to 
their diameter, and increasing the thickness of films to 520 µm only increases the total 
surface area of the films by 6 % when compared to the original films, a relatively small 
increase.  However, the NO release levels of the 5 wt% SNAP-doped films are nearly half 









Figure 3.4. The NO release comparison between 10 wt% SNAP-doped CarboSil films with 
thickness of 260 or 520 µm (A); and 260 µm thick SNAP-doped films with 5 wt% or 10 




Further, to understand whether the NO release rate is determined by the water-contacting 
surface area of the film or simply by the total surface area of the film, the NO release rates 
from three identical 10 wt% SNAP-doped CarboSil films were compared with no gold 
sputtering, one with 400 Å gold film sputtered on its front side, and one with 400 Å gold 
film sputtered on its back side.  The gold coating on either side of the film will prevent 
direct water contact on that side of the films when they are immersed in solution.  As shown 
in Figure 3.5, both of the gold sputtered CarboSil films exhibited half the NO release rate 
when compared to the non-coated films.  This demonstrates that the NO release rate from 
SNAP-doped CarboSil films is controlled by the total water-contacting surface area of the 
polymer film. It also suggests that the water rich layer in the outermost surfaces of the 







Figure 3.5. The NO release comparison between 10 wt% SNAP-doped CarboSil films with 
no gold film coating (square), front side 400 Å gold coating (triangle) and back side 400 Å 
gold coating (circle). 
 
From the results described above, the factors that control the NO release levels and 
longevity of release are summarized as follows.  Firstly, the results indicate that NO release 
levels do not increase as the thickness of the film increases, because the water-contacting 
surface area and the SNAP concentration in the film are the rate determining factors 
dictating the observed NO release kinetics.  Secondly, if the water-contacting surface area 
remains the same, the NO release rate decreases as the SNAP concentration decreases.  
Thirdly, the longevity of NO release from a given film is determined by the SNAP 




3.4.2 SNAP decomposition in solution 
We recently reported that when SNAP is doped into CarboSil 20 80A, 3.4-4.0 wt% of 
SNAP is dissolved in the polymer phase while any additional SNAP above this solubility 
threshold exists as crystals embedded within the polymer matrix 6.  It appears that the 
SNAP that is solubilized in the polymer matrix, analogous to SNAP dissolved in a solvent, 
is more reactive and more likely to decompose and releases NO, than crystalline SNAP 
that is stabilized by strong hydrogen bonding 6 as well as the low water uptake nature in 
the bulk region of the polymeric phase.  SNAP decomposition in liquid solution is 
investigated herein to determine SNAP stability in various solvents.  Such, solution phase 
decomposition experiments of SNAP in various solvents were conducted at 60 °C, in order 
to accelerate the decomposition and observe obvious signal changes over a short time 
period.  The SNAP concentrations in various solvent solutions were monitored by UV-Vis 
absorbance spectroscopy.  As illustrated in Figure 3.6, all decomposition reactions 
exhibited pseudo-first-order behavior relative to SNAP levels at low concentrations.  All 
experimental data fit into first-order reaction equation N$ = NLOB'$ + Q, where N$ is the 
concentration of reactant at time R , NL  is the initial concentration, #  is the first-order 




Figure 3.6. SNAP decomposition (formation of NO) in various solvents at 60 °C 
represented by absorbance of SNAP at 380 nm versus time (s).  The decomposition of 
SNAP in solvent is a pseudo-first-order reaction.  All decomposition reactions were fit into 
the equation A t = A 0 exp −kt + c , where A t  represents the concentrations of 
SNAP at time t, A 0  represents the initial concentration, k is the reaction rate coefficient, 
and c is the correct constant for instrumental system error. 
 
In agreement with previously reported results, in PBS without EDTA, the decomposition 
of SNAP is accelerated, due to the presence of trace levels of metal catalysts, such as Cu2+ 
ions.52,53  In PBS-EDTA solution, EDTA chelates any copper ions, and as a result, the rate 
constant of SNAP decomposition in PBS-EDTA is comparable to those in the other 
selected organic solvents, with half-lives all within a 3 h period (see Table 3.1).  When 
SNAP is in the CarboSil polymer “solid solution”, the SNAP decomposition is primarily 





Table 3.1. The reaction rate constants of SNAP decomposition in various solvents at 60 
°C. 
Solvent Reaction rate constant (10-7 s-1) Half-life (min) 
PBS (without EDTA) 1389 ± 3 83 ± 0 
PBS with EDTA 721 ± 0 160 ± 0 
EtOH 852 ± 7 136 ± 1 
THF 845 ± 11 137 ± 2 
MeOH-MEK 820 ± 2 141 ± 3 
 
 
3.4.3 SNAP crystallization process in CarboSil polymer 
It was proposed in our previous work 6 that during solvent evaporation, as the amount of 
the solvent decreases, SNAP eventually reaches to its saturation in CarboSil and then 
crystallizes.  As a follow-up, the crystallization of SNAP within CarboSil polymer was 
observed in situ by optical microscopy while the evaporation of the THF solvent was 
monitored by weight measurements.  Significant loss of weight was observed in the first 





Figure 3.7. The weight of 8 wt% SNAP-CarboSil (dissolved in THF) droplet (mg) 
decreases over time, as the polymer-crystal composite forms during the solvent evaporation. 
 
Formation of SNAP crystals was first visually detected after 40 min, when most of THF 
has evaporated, followed by rapid crystal growth. Such behavior is analogous to 
crystallization in a supersaturated liquid solution, except that the “solvent” for SNAP is the 
solid CarboSil polymer, once most of the THF has evaporated.  As THF evaporates, SNAP 
reaches its solubility limit in CarboSil and then forms a supersaturated solid “solution”.  
Once crystalline seeds form, crystal growth is relatively fast, as shown in Figure 3.8, which 
can stem from the mobility of SNAP molecule in the presence of any remaining THF 
solvent in the polymer.55–57  This crystallization process observed experimentally in real 




















Figure 3.8. Optical images of SNAP crystallization in CarboSil by evaporation.  The first 
image was the one taken after 25 min of solvent evaporation, followed by images captured 
at 10 min interval. 
 
3.4.4 Study of antimicrobial efficiencies 
To evaluate the potential of NO releasing catheters being used as antimicrobial devices, 
including both intravascular and urinary catheters, we examined the antimicrobial 
properties of CarboSil catheters (2 mm i.d. and 4 mm o.d.) containing 20 wt% SNAP 
against two common infection-causing bacteria: P. aeruginosa and P. mirabilis.  P. 
aeruginosa has been reported to be one of the leading bacterium that causes catheter-related 
blood stream infections, and represents 16% of all the CRBSI cases.58,59  Infections caused 
25 min 35 min 45 min 55 min 
65 min 75 min 85 min 95 min 
105 min 115 min 125 min 135 min 
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by P. aeruginosa also often occur in patients already battling with more severe illness, e.g., 
extensive trauma, burns, or malignancy.60  It is very important to examine the antimicrobial 
effect of NO against this particular strain of bacteria because P. aeruginosa possesses NO 
reductase enzyme that may enable the bacteria cells to metabolize and deactivate NO, by 
converting NO to nitrous oxide (N2O) and ultimately to nitrogen.61–63  On the other hand, 
the primary bacterium associated with persistent and complicated catheter-associated 
urinary tract infections (CAUTIs) is P. mirabilis,3,64,65 which is also known for its ability 
to elevate urine pH, induce calcium/magnesium phosphate precipitation and produce 
mature crystalline biofilms.3,64,66  The CDC biofilm reactor, a laboratory biofilm reactor 
system, was used in this study since it provides a good model system that offers an 
environment that mimics the bacterial growth on the polymer surface under moderate fluid 
sheer stress.67  The 20 wt% SNAP-doped CarboSil catheters can release NO at levels > 0.5 
x 10 -10 mol cm-2 min -1, the lower end of endothelial NO flux levels, for 3 weeks under 
physiological conditions (Figure 3.9).  Such long-term (21 d) continuous and stable NO 





Figure 3.9. NO release from 20 wt% SNAP-doped CarboSil catheters with CarboSil 
topcoats in PBS at 37 °C for 21 d.  Data are mean ± SEM (n=3). 
 
As shown in Figure 3.10, for P. aeruginosa, there was a 2 log-unit reduction in the number 
of viable bacteria adhered on the surface of the SNAP catheters after 14 d compared with 
other groups and there was no significant difference in the adhesion of bacteria on the three 
control groups, including NAP-doped catheters, indicating the bactericidal effect of the 
SNAP CarboSil catheter is solely related to the NO being released during the experiments.  
These findings were substantiated by the fluorescence imaging data, in which all three 
control catheter surfaces were covered by high biomass mature biofilm formed by live 
bacteria (green) while the SNAP catheter surfaces had noticeably less bacterial coverage 
and most of bacteria on SNAP catheter surfaces were either single or dead (red) bacteria 
cells.  It should be noted that during the process of forming mature biofilm, bacteria cells 
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that are located within the biofilm experience nutrient limitation, which can result in a 
stationary phase-like dormancy 68,69 or irregular shapes.70 
 
 
Figure 3.10. Upper image:  Bar graph of plate count data for adhesion of viable P. 
aeruginosa bacteria to the surfaces of silicone/CarboSil catheters run in CDC bioreactor 
for 14 d.  Lower images: fluorescence microscopic images of surface live (green) and dead 
(red) bacteria on different catheters, silicone catheters (A), CarboSil catheters (B), NAP-
doped CarboSil catheters (C), and SNAP-doped CarboSil catheters (D) (n=4 for each 




Results for the 14 d P. mirabilis biofilm culture experiments exhibited a 3 log-unit 
difference in adhered bacterial cell viability between SNAP catheters and the three 
different groups of control catheters (see Figure 3.11).  The fluorescence imaging data also 
show that bacterial coverage on the NO releasing catheter is noticeably less than the three 
controls.  Clearly, these results demonstrate that overcoming bacteria colonization and 
biofilm formation on the surfaces of NO releasing catheter through continuous NO release 
represents an innovative and highly desirable approach to prevent bacterial biofilm 
formation, reduce risks associated with catheter-related bloodstream infections and urinary 
catheter infections. Hence, the use of SNAP-doped CarboSil catheters should ultimately 












Figure 3.11. Upper image:  Bar graph of plate count data for adhesion of viable P. mirabilis 
bacteria to the surfaces of silicone/CarboSil catheters run in CDC bioreactor for 14 d.  
Lower images: fluorescence microscopic images of surface live (green) and dead (red) 
bacteria on different catheters, silicone catheters (A), CarboSil catheters (B), NAP-doped 
CarboSil catheters (C), and SNAP-doped CarboSil catheters (D) (n=4 for each condition) 
and their representative fluorescence images; scale bar 20 µm. 
 
3.5 Conclusion 
In summary, in this work we have provided the first real-time observation of the formation 
of SNAP crystallization within a polymer phase that creates a unique composite material 
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for potential biomedical applications.  SNAP crystals form and become embedded within 
CarboSil polymer when the SNAP concentration increases and exceeds its solubility during 
organic solvent (e.g., THF) evaporation.  It is also clear that in addition to the SNAP 
concentration in the polymer matrix, the NO release profile (level of NO release and 
longevity of NO release) from such polymers is directly related to the water-contacting 
polymer surface area and the thickness of specific SNAP-doped CarboSil polymeric 
material.  The decomposition of solubilized SNAP is a pseudo-first-order reaction 
proportional to the SNAP concentration.  The SNAP-doped CarboSil catheters were also 
shown to exhibit significant antimicrobial properties against the bacteria P. aeruginosa and 
P. mirabilis, which are known to be associated with high rates of hospital infections for 
intravascular and urinary cathetersrespectively.  Such an NO release composite material 
provides a cost-effective strategy to potentially improve the antimicrobial properties of 
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CHAPTER 4  
Reduction of Thrombosis and Bacterial Infection via 
Controlled Nitric Oxide (NO) Release from S-Nitroso-N-
acetylpenicillamine (SNAP) Impregnated CarboSil 
Intravascular Catheters 
 
Wo, Y.; Brisbois, E.J.; Wu, J.; Li, Z.; Major, T.C.; Mohammed, A; Wang, X; Colletta, A.; 




Intravascular (IV) catheters are indispensable in modern-day medical practice, especially 
within hospital intensive care units.1,2  They provide necessary vascular access that allows 
doctors to withdraw blood samples, monitor patients, and administrate medicine in a simple
                                                
* The principal experiments of this chapter were conducted by Yaqi Wo, with the help of Dr. Zi Li in 
conducting the solid-state measurements, Dr. Jianfeng Wu in assisting with the microbiology experiments, 
Mr. Terry C. Major and Dr. Azmath Mohammed in carrying out the animal testing, and Mr. Xianglong Wang 
for performing the mechanical strength testing of the NO release materials. 
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 fashion; however, their frequent and prolonged use increase patients’ risk for 
complications such as thrombosis and local or systematic infections.3  Catheter-related 
thrombosis (CRT) is a common complication in patients with long-term indwelling 
catheters,4 and it becomes symptomatic in about 5% of the patients.5  Device-initiated 
thrombus formation can lead to thrombi detachment from the device surface that can travel 
through the vasculature and cause life-threatening obstructions such as pulmonary 
embolism, deep vein thrombosis, stroke or heart attack.2,5,6  Use of systemic anticoagulants 
to prevent CRT is common but not always effective,5 and can increase the risk of causing 
hemorrhage7,8 and/or inducing thrombocytopenia.7 Another major complication associated 
IV catheter placement is infection.1,9–11  Bacterial biofilm, commonly formed on surfaces 
by microbes sticking to each other, are surrounded and protected by a self-produced 
extracellular polymeric matrix.  The presence of biofilm is one of the main causes of 
catheter-related blood stream infections (CRBSIs).3,11,12  Bacterial cells within biofilm are 
significantly more resistant to antibiotics as well as the patient’s innate immune defense 
system than planktonic phase microbes, and the minimal concentration of antibiotics for 
eradication of mature biofilm is typically 10-1000 times higher than for the planktonic 
cells.13,14.  CRBSIs are the most common cause of nosocomial bacteremia,10 and each year 
150 million IV catheters are implanted in the United States,15,16 and 250,000 CRBSIs occur 
annually due to their use.9,16,17  As a result, it has been reported that CRBSIs dramatically 





Many strategies have been suggested in the past to prevent thrombosis and infections from 
occurring on IV catheters, such as using a catheter lock solution that contains anticoagulant 
(e.g., heparin) and/or high concentration of antimicrobial agents (e.g., antibiotics).7,21  
Although there have been some success in clinical trials using these methods,21 others have 
reported no significant differences in thrombosis reduction between when using heparin 
lock solution vs. saline solution.7,22,23  And for most of the studies evaluating antimicrobial 
lock solutions, the treatment was only evaluated based on negative blood sample cultures, 
not the presence or absence of biofilm on the catheter itself, a much more specific infection 
risk indicator.11  Moreover, there are many concerns emerging from the potential toxicity 
to the patient resulting from the diffusion or inadvertent flushing of the lock solution into 
blood circulation,11,24 as well as the development of antimicrobial resistance.11,25   
 
Nitric oxide (NO) is synthesized in the human body from the substrate L-arginine26 and 
participates in a variety of physiological processes, including vasodilation, blood pressure 
regulation, inhibiting platelet activation, maintaining hemostasis in the vasculature, 
immune response, and wound healing.27–30  Nitric oxide can prevent activation of platelets, 
the first step in the coagulation cascade that ultimately leads to thrombus formation.29,31  
Nitric oxide has also been shown to exhibit broad-spectrum antibacterial activity against 
both gram-positive and gram-negative bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA).27,32 NO serves as a bactericidal agent at high levels (200 
ppm of gaseous NO),33–35 but low levels of  NO (picomolar to nanomolar range in solution 
phase) are also a key signaling molecule and mediator in bacterial quorum sensing to 
minimize bacterial adhesion and disperse biofilm formation.36,37  Various S-nitrosothiols 
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(RSNOs) are leading candidates as NO donors for incorporation into biomaterials for 
controlled NO delivery, due to their relatively high stability, and ability to release NO 
under physiological conditions.38–40  S-nitroso-N-acetylpenicillamine (SNAP) is a 
particularly attractive RSNO species for creating NO releasing biomedical devices because 
of its low cost, safety (e.g., penicillamine is an FDA approved drug41), and potential for 
long-term NO release applications when it is incorporated into biomedical polymers with 
very low water uptake.42,43  
 
Recently, our lab has developed a very simple impregnation procedure in which SNAP can 
be impregnated into commercial silicone rubber Foley urinary catheters to achieve long-
term NO release capabilities (> 30 d).44  In this previous work, Colletta et al. obtained 5.43 
wt% of SNAP-within the silicone Foley catheter by impregnating the tubing for 24 h in a 
125 mg/mL SNAP solution prepared in THF.  The antimicrobial efficiency of the NO 
releasing Foley catheters was demonstrated toward several strains of bacteria associated 
with catheter associated urinary tract infections.  In follow-up work, Brisbois et al. reported 
the impregnation of commercial Tygon formula 3350 silicone tubing using 25 mg/mL of 
SNAP in THF for 24 h and then used the tubing for preparing extracorporeal circuits 
(ECC).  These NO releasing ECC loops exhibited improved blood compatibility over 
corresponding controls without NO release in a 4 h rabbit thrombogenicity model.45   
 
It is well known that molecular interactions between polymer surfaces and protein 
molecules determine the biocompatibility of a polymer46 and the innate hemocompatibility 
of the polymer that contacts blood can greatly influence its ultimate efficacy in preventing 
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thrombus formation.47  Indeed, Handa et al. evaluated the intrinsic hemocompatibility of 
four different biomedical grade polymers in vivo and the results demonstrated that 
polyurethane copolymers (such as Elast-eon E2As, a block copolymer of polyurethane and 
polydimethylsiloxane) have enhanced inherent hemocompatibility compared to the other 
polymers, including polyurethanes (e.g., Tecoflex SG-80A) and poly (vinyl chloride) 
(PVC).47  CarboSil 20 80A, similar to Elast-eon E2As, is a tri-block copolymer of 
polyurethane, poly(dimethylsiloxane) and polycarbonate, synthesized from hard segments 
4,4’-methylene bisphenyl diisocyanate with glycol chain extender and soft segments of 
aliphatic polycarbonate and poly(dimethylsiloxane).46  Studies have shown that there is a 
strong interaction between fibrinogen and CarboSil polymer surface when fibrinogen is 
adsorbed onto CarboSil and very few conformational changes of the adsorbed fibrinogen 
is observed,46 which is an important step in preventing thrombus formation in the 
coagulation cascade initiated by protein adsorption.27  Therefore, CarboSil is a very 
attractive material for preparing IV catheters owing to its enhanced innate 
hemocompatibility.43,46  IV catheters or other biomedical devices made with NO releasing 
CarboSil should have more enhanced efficacy in reducing platelet activation and thrombus 
formation than CarboSil alone.  Of note, the impregnation method described earlier44,45 
was developed for silicone rubber and THF is a good solvent for silicone since it can swell 
the tubing to ca. 1.3 times its original size.45  However, the compatibility between various 
solvents and polymers are quite different in different scenarios.48  For example, since THF 
is known to be able to dissolve instead of swell CarboSil polymer,43 different solvents need 
to be selected in order to adapt this methodology to CarboSil.  Moreover, many other 
aspects of the previously reported impregnation process (e.g., the SNAP concentration, 
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impregnation time, etc.) needs to be optimized to achieve the best efficiency for SNAP 
impregnation into CarboSil.  Herein, we report our effort to modify the SNAP impregnation 
method to transform premade dip-coated CarboSil 20 80A IV catheters into NO releasing 
catheters.  The optimized SNAP impregnation process and material characterization 
(including solid-state analysis of the SNAP within the CarboSil polymer) are described in 
detail.  The resulting catheters are further evaluated for their antimicrobial efficacies in 
vitro against Staphylococcus epidermidis 16,49,50 and Pseudomonas aeruginosa,10 two 
bacteria that are commonly reported to cause CRBSIs.  In addition, the IV CarboSil 
catheters are also evaluated within the jugular veins of rabbits to examine their 
effectiveness at preventing thrombus formation. 
 
4.2 Experimental Section 
4.2.1 Materials 
N-Acetyl-D-penicillamine (NAP), sodium nitrite, L-cysteine, sodium chloride, potassium 
chloride, sodium phosphate dibasic, potassium phosphate monobasic, copper (II) chloride, 
ethylenediaminetetraacetic acid (EDTA), tetrahydrofuran (THF) and N,N-
dimethylacetamide (DMAc) were purchased from Sigma-Aldrich (St. Louis, MO).  N-
Acetyl-D,L-penicillamine disulfide (NAP disulfide) was obtained from Enzo Life Science, 
Inc. (New York, NY).  Methanol (MeOH), methyl ethyl ketone (MEK), hydrochloric acid, 
sulfuric acid, Luria Bertani (LB) broth and LB agar were products of Fisher Scientific 
(Hampton, NH).  CarboSil 20 80A was obtained from DSM Biomedical Inc. (Berkeley, 
CA).  An Agilent ZORBAX rapid resolution high definition (RRHD) Eclipse Plus C18 
column (2.1 x 50mm, 1.8 µm particle size) was purchased from Altmann Analytik GmbH 
 
 149 
& Co.KG (Munich, Germany).  All aqueous solutions were prepared with 18.2 MΩ-
deionized water using a Milli-Q filter from EMD Millipore (Billerica, MA).  Phosphate 
buffered saline (PBS), pH 7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium 
phosphate, and 100 µM EDTA was used for all in vitro experiments.  S. epidermidis ATCC 
14990 and P. aeruginosa ATCC 27853 were obtained from the American Type Culture 
Collection (ATCC) (Manassas, VA). 
 
4.2.2 Preparation of SNAP-impregnated films and catheters 
SNAP was synthesized as previously reported.42,43,51  In brief, an equimolar ratio of NAP 
and NaNO2 was added to a 1:3 mixture of water and methanol containing 2 M H2SO4 and 
2 M HCl.  The reaction vessel was placed in an ice bath for 5 h while the green SNAP 
crystals precipitated.  The crystals were collected by vacuum filtration, rinsed with iced DI 
water to remove any residues and allowed to air dry for 24 h before being stored in the 
freezer at -20 °C.  The entire synthesis process was performed in the absence of ambient 
light.  
 
In order to determine the ideal solvent combination for optimal SNAP impregnation into 
CarboSil, a series of solvents were screened for their ability to swell CarboSil polymer 
pellets and dissolve SNAP.  The swelling capability of the solvents was reported in percent 
as equation 4.1: 
swelling ratio (%) = (Rafter-Rbefore)/Rbefore x 100                                                             [4.1] 
where Rbefore and Rafter are the radius of the polymer pellets before and after the solvent 




Polymer films containing various wt% of SNAP were prepared by solvent impregnation.  
First, 200 mg of the CarboSil polymer was dissolved in 2 mL THF and then cast in a Teflon 
ring (d = 2.5 cm) on a Teflon plate and left to dry overnight under ambient condition to 
obtain the blank polymer films.  Small disks (d = 0.7 cm) were cut from the parent films 
and used as blank films.  Some blank CarboSil films were impregnated in SNAP solutions 
(120 mg/mL) in 30 % MeOH and 70 % MEK for different lengths of time and the amount 
of SNAP (wt %) in the final films were analyzed to obtain time needed to achieve 
maximum SNAP impregnation into the polymer films.  The CarboSil films were also 
treated with solutions containing different concentrations of SNAP (5.5 – 120 mg/mL) for 
2 h to achieve a polymer impregnation profile in regard to the SNAP concentration in the 
impregnation solution.  
 
The catheters used in the in vitro and in vivo experiments were prepared by dip coating 
CarboSil polymer solution on 20 cm long stainless steel mandrels of 1.0 mm diameter 
(McMaster Carr, IL).  The control catheters and SNAP catheters were preparing by dip 
coating 22 coats and 20 coats of polymer solution at 2 min intervals between each coat, 
respectively.  All catheters were allowed to dry overnight under ambient conditions, 
protected from light, and then removed from the mandrel.  Similar to the SNAP-
impregnated films, the SNAP-doped catheters were also prepared by soaking in a SNAP 
solution (120 mg/mL) for 2 h.  Then the catheters were removed from the solution, rinsed 
with MeOH to wash off the residual SNAP solution on the surfaces, and then allowed to 
air dry overnight to allow the MeOH and MEK solvents to evaporate further, while the 
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SNAP remains in the catheter.  To achieve a smoother surface after impregnation and to 
prolong NO release, two coats of plain CarboSil polymer solution were applied to the outer 
surface of the SNAP-impregnated catheters by dip-coating to achieve a total of 22 coats.   
All the cured films and catheters were dried under vacuum for additional 48 h to remove 
solvents more thoroughly.  The resulting catheters have an i.d. of 1 mm and an o.d. of 2.2 
mm. 
 
4.2.3 Characterization of SNAP-impregnated films and catheters 
4.2.3.1 UV-Vis 
All UV-Vis spectra of solvent dissolved pieces of known mass of the films or catheters (in 
DMAc) were recorded in the wavelength range of 250 nm - 650 nm with a UV-Vis 
spectrophotometer (Lambda 35, Perkin-Elmer, MA) at room temperature.  The molar 
absorptivity of SNAP in PBS at 340 nm was determined as εSNAP= 1075 M-1 cm-1.  The 
characteristic absorbance at 340 and 590 nm correlate to the π à π* and nN à π* electronic 
transitions of the S-NO functional group.52,53 
 
4.2.3.2 NO release measurement from SNAP-impregnated catheters 
Nitric oxide release from the SNAP-impregnated CarboSil catheters was measured using a 
Sievers chemiluminescence Nitric Oxide Analyzer (NOA) 280i (Boulder, CO).  For 
example, a 15 wt% SNAP-impregnated CarboSil catheter with 2 CarboSil topcoats was 
placed in the sample vial containing 4 mL of 10 mM PBS, pH 7.4, with 100 µM EDTA at 
37 °C to mimic physiological conditions.  Nitric oxide was continuously generated and 
immediately purged and swept into the chemiluminescence detection chamber by a N2 
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sweep gas and bubbler.  All catheters were placed in fresh PBS buffer during NO release 
measurements and incubated at 37 °C in the absence of ambient light after each 
measurement.  The reported NO flux was the average flux during 4 h of NO release 
measurements for each time point. 
 
4.2.3.3 Cumulative NAP, NAP disulfide and SNAP leaching from SNAP-impregnated 
catheters in soaking PBS buffer 
The cumulative leaching of NAP, NAP disulfide and SNAP from the impregnated catheters 
into 10 mM PBS, pH 7.4, with 100 µM EDTA at 37 °C were analyzed using liquid 
chromatography-tandem mass spectrometry (LC-MS), as previously described in detail.43  
Briefly, 15 wt% SNAP-impregnated CarboSil catheters were incubated in 10 mL PBS 
buffer, pH 7.4, with 100 µM EDTA in the dark at 37 °C to minimize trace metal catalyzed 
decomposition of SNAP.  At various time points, aliquots (15 µL) of the soaking solution 
were analyzed for the amount of NAP, NAP disulfide and SNAP in the soaking buffer.  
The total amount of SNAP-related species is calculated from the following equation 4.2: 
 
 [all SNAP-related species]total = [SNAP]total + [NAP]total + 2 x [NAP disulfide]total.    [4.2]   
 
The soaking buffer was replaced with new buffer immediately after the measurement.  The 
total amount of NAP, SNAP and SNAP disulfide leached from the catheter was determined 




4.2.3.4 Evaluation of the mechanical properties for catheters before and after impregnation 
Four different catheters (5 cm) were prepared for mechanical property tests, including the 
original CarboSil catheters prepared by dipcoating, CarboSil catheters swelled by solvents 
only (and then dried), CarboSil catheters impregnated with 7 and 15 wt% SNAP, 
respectively.  Tensile testing of the catheters was performed on an Instron 8800-series 
machine with Bluehill software (Instron, Norwood, MA).  To achieve a better grip on the 
catheters, the catheters were cut in halves along the axial direction before testing.  The 
catheters had an initial gauge length of 11.55 mm and were pulled at an extension rate of 
40 mm/min, corresponding to a strain rate of 0.0593 s-1.  The tensile strength (MPa) and 
maximum elongation (elongated length over the length of the original) were compared for 
each of the catheter materials tested. 
 
4.2.3.5 Polarized microscope images 
SNAP-impregnated polymer films with 5 wt% SNAP loading and a blank reference film 
of CarboSil, both without topcoats, were prepared as described above. Optical images were 
captured by a Leica DM2500 LED Microscope (from Leica Microsystems 2016) with a 
20× and a 50× objective under crossed polarizers. The images were taken using the 
Surveyor Software, specifically the 20 x objective image was taken by mosaic imaging and 
the 50 x objective image (insert) was taken by extended depth of field (EDF) imaging.  To 
better observe the crystal distribution within the impregnated CarboSil polymer, very thin 
slices (30 µm in thickness) of cross-sections of the 5 wt% SNAP-impregnated CarboSil 
slices were prepared and observed under the microscope.  The film was first cut to expose 
its cross-section and then embedded into optimal cutting temperature compound (OCT), 
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allowed to harden at -20 °C, and then cut carefully into 30 µm thick slices by the Leica 
CM3050S research cryostat.  The polymer film slices were then observed under the 
microscope plate for crystal distribution. 
 
4.2.3.6 Powder X-ray diffraction measurements  
SNAP-impregnated polymer films with various wt% SNAP loading and a blank reference 
film of corresponding polymer, all without topcoats, were prepared as described in Section 
4.2.2.  Powder X-ray diffraction (PXRD) patterns were collected at room temperature using 
a Rigaku R-Axis Spider diffractometer with an image plate detector and graphite 
monochromated Cu-Ka radiation (l = 1.54187Å) at 40 kV and 44 mA.  Synthesized SNAP 
crystals were finely ground to eliminate preferred orientation, whereas blank CarboSil and 
SNAP-impregnated CarboSil samples were cut into cubes with dimensions of 
approximately 250 µm.  All samples were mounted on a CryoLoopTM using heavy mineral 
oil, and images were collected for 15 min with a 0.3 mm collimator.  The w-axis was 
oscillated between 120° and 180° at 1°/sec, the f-axis was rotated at 10°/sec, and c-axis 
was fixed at 45°.  The obtained images were integrated from 2.5 to 70° with a 0.1° step 
size in AreaMax 2.0 software from Rigaku.  All powder patterns were processed using Jade 
9 XRD Pattern Processing, Identification & Quantification analysis software from 
Materials Data, Inc.  The simulated powder patterns of monoclinic and orthorhombic 
SNAP crystals were calculated in Mercury 3.3 from the CCDC and were compared with 
the experimental SNAP powder pattern in Jade 9.  Quantitation of peak intensity ratios 




4.2.3.7 Effects of ethylene oxide (EO) sterilization 
SNAP-impregnated CarboSil films (15 wt%) were prepared and sent to the University of 
Michigan hospital sterilization facility for ethylene oxide (EO) treatment, a standardized 
procedure for many medical devices used in clinical applications.  Briefly, the films went 
through 1 h of preconditioning and humidification process, followed by 2-3 h of EtO gas 
exposure, both performed in a high temperature (54 °C) and high humidity environment 
(40-80 %).  After the 1-2 h of EtO gas evacuation (54 °C), the films were subjected to 12 
h of air washes (54 °C).  The amount of SNAP remaining in the films was determined by 
UV-Vis absorbance measurements as previously reported.43   
 
4.2.4 Long-term (14 d) in vitro antibacterial experiments 
A CDC biofilm reactor system (Biosurface Technologies Corp., Bozeman, MT).  was used 
to test the anti-biofilm properties of SNAP/CarboSil catheters against biofilm formed by S. 
epidermidis and P. aeruginosa.  The CDC biofilm reactor, its coupon holders and all other 
connection tubing were autoclaved before use.  The EO sterilized catheters were first 
mounted onto the coupon holders within the reactor and the reactor was then supplemented 
with sterile nutrient medium (10% Luria Broth) inoculated with overnight bacteria culture 
(1 to 100 dilution, ~1 × 106 CFU/mL) for 1 h to allow bacterial cell adhesion on the catheter 
surfaces.  The continuous flow of LB broth was controlled at the flow rate of 100 mL/h by 
a peristaltic pump for 14 days, at 37 °C.  The liquid medium was circulated through the 
vessel and a magnetic stir bar rotated by a magnetic stir plate was used to generate shear 
force.  After incubation for 14 d, the catheters were aseptically removed and each catheter 
was cut into two 1 cm pieces, that were used for plate counting and imaging, respectively.  
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For plate counting, the catheter segment was homogenized (OMNI TH, Omni International, 
Kennesaw, GA) for 30 s in 2 mL of 10 mM sterile PBS (pH 7.4) in order to disintegrate 
the biofilm to a suspension of isolated cells, which was then diluted by 10-fold each time 
and plated onto LB agar plates.  For imaging, the catheter segment was stained with 
Live/Dead BacLight Bacterial Vaiability kit (Invitrogen, Carlsbad, CA) for 20 min in the 
dark, exactly per the kit’s instructions.  Fluorescence images were acquired with an 
inverted fluorescence microscope (Olympus IX71, Center Valley, PA) equipped with 
Fluorescence Illumination System (X-Cite 120, EXFO) and filters for SYTO-9 (excitation 
= 488 nm/emission = 520 nm) and Propidium Iodide (excitation = 535 nm/emission = 617 
nm).  Images were obtained using an oil immersed 60× objective lens, in which red 
indicates dead and green indicates live bacteria. 
 
4.2.5 In vivo antithrombotic evaluation of intravascular catheter in rabbit model 
All animal handling and surgical procedures employed in this research were approved by 
the University of Michigan Committee on the Use and Care of Animals in accordance with 
university and federal regulations.  A total of 3 New Zealand white rabbits (Covance, Battle 
Creek, MI) were used in this study.  All rabbits (2.5-3.0 kg) were initially anesthetized with 
intramuscular injections of 5 mg/kg xylazine injectable (AnaSed® Lloyd Laboratories 
Shenandoah, Iowa) and 30 mg/kg ketamine hydrochloride (Hospira, Inc. Lake Forest, IL).  
Maintenance anesthesia was administered via isoflurane gas inhalation at rate of 1.5-3% 
by mechanical ventilation via a tracheotomy and using an A.D.S 2000 Ventilator (Engler 
Engineering Corp. Hialeah, FL).  Peek inspiratory pressure was set to 15 cm of H2O) and 
the ventilator flow rate was 8 L/min.  To facilitate the maintenance of blood pressure 
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stability, IV fluids of Lactated Ringer’s were given at a rate of 10 mL/kg/h.  In order to 
monitor blood pressure and to collect intermittent blood samples for analysis during the 
experiment, the rabbit’s right carotid artery was cannulated using a 16-gauge IV 
angiocatheter (Jelco®, Johnson & Johnson, Cincinnati, OH).  The blood pressure and 
derived heart rate were monitored by a Series 7000 monitor (Marquette Electronics 
Milwaukee, WI) while the animal body temperature was monitored with a rectal probe and 
maintained at 40 °C using a water-jacketed heating blanket.  Sample blood analysis (arterial 
blood pH, PCO2, PO2, total hemoglobin and methemoglobin) was conducted using an ABL 
825 blood-gas analyzer and an OSM3 Hemoximeter (Radiometer Copenhagen, DK).  Prior 
to the placement of catheters, the rabbit left and right external jugular veins were isolated.  
Five cm lengths of the catheters (one SNAP and one control) were inserted into the veins.  
The animals were not treated with anticoagulant systemically during the experiments. 
 
During the experiment, the mean arterial pressure (MAP) of the rabbit was maintained at 
35 ± 5 mmHg for 7 h by continuous IV fluid maintenance.  The heart rate average was 225 
± 10 beats/min and no significant change was noted for the duration of experiments.  The 
blood gas was measured once every hour and the results were all within the normal ranges.  
Rabbit whole blood samples were collected in non-anticoagulated 1 cc syringes for 
activated clotting times (ACT) analysis at the beginning of the experiments.  The whole 
blood samples were also collected by 1 cc heparinized syringes (40 U/mL of sodium 




After 7 h of catheter implantation, all animals were first given (400 U/kg) sodium heparin 
(APP Pharmaceuticals, LLC Schaumburg, IL) systemically to prevent thrombosis during 
necropsy and were then euthanized with a dose of Fatal Plus (130 mg/kg sodium 
pentobarbital) (Vortech Pharmaceuticals, Dearborn, MI).  The jugular veins were clamped 
and the catheters were carefully removed from the vein, leaving the thrombus intact on the 
catheter surface.  After rinsing the catheter with saline, any residual thrombus was 
photographed and quantitated using Image J imaging software provided by the National 
Institutes of Health (Bethesda, MD).   
 
4.2.6 Statistical analysis 
All experiments were conducted in triplicate.  Data are all expressed as mean ± SEM 
(standard error of the mean).  Comparison of means using student’s t-test was utilized to 
analyze the statistical differences between SNAP-doped catheters and control catheters.  
Values of p < 0.05 were considered statistically significant for all tests. 
 
4.3. Results and Discussion 
4.3.1 Study of SNAP impregnation process of CarboSil polymer films 
In order to achieve desired SNAP loading into the CarboSil polymer, an ideal solvent or 
solvent mixture needs to be employed that has the following properties: 1) high solubility 
of SNAP; 2) ability to significantly swell CarboSil polymer without harming the material; 
and 3) evaporate to dryness in a reasonable time period.  Therefore, a series of solvents 
were examined for their ability to swell the CarboSil polymer pellets as well as their SNAP 
solubility limit.  The swell ratio (Rafter-Rbefore)/Rbefore x 100) of solvents were compared and 
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methyl ethyl ketone (MEK) was found to exhibit the highest swell ratio of 166 ± 9 % (with 
155 ± 4 % for acetone, 135 ± 3 % for ethyl acetate and 110 ± 3 % for methanol (MeOH)).  
However, solubility tests indicated that the SNAP solubility is only 30 mg/mL in MEK, 70 
mg/mL in acetone, and 30 mg/mL in ethyl acetate, but 330 mg/mL in MeOH.  As a result, 
a combination of MEK and MeOH was studied in order to determine the optimal solvent 
composition for maximized SNAP impregnation into CarboSil films and catheters, without 
destroying the structure of polymer. 
 
To optimize the MEK/MeOH solvent mixture for impregnation, CarboSil polymeric 
materials (pellets, films or catheters) were totally immersed into various MEK/MeOH 
swelling solutions (see Figure 4.1), then the material was removed from the swelling 
chamber, quickly rinsed with MeOH and DI water to decrease any residue on the surface, 
and then air dried in the ambient environment protected from light exposure.   
 
Figure 4.1. The schematic process of SNAP impregnation into CarboSil polymeric 
material using a CarboSil catheter as an example. 
 
After this process, the polymer material was weighed, and then the impregnated polymer 
was dissolved in DMAc for UV-Vis absorbance measurements to determine the total 
amount of SNAP incorporated into the final CarboSil material.  The results shown in Figure 
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4.2 demonstrate that the optimal solvent combination is 70 % MEK and 30 % MeOH 
(volume ratio).  However, 90 % MEK, 10 % MeOH and 80 % MEK, 20 % MeOH can 
technically incorporate more total SNAP into the CarboSil polymer, but the polymer pellets 
were easily destroyed and cracked apart during the drying process using these ratios of 
solvents.   
 
Figure 4.2. The weight percentage (wt%) of SNAP achieved in CarboSil pellets (mg 
SNAP/mg impregnated CarboSil pellet × 100%) using different solvent mixtures for the 
impregnation process. 
 
As shown in Figure 4.3, the amount of SNAP impregnated into CarboSil can be modulated 
and the level directly correlates with the concentration of SNAP employed in the swelling 
solution (70 % MEK and 30 % MeOH).  Indeed, the wt% of SNAP in the final CarboSil 
material increased from 2.5 % to 15.7 % in near linear fashion when the SNAP 































Figure 4.3. The wt % SNAP impregnated in the final CarboSil polymer films correlated 
with the SNAP concentration in swelling solution consisting of 70% MEK and 30% MeOH 
and various concentrations of SNAP. 
 
To study the SNAP impregnation kinetics as a function of polymer film thickness and to 
determine the time required to achieve maximum impregnation, blank CarboSil films of 
both 250 µm and 500 µm in thickness were prepared.  The films were then soaked into a 
solution of 120 mg/mL SNAP in 70 % MEK/30 % MeOH (n=3 for each condition), for 1, 
2, 3, 5, 10, 30, 60, 90, 120 and 150 min, respectively.  After thorough drying, the films 
were weighed and then dissolved in DMAc to quantify the SNAP wt % within the films.  
The impregnation profile (Figure 4.4) indicated that the maximum impregnation is 
achieved within 2 h, and there is no significant difference between 250 µm thick films and 
































incorporating SNAP into various sized catheters (different wall thicknesses, etc.) without 
requiring any significant additional time to the impregnation process. 
  
Figure 4.4. The kinetics of SNAP impregnation in CarboSil film using 120 mg/mL SNAP 
in swelling solution (70% MEK and 30% MeOH), with respect to swelling time and 
polymer thickness.  The results indicate that maximum SNAP incorporation is achieved 
within 2 h of swelling and there is no significant difference in loading when using films 
with different thickness (250 µm vs. 500 µm). 
 
4.3.2 Solid-state analysis of SNAP-impregnated CarboSil polymer system 
Our group has previously reported solid-state studies of SNAP-doped CarboSil films 
formed by casting a THF solution containing SNAP and CarboSil polymer into a Teflon 
plate and allowing the solvent to completely evaporate.43  The elevated shelf-life stability 
of SNAP in CarboSil was only observed when the SNAP level within the CarboSil exceeds 






























polymer matrix.  In this work that demonstrates the SNAP impregnation approach using 
premade CarboSil films, similar solid-state characterizations were conducted to examine 
the resulting films.  As shown in Figure 4.5, clear SNAP crystalline patterns were observed 
for the 5 wt% SNAP-impregnated samples under a polarized microscope, indicating to the 
presence of SNAP crystals in the polymer matrix at this SANP concentration.   
 
Figure 4.5. Optical image of A) blank CarboSil film and B) 5 wt% SNAP-impregenated 
CarboSil film surfaces taken under crossed polarizers in combination with a quarter-wave 
plate.  The 5 wt% films present patterns which suggest the presence of crystalline SNAP 
in the polymer.  
 
Additional microscope images of the cross-section of the SNAP-impregnated CarboSil 
films were also taken to determine if SNAP impregnated into the bulk polymer matrix or 
if the crystals exhibit depth dependent distribution when they are formed after the solvent 
evaporates.  Thin slices (30 µm) of the cross-section of 5 wt% SNAP-impregnated CarboSil 
films were obtained by using the Leica 3050S cryostat.  Figure 4.6 shows examples of the 
optical images of the cross section of the film, which clearly illustrate that SNAP crystals 
are distributed relatively uniformly within the polymer matrix after impregnation, rather 





Figure 4.6. Representative optical images of the cross section of 5 wt% SNAP-
impregnated. The images were captured by Leica DM2500 LED microscope with a 20× 
and a 50× (inset) objective under crossed polarizers.  The cross-section of film samples 
was cut into 30 µm thick slices by the Leica 3050S cryostat.  The SNAP was impregnated 
successfully into the bulk of the polymer film and distributed relatively evenly throughout 
the cross-section. 
 
In principle, SNAP’s solubility limit in the CarboSil polymer should be constant regardless 
of preparation methodology, e.g., casting polymer solution or solvent impregnation.  The 
PXRD patterns of the CarboSil films impregnated with various loading of SNAP were 




Figure 4.7. Representative PXRD patterns of orthorhombic SNAP crystal, CarboSil blank 
polymer, and CarboSil impregnated with SNAP of different weight percentages.  
Characteristic peaks of orthorhombic SNAP were detected in samples.  Peak intensity of 
crystalline SNAP increased with higher loading of SNAP in polymer.   
 
 In our previous work, the solubility of SNAP in CarboSil when SNAP was added into 
polymer solution before casting was calculated by using the ratio of selected SNAP 
crystalline peak area over the total area of the sample pattern.43  Herein the method used to 
calculate the SNAP solubility in the polymers used the ratio of peak heights instead of peak 
area because this is more generally applicable to various polymers that have broad 
diffraction peaks.  In short, based on the following assumptions that (1) crystalline SNAP 
is uniformly distributed in the polymer phase, and (2) that the preferred orientation of 
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SNAP crystals in the polymer could be eliminated by cutting samples into cubes and 
rotating the samples during data collection, the ratio of a specific SNAP crystalline peak 
height over the polymer peak height should be proportional to the ratio of crystalline SNAP 
wt% over the polymer wt % in the sample.  By using the height ratio for quantification, all 
of the other factors that can potentially influence peak intensity (e.g., the volume of the 
sample irradiated by the X-ray source, the exposure time of sample under the X-ray, etc.) 
can be eliminated.  Here, the SNAP solubility in polymer, represented as "J , can be 
calculated from &ef, the height ratio of a SNAP peak over the height of a polymer peak is 







                                                                                      [4.3] 
where tuvwxef and tyJz{|}~ef are the signal intensities of SNAP and polymer in a SNAP 
impregnated polymer sample at angle 2q, obtained in each measurement.  For a PXRD 
pattern of a unit volume sample taken with a unit exposure time, H and I correspond to the 
peak height of pure orthorhombic crystal and blank CarboSil pattern at a given 2q, 
respectively.  When the SNAP weight percentage is ", the height ratio of SNAP peak height 
over CarboSil peak height at a given 2q (&ef ), should be proportional to the weight 
percentage ratio of the undissolved SNAP crystal (" − "J) over the weight percentage of 
CarboSil (1 − ").  By substituting various " and &ef at chosen 2q angles, the solubility "J 
can be determined.  Based on this calculation, the solubility of SNAP in the impregnated 
CarboSil material was found to be 2.4 ± 0.1 wt%, which is significantly lower than the 
result of 4.3 ± 0.3 wt%, calculated from films obtained by casting SNAP and CarboSil 




We attribute the decrease in calculated SNAP solubility to insufficient “dissolution” of 
impregnated SNAP molecules in the polymer to reach its solubility equilibrium in the 
polymer phase during the solvent impregnation method.  When the polymer film is 
prepared by casting dissolved SNAP in a CarboSil solution (in THF),43 the SNAP 
molecules and CarboSil polymer chains are uniformly mixed within the solvent.  Therefore, 
the SNAP molecules are well dispersed in the polymer matrix to form a solid polymer 
solution before the solvent completely evaporates and the solution reaches its SNAP 
solubility limit which ultimately leads to the SNAP crystallization (Figure 4.8A).  However, 
during the swelling-impregnation process, SNAP can only be “inserted” into the space 
between polymer chains when the pre-made CarboSil film is swelled by the MEK/MeOH 
solvent mixture.  The diffusion of SNAP molecules within solid polymers may be less 
efficient compared to the polymer casting method when SNAP and polymer are all 
completely dissolved and well mixed.  In addition, the swelling effect of solvent mixture 
may also vary for different polymer segments.  For example, the interspace between the 
soft segments of CarboSil may be swelled more by the solvent and enable easier 
impregnation of SNAP molecules, which may result in different microenvironments for 
SNAP crystallization at the different polymer segment sites (see Figure 4.8B).  In summary, 
we hypothesize that SNAP cannot diffuse and reach solubility equilibrium in the polymer 
during solvent impregnation as easily as it does when SNAP and polymer are well mixed 
in a solvent, as is in the polymer casting method.  Therefore, SNAP aggregates as crystals 
and forms a polymer crystal composite more readily in the solvent impregnation process 




Figure 4.8. Schematic diagram of SNAP distribution in CarboSil polymer prepared by A) 
casting SNAP and CarboSil polymer solution; and B) polymer solvent impregnation. The 
lines in the diagram correspond to CarboSil polymer chains, the diamonds correspond to 
SNAP molecules, and the dots correspond to solvent used in the preparation. 
 
4.3.3 Mechanical properties tests 
Tension testing was performed in order to assess the changes in mechanical properties 
caused by solvent and SNAP impregnation.  Of note, the Instron machine was not able to 
obtain a firm grip on the original CarboSil catheters during the elongation process with the 
current experimental setup.  Thus, the analysis results below only contain three 





triplicates of each type of sample tested (n=3).  One-way ANOVA results revealed no 
significant difference in tensile strength (p=0.15) or maximum elongation (p=0.42) among 
the three groups (see Figure 4.9).  The results indicate that the catheters are still 
mechanically suitable for biomedical use after the impregnation process. 
 
Figure 4.9. Tensile strength testing (A) and the maximum elongation (B) results for 
CarboSil tubing impregnated by solvents only, and CarboSil tubing with 7 wt% and 15 wt% 




4.3.4 NO release measurement of SNAP-impregnated CarboSil catheters 
The 15 wt% SNAP-impregnated CarboSil catheters with CarboSil topcoats release NO 
above a flux rate of 0.5 x 10-10 mol cm-2 min-1, for 14 d in PBS buffer at 37 °C.  The NO 
release rate from the catheters was quantitated and recorded by chemiluminescence 
measurements.  A burst of NO release (~4 x 10-10 mol cm-2 min-1) was observed on day 0, 
and this correlates with rapid SNAP leaching from the outermost layer of the catheter 
surface into the buffer.  After depletion of the SNAP reservoir in this outermost region, the 
NO release rate drops to its minimal level at day 2 (~1 x 10-10 mol cm-2 min-1) and then 
gradually increases to 4 x 10-10 mol cm-2 min-1 over the next 10 d period (Figure 4.10).  The 
NO release levels then drop below 0.5 x 10-10 mol cm-2 min-1 after d 14, as all the SNAP in 
the bulk of the polymer has decomposed.   
 
Figure 4.10. The NO release profile of 15 wt% SNAP-impregnated CarboSil catheters over 




























As indicated in Section 4.3.2 above, the majority of the SNAP molecules impregnated in 
the catheters are in their crystalline form, and it takes time for the crystalline SNAP 
embedded in the bulk of the polymer to dissolve and release its NO.  We believe that this 
slow crystal dissolution process is the reason for the long-term NO release observed from 
these new SNAP-impregnated CarboSil catheters. 
 
4.3.5 Cumulative leaching of NAP, NAP disulfide and SNAP from SNAP-impregnated 
CarboSil catheters 
The concentrations of NAP, NAP disulfide and SNAP leached from SNAP-impregnated 
CarboSil catheters were monitored by LC-MS using a method previously reported.43  As 
shown in Figure 4.11, 12 % of the initial SNAP (80 nmol/mg polymer) diffuses out of the 
catheter over the 14 d test period.  The rate of SNAP leaching is the greatest in the first few 
hours after introducing the catheter to the soaking buffer, and then a significant lower 
amount of SNAP continues to diffuse into the buffer over the following days.  Similar 
leaching patterns were observed for both NAP and NAP disulfide.  A total of 12 nmol/mg 
polymer NAP and 46 nmol/mg polymer NAP disulfide (2 % and 14 % of the initial SNAP 




Figure 4.11. Cumulative leaching of NAP, NAP disulfide and SNAP into 1 mL of PBS 
(soaking buffer) from 15 wt% SNAP-impregnated CarboSil catheters over a period of 14 
days, at 37 °C in the dark.  Data are mean ± SEM (n=3). 
 
NAP is the parent thiol used in SNAP synthesis, and NAP has been a widely used chelating 
and detoxifying agent for treating patients with heavy metal ion poisoning (e.g., cadmium, 
arsenic and mercury) for many years.54,55  Therefore, NAP and NAP dimer (NAP disulfide) 
emitted from the SNAP catheter into the buffer or blood stream is considered relatively 
safe and unlikely to cause any adverse or toxic response in potential clinical applications.43   
Overall, the total moles of SNAP-related species ([all SNAP-related species]total) leached 
out over the 14 d test period is approximately 28 % of the total NO (in moles) released 

































molecules residing within polymeric matrix.  Since NO is highly reactive in vivo and will 
be rapidly scavenged by surrounding species (e.g., oxyhemoglobin, oxygen),56,57 to achieve 
therapeutic functions of NO, it is essential for the catheters to deliver localized NO release 
at their surface with minimal NO donor leaching.  Based on results from the leaching 
studies, this appears to be the case for the new SNAP impregnated CarboSil biomaterial.  
 
4.3.6 Prevention of mature microbial biofilm formation 
Because stable NO release from biomedical devices is expected to reduce bacterial 
adhesion and proliferation, in vitro antimicrobial experiments were conducted to evaluate 
the efficacy of SNAP-impregnated Carbosil catheters against bacterial infections caused 
by microbes, S. epidermidis and P. aeruginosa, commonly responsible for catheter-related 
blood stream infections.  S. epidermidis has always been regarded as an innocuous and 
commensal inhabitant of healthy mucosal microflora and possesses lower pathogenic 
potential than S. aureus and P. aeruginosa,58 but more recently S. epidermidis has been 
shown to be the most frequent cause of infections on indwelling medical devices.50,59  This 
likely stems from the prevalence of S. epidermidis on human skin which results in a high 
probability of contamination during IV catheter insertion.  It has also been reported that 
the primary virulence factor of S. epidermidis is its potential capability to form high-
biomass biofilm.44,60–62  Moreover, many studies have shown that treatment of S. 
epidermidis biofilm cells with high dose of antibiotics e.g., rifampicin, vancomycin, etc. 
accelerates the emergence of highly resistant cells.16,63,64  Indeed, genome sequence studies 
of S. epidermidis strains isolated from IV catheters in the hospital have expressed specific 
antibiotic resistance genes and required much higher concentrations of antibiotics for 
 
 174 
treatment.50,59,64,65  The cost related to CRBSIs caused by S. epidermidis alone is estimated 
to $2 billion annually in US.66  In contrast, gram-negative bacteria account for ~30 % of 
all episodes of nosocomial bacteremia,67,68 and P. aeruginosa is reported to cause 16 % of 
all the CRBSIs.1,69  Infections caused by P. aeruginosa often occur in patients with more 
serious underlying disease, e.g., extensive trauma.70  Further, it is important to examine the 
antimicrobial effect of NO release catheters against this particular strain of bacteria because 
P. aeruginosa possesses the NO reductase enzyme which makes the bacteria cells able to 
metabolize and deactivate NO, and convert NO to nitrous oxide (N2O) and ultimately 
nitrogen.71,72 
 
The CDC biofilm reactor used in this study provides a model that offers an environment 
that mimics the bacterial growth on the polymer surface under moderate fluid sheer stress.73 
Therefore this methodology was utilized to stimulate bacterial biofilm development on the 
surface of IV catheters in the blood stream.  All SNAP catheters and control catheters were 
initially sterilized by ethylene oxide (EO) and kept antiseptic before use.  Ethylene oxide 
sterilization is a routine procedure for sterilizing clinical appliances within hospitals, 
during which the devices are subjected to high temperature and high humidity level.74,75  
The amount of SNAP remaining in the catheter after EO sterilization was determined to be 
97.4 ± 0.8%, suggesting that SNAP is very stable as crystals embedded within the CarboSil 
polymer during the sterilization process.  The sterilized SNAP catheter segments and 
control catheter segments (n=4) were mounted onto coupons within the CDC bioreactor 
and bacterial biofilms were formed on the surface of both catheters over a 14 d period at 
37 °C.  After that time period, the number of live microbes on the surface of the catheters 
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was determined by plate counting as well as fluorescence imaging.  As shown in Figure 
4.12 and 4.13, the number of viable S. epidermidis and P. aeruginosa adhered on the 
surface of SNAP impregnated catheter segments after 14 d was reduced by 2.0 and 2.5 log 
units, respectively.  These findings were substantiated by the fluorescence imaging data, in 
which the control catheter surfaces were covered by a high biomass biofilm while the 
SNAP catheter surfaces had noticeably less bacterial coverage and most of the bacteria on 
SNAP catheter surfaces were single bacteria cells.  The results demonstrate that decreasing 
bacteria colonization and biofilm formation on the surfaces of SNAP-impregnated 
CarboSil catheter through continuous NO release may lead to reduced risk of catheter-






Figure 4.12. S. epidermidis biofilms developed on catheter segments in a CDC biofilm 
reactor for 14 d at 37 °C.  Upper image:  Bar graph of plate count data for adhesion of 
viable S. epidermidis bacteria to the catheter surfaces.  Lower images: Representative 
fluorescence microscopic images of surface live (green) (A) and dead (red) (B) bacteria on 
different catheters, acquired by oil immersion 60× objective lens of the biofilms on the 




Figure 4.13. P. aeruginosa biofilms developed on catheter segments in a CDC biofilm 
reactor for 14 d at 37 °C.  Upper image:  Bar graph of plate count data for adhesion of 
viable P. aeruginosa bacteria to the catheter surfaces.  Lower images: Representative 
fluorescence microscopic images of surface live (green) (A) and/or dead (red) (B) bacteria 
on different catheters, acquired by oil immersion 60× objective lens, scale bar 20 µm. 
 
4.3.7 Reduction of thrombus formation in rabbit model 
In vivo experiments using an acute 7 h rabbit thrombogenicity model were conducted to 
examine the benefits of the SNAP-impregnated CarboSil IV catheters with respect to 
decreasing clot formation.  One SNAP catheter and one control catheter were placed into 
the external jugular veins of each rabbit (n=3) for 7 h.  At the end of the 7 h implantation, 
the catheters were carefully removed from the blood vessel while any thrombus formation 
was left intact on the catheter surface.  In order to determine the area of clot formation, 
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digital images of both the SNAP impregnated and control catheters were taken and the two-
dimensional representation of the clot areas were quantitated using Image J software from 
NIH.  The clot area on the control catheter was 0.84 ± 0.19 cm2/catheter while the clot area 
on the SNAP catheter was 0.03 ± 0.01 cm2/catheter, considerably less than the controls 







Figure 4.14. Five cm of the catheters (left of the dash line) were inserted into the rabbit 
external jugular veins for 7 h. (A) Representative pictures of the thrombus formation on 
the SNAP-impregnated CarboSil and control CarboSil catheters from one rabbit 
experiment. (B) Two-dimensional representation of the clot area (cm2) on SNAP and 
control catheter in rabbit veins for 7 h, as quantitated using Image J software by NIH.  Data 
are mean ± SEM for n=3 animal experiments. * = p < 0.05 
 
The NO release rates from the post-surgery SNAP catheters were quantitated using 
chemiluminescence and the SNAP catheters were shown to maintain NO release at an 
average flux of 4.4 ± 1.1 x 10-10 mol cm-2 min-1 at 37 °C.  This result clearly illustrates that 
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continuous localized NO release from the SNAP impregnated CarboSil catheter has the 
potential to greatly reduce the risk of clot formation on the catheter’s surface, thereby 
maintaining the functionality of IV catheters during use and reduce the risk of stroke or 
deep vein thrombosis associated with detached blood clots. 
 
4.4. Conclusion 
In summary, a simple solvent impregnation procedure has been adapted to incorporate 
SNAP into CarboSil 20 80A polymer.  The impregnation process was optimized to achieve 
maximized SNAP loading and long-term NO release.  The majority of the SNAP 
incorporated in 15 wt% SNAP-impregnated CarboSil films exists in its crystalline form, 
and more than 70 % of the total NO release originates directly from the SNAP 
decomposition within the bulk of the polymer phase.  The 15 wt% SNAP-impregnated 
CarboSil catheters release NO at physiological levels for at least 14 d.  The NO release 
catheters reduce viable S. epidermidis and P. aeruginosa bacteria adhesion to the surface 
of the catheters after 14 d was by 2 and 2.5 log units, respectively.  The SNAP catheters 
also exhibit minimal clot formation after 7 h of animal implantation in a rabbit model when 
compared to the control CarboSil catheters.   Overall, both the in vitro and in vivo studies 
clearly demonstrate the potential of the SNAP impregnation method to improve the 
hemocompatibility/antimicrobial activity of IV catheters made with CarboSil polymer.  It 
is anticipated that these results will encourage further pursuit of this strategy in designing 
the next generation commercial IV catheters and other implantable biomedical devices to 
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CHAPTER 5  
Inhibition of Bacterial Adhesion and Biofilm Formation by 
Dual Functional Textured and Nitric Oxide Releasing Surfaces 
 
Xu, L.; Wo, Y.; Meyerhoff, M.E.; Siedlecki, C.A. “Inhibition of Bacterial Adhesion and 
Biofilms Formation by Dual Functional Texturing and Nitric Oxide Releasing Surfaces.” 
Acta Biomater, In Press.* 
 
5.1 Introduction 
The long-term use of biomaterials designed for fabricating implantable medical devices 
such as intravascular catheters, urinary catheters, indwelling blood pumps, vascular assist 
devices, and orthopedic implants is complicated by the potential for microbial infection 
due to pathogenic bacterial adhesion and biofilm formation on biomaterial surfaces.1-3  Due 
to the difficulty in treating bacterial biofilms via antibiotics and the increasing levels of
                                                
* The textured polymer fabrication, material characterization and antibacterial/antibiofilm testing reported in 
this chapter were conducted by Dr. Lichong Xu, while the SNAP synthesis and all NO release measurements 
were carried out by this Ph.D. candidate. 
 
 185 
 antibiotic resistance of pathogens, surgical removal and replacement of the implanted 
devices is often the only treatment for device-centered infections, causing a significant 
increase in morbidity and cost.4  Combatting  device-associated infections has been a great 
challenge in the field of implant-associated health care.5  Bacterial adhesion to the device 
surface is the first and critical step in the pathogenesis of implant related infections.  As an 
alternative to traditional methods in which antibiotics or biocides are released or infused 
(e.g., catheter lock solutions), methods to design and control material properties to 
reduce/control bacterial adhesion and thereby reduce microbial infection are more 
attractive approaches.6, 7  One promising method is the generation of functional surfaces 
through topographic modifications (e.g., surface texturing) that significantly reduce the 
initial attachment of microorganisms and the number of persistent pathogens to the surfaces 
of the implant.8  By analogy to natural antifouling surfaces such as shark skin, shell or lotus 
leaf, etc., the physical topographic surface modification with micro- or nano-size features 
reduces the surface contact area and changes the surface energy, and this approach has been 
shown to be effective in controlling bacterial adhesion and biofilm formation.9-12  With 
interest in this area and the related research increasing, over the past two decades 
biomimetic or bio-inspired materials have been developed to prepare the sterile 
biomaterials for the use in medical devices.13, 14  For example, the topographical features 
mimicking the shark’s skin were applied into polydimethylsiloxane (PDMS) elastomer and 
it was found that such surfaces disrupt biofilm formation of Staphylococcus aureus (S. 
aureus), suggesting the possibility for application of this approach in biomedical devices.15  
Furthermore, an in vitro study showed that the micro-patterned surface inhibited the 
bacterial colonization and migration of uropathogenic Escherichia coli (E. coli); thereby it 
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could be applied to reduce the risk of catheter-associated urinary tract infection.16  Our 
group has previously developed submicron-textured polyurethane biomaterial surfaces 
featuring patterns with pillars of diameter and spacing of 400/400 nm and 500/500 nm, and 
demonstrated that both textured surfaces decreased the adhesion of Staphylococcal 
epidermidis (S. epidermidis) and S. aureus and inhibited biofilm formation under shear and 
static conditions.17  Such submicron-textured surfaces have also been shown to reduce 
platelet adhesion, thereby reducing the potential of implant associated blood  
clotting/thrombosis of the device if implanted in the blood stream.18  These in vitro 
successes of textured materials have demonstrated the great potential for their use in 
clinical applications to combat health-care infections and thrombosis caused by catheters 
and other implanted devices.   
 
Nitric oxide (NO) releasing biomaterials represent another biomimetic strategy with great 
potential for clinical use.  NO is an endogenous gas molecule and its continuous release 
from the endothelial cells that line all blood vessels can effectively prevent the 
adhesion/activation of platelets on normal blood vessel walls.19  NO also plays an important 
role in the immune response as an antimicrobial agent and host defense against pathogenic 
bacteria.20  As a diatomic free radical, NO can cross the membranes to enter the microbial 
cell readily and kill the microbe by directly damaging DNA, proteins, and lipids through 
production of potent nitrosating species or by combining with reactive oxygen species (e.g., 
superoxide, peroxide) and oxidizing the same targets.21, 22  Furthermore, the rapid reduction 
of microbial loads reduces the pressure for the evolution and spreading of variant bacteria 
and limits the possibility of promoting NO resistant strains.23  For these reasons, polymeric 
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materials that mimic endogenous NO release provides a potential solution against medical 
device-associated microbial infection and also can prevent platelet activation and thereby 
reduce risk of thrombus formation. Extensive studies have already demonstrated that NO 
release can effectively inhibit bacterial adhesion and reduce biofilm development on 
material surfaces.24-27  
 
Since NO is highly reactive and short-lived under physiological conditions, NO donor 
molecules with functional groups that can store and release NO are necessary.  These NO 
donors are incorporated into materials either by blending discrete NO donors within 
polymeric films, or by covalently attaching them to polymer backbones and/or to the 
inorganic polymeric filler particles that are often employed to enhance the strength of 
biomedical polymers (e.g., fumed silica or titanium dioxide).28  N-diazeniumdiolates26, 29, 
30 and S-nitrosothiols30-32 are commonly used to prepare NO releasing polymeric matrices 
for improved biocompatibility of blood-contacting medical devices.  The N-
diazeniumdiolates are generally synthesized by reaction of amines with NO gas to form 
relatively stable compounds that release NO when in contact with bodily fluids through 
proton or thermally driven mechanisms.  The S-nitrosothiols are generally formed by 
reaction of nitrous acid with the parent thiol, and undergo thermal decomposition to release 
NO, which are generally catalyzed by metal ions (e.g., copper), and light.30  Nitric oxide 
can also be generated via other techniques, such as electrochemical reduction of nitrite,33 
or reduction of sodium nitroprusside.34  However, the current NO release strategies have 
the challenges in terms of storage, stability, costly synthesis or short NO release lifetime.  
Among the NO donors reported to date, S-nitroso-N-acetylpenicillamine (SNAP) is among 
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the most attractive ones in terms of its long-term NO release capability and enhanced 
stability when incorporated into low water uptake biomedical polymers.  Indeed, SNAP 
has already been incorporated into a number of low water uptake polymers to yield 
promising new biomaterials,  For example, it was reported that SNAP-doped polyurethane 
Elast-eon E2As polymer retained 82% of the initial SNAP after 2 month storage at 37°C 35 
and released NO slowly at the physiological flux level for 3 weeks.  Similarly, SNAP in 
CarboSil 20 80A also exhibits a stability at 88.5 % ± 4.3% of the initial amount after 8 
months storage in the dark at 37 °C.36  The increased stability of SNAP within these 
polymers is believed to be due to the intermolecular hydrogen bonds between crystallized 
SNAP molecules.  For example, long-term storage stability of SNAP in the CarboSil 
polymer was found to originate from the formation of a polymer-crystal composite during 
the solvent evaporation.  This composite led to sustained NO release at the physiological 
flux levels that can last for >3 weeks with the cross-linked silicone rubber as a topcoat.36 
 
The SNAP-doped polymers exhibit good blood compatibility.  The E2As catheters doped 
with SNAP significantly reduced the amount of thrombus and bacterial adhesion compared 
the E2As control catheters when they were implanted in sheep veins for 7 d.37  An in vitro 
experiment of S. aureus biofilm formation over a 7 d period showed that SNAP-doped 
CarboSil 20 80A intravascular catheters had 5 log units reduction of viable cell count on 
their surfaces.36  All results reported to date suggest that SNAP-doped low water uptake 
polyurethane copolymers could be attractive for clinical applications, providing long-term 
storage stability, long-term NO release capability in vivo, and increased biocompatibility 




Although each biomimetic approach described above (surface texturing modification or 
NO release) has been shown to exhibit significant antimicrobial and antithrombotic effects, 
the use of a single approach is still far from ideal for achieving more complete control of 
thrombosis and microbial infection on implanted biomedical devices.  Each strategy has its 
inherent drawbacks. For example, physical surface defects such as missed pillars during 
fabrication is always unavoidable, leading to local adhesion and accumulation of platelets 
or bacteria, while the NO release polymers have the limit of lifetime and storage stability.  
To overcome the shortcomings of each individual approach, the combination of surface 
texturing and NO release to control bacterial adhesion and biofilm formation would 
provide potentially additive or synergetic effects to decrease bacterial adhesion and/or 
platelet activation. In this study we fabricated new polyurethane films that bear ordered 
pillar topographies at the top surface as well as a NO releasing material in the sublayer.  
Such a combination produces dual functional materials with the reduced accessible surface 
contact area for bacteria adhesion and providing continuous NO release.  Experimental 
data demonstrate that the dual functional surfaces provide a further improvement in the 
surface antimicrobial activity and anti-biofilm functionality than either of the approaches 
can provide when employed alone.  Results show that textured surfaces with NO release 
inhibit biofilm formation over a relatively long term (> 28 d) and this provides a practical 
approach to improve the biocompatibility of current biomimetic biomaterials and reduce 
the risk of pathogenic infection.  The successful implementation of such materials in 
clinical practice could ultimately reduce costs by decreasing the number of implant 




5.2 Experimental Section 
5.2.1 Materials 
CarboSil® 20 80A silicone-polycarbonate-urethane (PU, DSM) was supplied as a solid and 
dissolved in N,N-dimethylacetamide (DMAc, Sigma-Aldrich, St. Louis, MO) at a 
concentration of 15 w/v% (1.5 g PU in 10 ml DMAc) for preparing the films.  The SNAP-
doped PU solutions were prepared by dissolving SNAP at 5, 10, or 15 w/w% relative to 
solid polymer within 15 w/v% Carbosil PU DMAc solutions.  After extensive mixing, films 
can then be cast from these solutions by a spin coater (Specialty Coating System Inc., 
Indianapolis, IN).  CarboSil PU contains 4,4’-methylene bisphenyl diisocyanate (MDI) as 
a hard segment and poly(dimethylsiloxane) (PDMS) and polycarbonate as soft segments.  
N-Acetyl-D-penicillamine was purchased from Sigma-Aldrich for the synthesis of SNAP, 
which has been described in previous publications.35, 37  All aqueous solutions were 
prepared with Millipore water (18.2 MW) and phosphate buffered saline (PBS 0.01 M, pH 
7.4, Sigma-Aldrich) was used for in vitro experiments.  All culture media and containers 
for bacteria study were autoclaved at 121°C for 20 min, and the Carbosil films were 
sterilized by washing with 70% ethanol prior to experiments.  All films were prepared in a 
clean room to avoid contamination. 
 
5.2.2 Preparation of textured and NO releasing PU films 
The CarboSil 20 80A PU film surfaces were textured with ordered arrays of pillars using a 
modified soft lithography two-stage replication molding technique that has been described 
previously.17, 18  Briefly, a master pattern with ordered arrays of pillars was first fabricated 
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on a silicon wafer.  Then a silicone mold (PDMS) was cast against the master pattern to 
provide the negative silicone mold (see Figure 5.1A).  To obtain the highest replication 
efficiency of surface topography, the PU films were prepared by spin casting CarboSil onto 
a PDMS mold at 1200 rpm for 1 min in one thin layer first, followed by degassing and 
curing overnight at room temperature under vacuum.  Then, additional layers of CarboSil 
PU were added by spin casting at 600 rpm for 1 min, respectively. Each layer was degassed 
and cured at room temperature under vacuum.  The CarboSil PU solutions doped with 
different concentrations of SNAP (5, 10, 15 % (w/w) were repeatedly added on the PU 
films by spin casting at 600 rpms for 1 min, followed with degassing and curing overnight 
under vacuum (Figure 5.1B).  Finally, the regular CarboSil PU without SNAP was added 
on the SNAP-PU layer by spin casting, and cured under vacuum, so that the SNAP-doped 
textured PU films were composed of 3 main layers with a base of PU, a middle layer 
containing SNAP, and a textured PU top layer with patterns and having a total film 
thickness of approximately 700 µm (Figure 5.1C).  Two patterns of silicon wafers with 
pillar geometries having diameter (d) and separation (s) and d/s values of 400/400 nm and 
500/500 nm were used as the masters for replicating PU films.  The height of pillars in both 
patterns was 600 nm.  Textured silicon wafers were fabricated by RTI International 




Figure 5.1. Schematic diagrams of a soft lithography two-stage replication molding 
technique employed to prepare textured films examined in this study. 
 
5.2.3 NO release measurements 
Nitric oxide release from the films was measured using a Sievers chemiluminescence Nitric 
Oxide Analyzer (NOA) 280i (Boulder, CO) using a method described previously.35, 38  
Briefly, films with diameter of ~10 mm were placed in the sample vessel immersed in PBS 
containing 100 µM EDTA at 37°C.  NO was continuously purged from the buffer and 
swept from the headspace using nitrogen gas and a bubbler into the chemiluminescence 
detection chamber of the NOA.  When not being tested with the NOA, the SNAP-doped 
samples were incubated in PBS under same conditions avoiding exposure to light. The NO 
flux was calculated based on assuming a flat surface area of two sides of films exposed to 




5.2.4 Surface water wettability measurement  
The water wettability of CarboSil PU films was determined as the advancing water contact 
angle measured by sessile drop method using a Krüss contact angle goniometer.  All 
measurements were made using water as a probe liquid and an ~ 8 µl of water droplet was 
used for the measurement.  Advancing contact angles were obtained by a minimum of eight 
independent measurements and are presented as mean ± standard deviation. 
 
5.2.5 Characterization of surface topography by atomic force microscopy (AFM)  
A Multimode AFM with a Nanoscope IIIa control system (software version 5.12r3, Veeco, 
Santa Barbara, CA) was used to examine the surface textures of PU films operated in 
tapping mode (intermittent contact) using Si probes having aspect ratio of ~ 4:1 (TETRA, 
K-Tek Nanotechnology, Wilsonville, OR) in air.  AFM was also used to image the bacterial 
adhesion on CarboSil PU surfaces.  AFM images were treated and analyzed by off-line 
AFM software (version 5.12r3, Veeco, Santa Barbara, CA). 
 
5.2.6 Bacterial growth, adhesion, and biofilm formation on SNAP-doped textured PU 
surfaces  
S. epidermidis RP62A is a strongly adherent, slime-producing, pathogenic strain isolated 
from a patient with intravascular catheter-associated sepsis.39  S. epidermidis RP62A 
(ATCC 35984) was used to test the bacterial growth inhibition, and adhesion to various 
CarboSil surfaces in this study.  The culturing and collection of bacteria have been reported 
in a previous publication.17  Bacterial colonies of the strain were cultured in tryptic soy 
broth (TSB) at 37 °C for 24 h and collected by centrifuge at 1360g for 10 min.  The pellet 
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was re-suspended in PBS and the concentration of bacteria was measured via a 
spectrophotometer at 600 nm (turbidity measurement).  To test the effect of NO release on 
bacterial growth, the polymer films were cut into round disks with 9 mm diameter, and 
soaked in PBS for 1 h, and placed in 24 well plates.  Two ml of TSB culture medium 
containing S. epidermidis RP62A with a concentration of 1´106 CFU/ml was added and 
incubated at 37°C with shaking at 180 rpm.  At 6, 24, and 48 h time points, 0.25 ml medium 
was drawn and diluted into 1 ml with sterile TSB, and the optical density (OD) was 
measured at 600 nm, where OD600 values indicated the growth of bacteria. 
 
To test bacterial adhesion, the bacterial suspension was diluted in PBS to a final 
concentration of 1×108 CFU/ml.  PU films were cut into the round pieces with diameter of 
10 mm and pre-hydrated in Millipore water for 24 h and conditioned in PBS for 1 h, to 
fully equilibrate the outermost surface of the polymer films.  Such pre-hydration also 
washes away any SNAP on the surface of the films that would lead to an initial burst of 
NO release from the surface of the film.  This provides a more reliable approach to evaluate 
the effect of stable NO release on bacterial adhesion over longer periods by removing the 
initial NO burst.  Bacterial adhesion was carried out in a micro-well plate with the volume 
of ~ 0.5 ml at 37°C for 1 h at near static condition with slight orbital shaking.  After 
adhesion, the bacteria suspension was exchanged with PBS for 3 times, and then the 
samples were fixed in 2.5 % glutaraldehyde for 2 h.  After being rinsed with PBS, bacteria 
on the PU films were stained with Hoechst 33258 (Invitrogen) and analyzed under a 




Biofilm formation was assessed under static and shear conditions.  PU films were incubated 
with S. epidermidis RP62A in tryptic soy broth medium containing bacteria at an initial 
concentration of 1×108 CFU/ml in a 12 well plate for 2 days at 37°C.  A rotating disk 
system with a speed control (model: AFMSRX, Pine Instrument, PA) was used to assess 
biofilm formation and slime production on surfaces under shear condition.17  PU films were 
incubated in TSB under same conditions and run at speed of 431 rpm.  Every 2 days, 25 % 
of media was replaced for supplement of nutrients.  After desired time periods, the samples 
were washed with PBS by sequential addition and aspiration, stained with 100 µg/ml wheat 
germ agglutinin-FITC (Sigma) for 1 min, and fixed in 1% paraformaldehyde for 30 min.  
The samples were then examined by fluorescence optical microscopy.  
 
5.2.7 Statistical Analysis 
Statistical analysis was performed using SAS software (version 9.4).  Means of 
experimental data were compared by 2-sample t-test and differences were considered 
statistically significant for p< 0.05.  Significance is denoted in figures of this paper with 
one symbol denoting p< 0.05, two symbols p < 0.01, and three symbols denoting p< 0.001.  
The bacterial adhesion was further regressed with the factors by ANOVA general linear 
model (GLM), and differences in bacterial adhesion means were analyzed by the least 




5.3 Results and Discussion 
5.3.1 Preparation SNAP- textured polyurethane films  
In a previous study,35 we examined the NO release and stability of 5wt% and 10 wt% 
SNAP-doped Elast-eon E2As polymers. In this study, we examined a different polymer, 
CarboSil 20 80A, and combined the SNAP-doped PU in the middle layer and the top layer 
with textured pattern to make the “sandwich-like” polymer films.  To study the NO release 
profiles and the response of bacterial adhesion to the polymer films that contain different 
concentrations of NO donor SNAP, a series of SNAP-textured films with CarboSil 20 80A 
polyurethane, in which the middle layer of PU was doped with 5 wt%, 10 wt%, and 15 
wt% SNAP and the top surface layer was textured with patterns of 400/400 nm or 500/500 
nm, were fabricated by a soft lithography two-stage replication molding technique.  
Generally, we obtained regular textured patterns on the outer polyurethane surfaces, similar 
to the features that we described in previous publications for the regular textured surface 
(without NO release).17, 40  Both the diameter of pillars and distance of inter pillars are less 
than the dimensions of bacterial cells, ensuring a reduction of available contact area when 
bacterial cells contact the surface, with minimal opportunities for bacteria to become 
lodged in the spaces between pillars.  
 
Initially we observed some shallow areas on the textured surfaces after we applied only a 
thin layer at the top surface (composed with PU layers which were spin coated at 1200 rpm 
and 600 rpm for 1 min, respectively) and with SNAP-doped polyurethane added as the 
middle layer (Figure 5.2A).  The shallow areas are believed to be SNAP that diffused into 
the thin top polyurethane layers during fabrication, leading to a reduction of pillar height.  
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To improve the texturing pattern, two more layers were added to the top textured layer by 
spin coating at 600 rpm for 1 min.  The thicker top layer of PU significantly limited the 
diffusion of SNAP into the textured layer during drying/curing and the resulting textured 
surface had a more uniform distribution of pillars, with a pillar yield of > 99.8% (see Figure 
5.2B).   
 
Figure 5.2. 3D AFM image of NO releasing 500/500 nm textured polyurethane film 
surface; (A) thin top layer showing the diffusion of SNAP onto top surface, and (B) thick 




To ensure that the NO release can be controlled, a base layer of PU was subsequently 
applied onto the middle SNAP-PU layer by spin coating at 400 rpm for 1 min, and 
application of such layers was repeated for 3 times.  In this manner, the sandwich-like PU 
films with SNAP and texturing were fabricated.  The subsequent measurement of NO 
generation showed that a thicker top layer of PU extended the lifetime of NO release, 
suggesting that the thickness of top layer can control the release rate of NO (see Section 
5.3.3).  Further, a thicker top layer of PU can also reduce the leaching of SNAP, NAP and 
NAP dimer from the films.     
  
The SNAP-textured polymer film was prepared by solvent evaporation under vacuum.  In 
this study, DMAc was used as the solvent to dissolve the polyurethane and/or SNAP to 
form the thin layer on the mold by spin casting.  Such process enables easy control of the 
thickness of films and produces well textured patterns with high yield of pillars, but is time-
consuming.  Brisbois et al.35 used the alternative solvent tetrahydrofuran (THF) to prepare 
the SNAP-doped Elast-eon E2As polymer as a homogenous coating on a Teflon plate.  
However, it appears that this approach is unsuitable for spin casting in a soft lithography 
two-stage replication process since the fast evaporation of THF often causes a 
heterogeneous film thickness during the spinning process.  Furthermore, the pattern 
produced was found to be unacceptable and pillar yield was low because the PU polymer 
solution did not have good access into the submicron size holes within the PDMS mold.        
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5.3.2 Surface wettability 
The regular smooth CarboSil 2080A PU surface is hydrophobic with a water contact angle 
of 91.0±1.4°.  Surface texturing increased the hydrophobicity with water contact angle of 
139.3 ±1.6° due to air captured in the spaces between pillars (Figure 5.3). This is similar 
to the BioSpan® MS/0.4 polyurethane textured surfaces that have been described 
elsewhere.40  Adding the SNAP-doped polyurethane as the middle layer of films did not 
affect the water contact angle significantly for the smooth surfaces while it appeared to 
decrease the water contact angles for the textured surfaces as the SNAP content increased.  
This is probably due to the diffusion of SNAP into top layer of PU film.  However, since 
the observed differences of water contact angles between textured surfaces having 0, 5 and 
10 wt% SNAP was only approximately 5°, this is generally within the variability of the 
measurement method.  
 
Figure 5.3. Water contact angle of smooth and textured (500/500 nm pattern) PU films 




5.3.3 NO generation from SNAP-doped PU films   
S-Nitrosothiols (RSNOs) are one of the most widely used NO donors.  SNAP can 
decompose into the disulfide, dimer of NAP or (NAP)2, and release NO in the presence of 
light, heat, or moisture.  In the presence of certain metal ions (e.g. Cu(II)) a reductive 
catalytic reaction is possible that leads to formation of initially NAP (and then (NAP)2 after 
oxidation of NAP thiols) and NO.  SNAP is a synthetic tertiary RSNO and is more stable 
than most physiological RSNOs due to the steric hindrance of the sulfur atom.41, 42 Upon 
placing the SNAP-doped CarboSil PU films into PBS at 37°C, the decomposition of SNAP 
within polymer film occurs simultaneously to release NO (equation. 5.1) owing to the 
combination of moisture and temperature.   
 
2 SNAP à 2 NO + (NAP)2                                                                                           [5.1] 
 
The NO release flux rate depends on the topcoat polymer layer thickness, the surface 
topography, and level of SNAP content within the ‘sandwich’ middle layer of the polymer 
film.  We found that the NO release was fast for the SNAP-polymer with a thin top layer 
and lasted only 3-4 days.  Also, we found that NO flux was generally higher in the presence 
of the textured surface than on the normal smooth surface, likely due to the increased water 
contacting surface area of the textured film (Figure 5.4A).  To control the NO release flux, 
we fabricated CarboSil PU films containing 5, 10, and 15 wt% SNAP in a middle layer 
sandwiched by a base PU and a thick textured PU surface.  Figure 5.4B illustrates the NO 
flux release from 15 wt% SNAP-doped surface in contact with water at 37°C.  It was found 
that the NO flux release was delayed initially, then gradually increased with time and then 
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reached a peak.  The average NO flux was as high as 15 ´10-10 mol min-1 cm-2 on day 1, 
and then decreased in the following days.  The lifetime of NO release varied with the 
concentration of SNAP-doped within the films.  The NO flux release from SNAP textured 
surfaces with 500/500 nm patterns was found to last only about 2 and 4 days for 5 wt% and 
10 wt% SNAP-doped films, respectively, while the lifetime of NO release for 15 wt% 
SNAP-doped materials can last up to 10 d at an NO flux > 0.5 ´10-10 mol min-1 cm-2 (see 
Figures 5.4C-5.4E).  Healthy endothelial cells produce NO fluxes generally in the range of 




Figure 5.4. NO release from SNAP-doped textured polyurethane film in PBS at 37°C 
without light. (A) smooth, 400/400nm, and 500/500nm textured PU films with 5 wt% 
SNAP-doped; (B) NO release on day 1 from 500/500 nm textured PU films with 15 wt% 
SNAP-doped; and the average NO flux released from surface as the function of time (day) 
from 500/500 nm textured PU films with (C) 5 wt%, (D) 10 wt%, and (E) 15 wt% SNAP 
doped. Data collection ended when the flux went below physiological levels of 0.5 ´10-10 
mol min-1 cm-2. 
 
The sustained NO release originates from the formation of a composite of SNAP crystals 
within the polymer phase.  Wo et al.36 proposed a 2-step mechanism of NO release from 
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the SNAP-doped CarboSil polymer.  Upon hydration at 37°C SNAP in the polymer matrix 
decomposes and releases NO, primarily in the water-rich regions near the polymer/solution 
interface, and the dissolved SNAP in the bulk polymeric phase becomes unsaturated, 
resulting in the dissolution of crystalline SNAP within the bulk of the polymer.  The SNAP-
textured CarboSil polyurethane film examined in this study consists of top, middle, and 
base layers with same CarboSil 20 80A polymer and the SNAP doped in the middle layer.  
Comparing the long-term NO release from SNAP-doped E2As polymer35 or silicon rubber 
top coated CarboSil polymer,36 the lifetime of NO release from SNAP-textured PU films 
in this study is relatively shorter (10 d) vs. these prior reports.  One probable reason for this 
is that the top layer in the textured films is a relatively thin film formed by the spin coating 
process, and SNAP from the underlying layer can enter this outermost layer during the 
preparation process leading to a greater release rate of NO at the initial time point (e.g., 
first day).  Additional spin coating of layers within the top portion of the film reduces the 
diffusion of SNAP into top textured layer during film preparation, and increases the 
lifetime of NO release (Figure 5.4E).  Another plausible explanation for reduced longevity 
of NO release from the textured films that have relatively thin top layers is that the repeated 
dissolution and recrystallizing of SNAP during fabrication process may lead to the 
instability and partial decomposition of SNAP within polymer.  Clearly, the fabrication 
process of preparing optimal SNAP-textured films still needs to be optimized.     
 
5.3.4 Surface topography of SNAP-doped PU films   
NO release from SNAP-doped polymer film changes the nano-topography of top surface.  
Figure 5.5 illustrates the AFM surface image of a smooth film containing 15 wt% SNAP 
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in middle layer before and after hydration.  Surprisingly there are particle-like spots 
distributed on the smooth surface before hydration, and these spots had diameters in the 
range of 250-350 nm and height of 35-60 nm.  These spots were likely due to the SNAP 
diffusion into the very top thin layer of PU during fabrication and some of SNAP crystals 
extending out from the surface.  We did not observe such particle-like spots on the films in 
absence of SNAP.  After hydration in PBS for 24 h at 37°C, there were few particle-like 
spots found on surface.  Instead, only small pits with a depth of around 5-30 nm were 
observed, suggesting that SNAP decomposed/dissolved and generated NO flux, which led 
to the formation of these observed pits. 
       
 
Figure 5.5. AFM images of smooth polyurethane surface with 15 wt% SNAP in the middle 
layer (a) before hydration and (b) after hydration. (scale bar= 2 µm)   
 
5.3.5 Antimicrobial properties of SNAP-doped PU films  
The antimicrobial properties of polymers were evaluated by the measurements of bacterial 
turbidity of media inoculated with bacterial strains and incubated with polymer films.  
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Figure 5.6 shows that the values of OD600 of media incubated with polymers without SNAP 
or doped with 5 wt% SNAP increased sharply after 24 h, suggesting that the polymers with 
5 wt% SNAP doped in middle layer had no significant inhibition on bacterial growth in the 
bulk of the culture; however, the OD600 values of media incubated with 10 wt% and 15 
wt% SNAP-doped polymers increased only slightly at 24 and 48 h.  The values were about 
half of the values of OD600 for polymers without SNAP or with 5 wt% SNAP, suggesting 
that bacteria in the bulk media solution were inhibited by the NO released by the SNAP-
doped films.  Of interest is that the OD600 values of media in contact with the 15 wt% 
SNAP-doped polymers decreased at 48 h (p-values =0.08 and 0.13 for textured 400/400nm 
and 500/500 nm surfaces, respectively) compared to the values at 24 h, indicating that 
bacteria were inhibited by the high NO flux released from these polymers during the initial 
2 d of incubation.  
 
Figure 5.6. Optical density of bacterial culture medium measured at 600 nm wavelength 




5.3.6 Bacterial adhesion on SNAP-doped PU film surfaces   
Bacterial adhesion to the various PU film configurations was assessed under static 
condition in PBS and evaluated by the bacteria counts per unit area.  Generally, both the 
textured surfaces alone and the use of SNAP alone (without texturing (smooth), 
significantly reduced bacterial adhesion on CarboSil PU film surfaces (Figure 5.7a).  
Without NO release from polymers (0% SNAP), surface texturing alone (400/400 nm and 
500/500 nm) reduced bacterial adhesion by ca. 61-64%, when compared to the smooth 
samples. With SNAP present in the middle layer of the polymer films, the reduction rate 
increased to up to 88% on the films containing 15 wt% SNAP and the 500/500 nm pattern 
surface texture.  The response of bacterial adhesion to the NO release is dependent on the 
concentration of SNAP doped in the middle layer of polymer films.  Bacterial adhesion 
generally decreased with the increase of SNAP concentration due to the increase of NO 
release level, as expected (Figure 5.7b).  We used the general linear model (GLM) to 
regress the factors of SNAP content, surface texturing, and interaction of SNAP´texturing, 
and found that both surface texturing and SNAP were significant factors influencing S. 
epidermidis bacterial adhesion (both p-values <0.0001). Furthermore, the interaction of 
SNAP and texturing also significantly affected bacterial adhesion (p-value <0.0001), 
strongly suggesting that the bacterial adhesion linearly decreased with increasing SNAP 
concentration, but the slopes for different surfaces (Smooth, 400/400 nm, and 500/500 nm 
patterns) were significantly different (Figure 5.7b), suggesting that the combination of 





Figure 5.7.  (a) Bacterial adhesion and reduction rates (against smooth regular PU 
polymer) on NO releasing textured polyurethane surfaces under static condition at 37°C 
for 1 h; (b) linear regression of bacterial adhesion against SNAP content. 
 
These differences in bacterial adhesion were further compared by the least square means 
method. Table 5.1 shows that the differences of means between smooth and textured 
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surfaces (either 400/400 nm or 500/500 nm) at SNAP levels of 0 wt%, 5 wt%, and 10 wt% 
are significant, but not significant at SNAP level of 15 wt% (all p-values >0.05 for smooth 
and textured surfaces). Results suggest that both NO release and texturing contributed to 
inhibition of bacterial adhesion at lower levels of SNAP content, but the NO release 
dominates the degree of reduction in bacterial adhesion at high levels of SNAP (15 wt%), 
indicating that the effect of surface texturing becomes less significant when the 
concentration of SNAP is as high as 15 wt%.  A comparison of bacterial adhesion between 
two textured surfaces with different dimensions, 400/400 nm and 500/500 nm, indicates 
that there is no statistically significant difference of mean for these two differently 
patterned films (all p-values >0.05) regardless of the levels of SNAP concentration present.  
This is due to the similar pillar geometry of the patterns with each having the submicron 
dimensions (400 nm and 500 nm).  The effect of significantly larger or smaller pattern sizes 
on bacterial adhesion in combination with NO release still needs to be examined in the 
future. 
Table 5.1.  Statistical analysis of difference of least square means in bacterial adhesion 
Staphylococcus epidermidis between every two groups of biomaterial surfaces examined 
in this work. 
 
SNAP (wt%) Comparison P value 
 
0 
Smooth vs 400/400 <  0.0001 
Smooth vs 500/500 <  0.0001 
400/400 vs 500/500     0.2841 
 
5.0 
Smooth vs 400/400 <  0.0001 
Smooth vs 500/500 <  0.0001 
400/400 vs 500/500     0.4711 
 
10.0 
Smooth vs 400/400     0.0002 
Smooth vs 500/500 <  0.0001 
400/400 vs 500/500     0.8381 
 
15.0 
Smooth vs 400/400     0.9991 
Smooth vs 500/500     0.4598 





The above bacterial adhesion experiment was carried out in PBS, although the presence of 
proteins are potentially quite important in influencing bacterial adhesion on implanted 
medical devices surfaces.  When a foreign material is implanted in the body, plasma 
proteins rapidly adsorb on the surfaces and form a layer of proteins.  The nature of adsorbed 
proteins modulates the bacterial adhesion, aggregation and biofilm formation.  In vitro 
studies have shown that the presence of the serum proteins generally suppresses the initial 
bacterial adhesion due to the nonspecific interactions of albumin and the surfaces of 
bacteria 44 while adhesive proteins (e.g., fibrinogen and fibronectin) were reported to 
increase adhesion via forming the specific ligand/receptor bonds between proteins and the 
surfaces of bacterial cells.45, 46  In our previous study of bacterial adhesion on submicron 
textured polyurethane surfaces, a greater decrease in adhesion was observed when textured 
surfaces were incubated in solutions containing plasma or serum compared with the 
adhesion in PBS.17  Similarly, we expect a decrease in bacterial adhesion on SNAP-
textured PU surfaces in the solution containing serum proteins compared to the adhesion 
in PBS (Figure 5.7).  We also expect that surface texturing and NO release could exert the 
similar ability in controlling bacterial growth and adhesion on SNAP-textured surfaces in 
solutions containing plasma proteins.  Such studies will be conducted during the next phase 
of this research project.   
 
5.3.7 Biofilm formation on SNAP-Textured PU films   
S. epidermidis RP62A biofilm formation on dual functionalized CarboSil films was 
assessed in TSB culture under static conditions as well as shear conditions over different 
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periods, respectively. Under static conditions, biofilm was observed on un-doped (0 wt% 
SNAP) and 5 wt% SNAP doped CarboSil film surfaces, either smooth or textured, within 
2 d (Figure 5.8); however, there were only a few of clusters of bacteria or small biofilms 
formed on 10 wt% SNAP (both smooth and textured surfaces), and no biofilms were 
observed on the film surfaces with 15 wt% SNAP, for both smooth and textured surfaces.  
This suggests that the higher rates of NO release inhibit the growth of bacteria biofilm on 
the polymeric surfaces.   
 
Figure 5.8. Fluorescent optical microscopy images of biofilms formed on a variety of PU 




This is consistent with the antimicrobial properties of these new materials (Figure 5.6), 
where bacteria growth was inhibited in culture medium.  Similar bacterial growth and 
biofilm formation were observed on PU surfaces with the same SNAP-doping level, 
suggesting that texturing had no significant effect on inhibition of biofilm formation under 
static conditions.  Under static conditions, NO release exerts the more powerful ability to 
inhibit bacterial growth.  In contrast, the combination of texturing and NO release is much 
more effective in controlling bacterial growth and biofilm formation under shear conditions 




Figure 5.9. Fluorescent optical microscopic images show the biofilm formation on 
polyurethane film surfaces at 37°C under shear, (a) 15 wt% SNAP – smooth and (b) 15 
wt% SNAP and 500/500 nm textured surfaces for 8 d; (c) 15 wt% SNAP – smooth and (d) 
15 wt% SNAP and 500/500 nm textured surfaces for 14 d; (e) 15 wt% SNAP smooth and 
(f) 15 wt% SNAP-500/500 nm textured surfaces for 28 d; (g) regular textured 500/500 nm 
surface and (h) 15 wt% SNAP-500/500 nm textured surface for 21 d. (image size: 432 µm 




The polymer films were further examined for biofilm formation under shear conditions by 
using a rotating disk system for different periods.  There was no significant biofilm 
observed on 15 wt% SNAP-doped CarboSil film surfaces that were either smooth or 
textured (with 500/500 nm pattern) over an 8 d period (Figure 5.9a and 5.9b).  A small area 
with biofilm slime was observed on the 15 wt% SNAP smooth surface (Figure 5.9c) after 
sample was run in culture medium for 14 d, while no biofilm was observed on the 15 wt% 
SNAP-textured surface under same condition (Figure 5.9d).  The duration of experiments 
was extended to 28 d with the smooth and textured films containing 15 wt% SNAP. It is 
obvious that there was no biofilm formation on the textured surface while biofilm did form 
on the smooth surfaces (see Figures 5.9e and 5.9f).  To further examine the effect of NO 
release on biofilm formation, the textured films with or without SNAP were run in culture 
medium for 21 d.  Results show biofilm/slime formed on the regular (0 wt% SNAP) 
textured surface while no biofilm/slime was observed on 15 wt% SNAP-textured surface 
(Figures 5.9g and 5.9h).  Overall, CarboSil 20 80A PU films containing 15 wt% SNAP 
doped in the middle layer and the 500/500 nm textured pattern as the top layer can inhibit 
the biofilm growth for > 28 d.  Since the NO release from 15 wt% SNAP-doped PU films 
can only last up to 10 d, the long term (> 28 d) inhibition of biofilm growth is attributed to 
the combination of early NO release and the physical surface topography modification 
created by the pillars.  The high NO flux inhibits or kills the bacteria in the initial period 
and protects the material from biofilm formation.  As the NO flux decreases, the surface 
textured topography continues reducing the bacterial adhesion and inhibiting biofilm 
formation on surface for longer periods.  Results suggest that the combination of NO 
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release and topography modification provides a promising approach to greatly inhibit 
biofilm growing for long-term on the polymer surface.       
 
This study has demonstrated the fabrication of the PU films that bear ordered pillar 
topographies at the top surface and NO release PU in the sublayer.  Such a unique 
combination of surface texturing and NO release can provide a biomimetic surface that 
exhibits substantial antimicrobial/antibiofilm activity.  On one hand, the topographical 
feature reduces the accessible surface contact area for potential bacterial adhesion.  The 
fractions of total top surface areas for these textured patterns are ~ 25% of the nominal 
surface area and these textured surfaces alone reduce adhesion of S. epidermidis by 61-
64% under near static condition in PBS solution for 1 h.  The reduction of bacterial 
adhesion by topographical surface modification may also be attributed to the change of 
surface energy and surface wettability. The textured pattern makes the surface more 
hydrophobic due to the Cassie – Baxter effect.47  Our previous studies showed that the 
increase of surface hydrophobicity is necessary for the inhibition of bacterial adhesion and 
biofilm formation on textured surfaces, especially when the size of textured pattern is larger 
than the dimension of bacterial cells.40  The submicron textured CarboSil PU surface 
examined in this study physically reduced the availability of surface contact area and 
increased the surface hydrophobicity, which both contribute to lowering bacterial adhesion.  
On the other hand, the addition of SNAP-doped sublayer between base layer and the outer 
textured surface layer can provide controlled release of NO over an extended period of 
time.  This NO release largely inhibited the growth of bacteria (Figure 5.6) and reduced 
the bacterial adhesion on the surface overall.  Without surface texturing, the 15 wt% SNAP 
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in middle layer increased the bacterial adhesion inhibition rates up to 75 % after 1 h (Figure 
5.7a) and there was no biofilm formed on smooth surface after 2 d under static conditions 
(Figure 5.8).  This clearly suggests the importance of NO release in control of bacterial 
adhesion and biofilm formation on biomaterial surfaces.  Under shear conditions, biofilm 
formation was found on the smooth surfaces with 15 wt% SNAP within 14 d and on the 
textured 500/500 nm surface within 21 d, suggesting that each individual treatment alone, 
either NO release or physical topography modification, can only protect polymer materials 
less than 21 d.  However, integration of NO release and surface texturing together can 
synergistically inhibit S. epidermidis biofilm formation for the longer 28 d period.  Since 
the lifetime of NO release from SNAP-textured films employed in this study only lasted 
about 10 d, much shorter than the NO release lifetime in other studies,35, 36 there is also 
room for improvement in the preparation and design of these new biomimetic polymeric 
surfaces that may further increase useful lifetime.   
 
Bacterial adhesion is the critical step in the pathogenesis of biomaterial associated 
infection.  Once implanted, a biomaterial surface faces a competition between integration 
of the material into the surrounding tissue and the adhesion of bacteria.  As a successful 
implant, tissue integration should occur prior to bacterial adhesion and colonization.  
Therefore, the prevention of bacteria adhesion within the initial hours following 
implantation, especially in the first 6 h of post-implantation “decisive period”, is critical 
for the long-term success of an implant since the implant is particularly susceptible to 
surface colonization during this period.48, 49  The NO possesses a broad-spectrum 
antibacterial activity against both Gram-positive and Gram-negative bacteria.  The NO flux 
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released from SNAP doped films controls the bacteria growth and inhibits the bacterial 
adhesion within the initial hours (Figure 5.6), and this helps accelerate the integration of 
tissue onto the material’s surface thereby inhibiting microbial infection.  The other benefit 
of using NO to control bacterial adhesion is the very limited possibility of it promoting 
bacterial resistance, a common issue for the antibiotic therapy.  It has not been reported 
that NO treatment would cause potential antibiotic resistance.50  Therefore, the controlled 
release of NO over a long period (>10 d) is desirable and will provide additional benefits 
for the long-term success of polymeric implants. 
 
5.4 Conclusion 
SNAP-doped and textured CarboSil 20 80A polyurethane films were fabricated with the 
top layer bearing ordered submicron pillars and a SNAP-doped sublayer for NO release, 
via a two-stage replication process. Controlling the thickness of top layer can limit and 
control the diffusion of SNAP during fabrication process and produce the desired uniform 
pillars on the outermost surface.  The NO release rate depends on the SNAP concentration 
in the sublayer.  The 15 wt% SNAP-doped textured polyurethane film release NO for up 
to 10 d above the lower end of the physiological flux level, 0.5 ´10-10 mol min-1 cm-2.  The 
combination of NO release and surface texturing produced a synergistic effect on inhibition 
of S. epidermidis bacterial adhesion, significantly greater than the inhibition of bacterial 
adhesion achieved by either the use of NO release or texturing alone.  The long-term study 
of biofilm formation on biomaterial surface showed that the biomimetic SNAP-textured 
CarboSil PU surface reduced the bacterial adhesion and inhibited biofilm formation for at 
least 28 d, providing a practical approach to improve the biocompatibility of current 
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biomaterials to control and potentially reduce the rate of pathogenic infections caused by 





5.5 References  
1. R. M. Donlan, Emerging Infectious Diseases, 2001, 7, 277-281. 
2. I. Francolini and G. Donelli, Fems Immunology and Medical Microbiology, 2010, 
59, 227-238. 
3. L. Zhang, J. Gowardman and C. M. Rickard, International Journal of Antimicrobial 
Agents, 2011, 38, 9-15. 
4. R. M. Klevens, J. R. Edwards, C. L. Richards, T. C. Horan, R. P. Gaynes, D. A. 
Pollock and D. M. Cardo, Public Health Reports, 2007, 122, 160-166. 
5. R. P. Wenzel, Clinical Infectious Diseases, 2007, 45, 85-88. 
6. D. Campoccia, L. Montanaro and C. R. Arciola, Biomaterials, 2013, 34, 8018-
8029. 
7. D. Campoccia, L. Montanaro and C. R. Arciola, Biomaterials, 2013, 34, 8533-
8554. 
8. A. B. Estrela, M. G. Heck and W. R. Abraham, Current Medicinal Chemistry, 2009, 
16, 1512-1530. 
9. A. J. Scardino, D. Hudleston, Z. Peng, N. A. Paul and R. de Nys, Biofouling, 2009, 
25, 83-93. 
10. A. J. Scardino, H. Zhang, D. J. Cookson, R. N. Lamb and R. de Nys, Biofouling, 
2009, 25, 757-767. 
11. W. Barthlott and C. Neinhuis, Planta, 1997, 202, 1-8. 
12. B. Bhushan and Y. C. Jung, Progress in Materials Science, 2011, 56, 1-108. 
13. T. Sun, G. Qing, B. Su and L. Jiang, Chemical Society Reviews, 2011, 40, 2909-
2921. 
14. S. Shin, J. Seo, H. Han, S. Kang, H. Kim and T. Lee, Materials, 2016, 9, 116. 
15. K. K. Chung, J. F. Schumacher, E. M. Sampson, R. A. Burne, P. J. Antonelli and 
A. B. Brennan, Biointerphases, 2007, 2, 89-94. 
16. S. T. Reddy, K. K. Chung, C. J. McDaniel, R. O. Darouiche, J. Landman and A. B. 
Brennan, Journal of Endourology, 2011, 25, 1547-1552. 
17. L.-C. Xu and C. A. Siedlecki, Acta Biomaterialia, 2012, 8, 72-81. 
18. K. R. Milner, A. J. Snyder and C. A. Siedlecki, Journal of Biomedical Materials 
Research Part A, 2006, 76A, 561-570. 
19. M. W. Radomski, R. M. J. Palmer and S. Moncada, Biochemical and Biophysical 
Research Communications, 1987, 148, 1482-1489. 
20. C. Bogdan, Nat Immunol, 2001, 2, 907-916. 
21. F. C. Fang, Journal of Clinical Investigation, 1997, 99, 2818-2825. 
22. M. L. Jones, J. G. Ganopolsky, A. Labbé, C. Wahl and S. Prakash, Applied 
Microbiology and Biotechnology, 2010, 88, 401-407. 
23. B. J. Privett, A. D. Broadnax, S. J. Bauman, D. A. Riccio and M. H. Schoenfisch, 
Nitric Oxide, 2012, 26, 169-173. 
24. A. B. Seabra, D. Martins, M. Simoes, R. da Silva, M. Brocchi and M. G. de 
Oliveira, Artificial Organs, 2010, 34, E204-E214. 
25. J. Park, J. Kim, K. Singha, D.-K. Han, H. Park and W. J. Kim, Biomaterials, 2013, 
34, 8766-8775. 
26. W. Cai, J. Wu, C. Xi and M. E. Meyerhoff, Biomaterials, 2012, 33, 7933-7944. 
 
 219 
27. N. Barraud, M. J. Kelso, S. A. Rice and S. Kjelleberg, Current Pharmaceutical 
Design, 2015, 21, 31-42. 
28. M. C. Frost, M. M. Reynolds and M. E. Meyerhoff, Biomaterials, 2005, 26, 1685-
1693. 
29. H. Handa, E. J. Brisbois, T. C. Major, L. Refahiyat, K. A. Amoako, G. M. Annich, 
R. H. Bartlett and M. E. Meyerhoff, Journal of materials chemistry. B, Materials 
for biology and medicine, 2013, 1, 3578-3587. 
30. V. N. Varu, N. D. Tsihlis and M. R. Kibbe, Vasc Endovascular Surg, 2009, 43, 
121-131. 
31. P. N. Coneski and M. H. Schoenfisch, Polymer Chemistry, 2011, 2, 906-913. 
32. J. R. Laver, S. McLean, L. A. Bowman, L. J. Harrison, R. C. Read and R. K. Poole, 
Antioxid Redox Signal, 2013, 18, 309-322. 
33. H. Ren, J. Wu, C. Xi, N. Lehnert, T. Major, R. H. Bartlett and M. E. Meyerhoff, 
ACS Appl Mater Interfaces, 2014, 6, 3779-3783. 
34. C. M. Moore, M. M. Nakano, T. Wang, R. W. Ye and J. D. Helmann, Journal of 
Bacteriology, 2004, 186, 4655-4664. 
35. E. J. Brisbois, H. Handa, T. C. Major, R. H. Bartlett and M. E. Meyerhoff, 
Biomaterials, 2013, 34, 6957-6966. 
36. Y. Wo, Z. Li, E. J. Brisbois, A. Colletta, J. Wu, T. C. Major, C. Xi, R. H. Bartlett, 
A. J. Matzger and M. E. Meyerhoff, ACS Appl Mater Interfaces, 2015, 7, 22218-
22227. 
37. E. J. Brisbois, R. P. Davis, A. M. Jones, T. C. Major, R. H. Bartlett, M. E. 
Meyerhoff and H. Handa, Journal of materials chemistry. B, Materials for biology 
and medicine, 2015, 3, 1639-1645. 
38. A. Colletta, J. Wu, Y. Wo, M. Kappler, H. Chen, C. Xi and M. E. Meyerhoff, ACS 
Biomaterials Science & Engineering, 2015, 1, 416-424. 
39. S. R. Gill, D. E. Fouts, G. L. Archer, E. F. Mongodin, R. T. Deboy, J. Ravel, I. T. 
Paulsen, J. F. Kolonay, L. Brinkac, M. Beanan, R. J. Dodson, S. C. Daugherty, R. 
Madupu, S. V. Angiuoli, A. S. Durkin, D. H. Haft, J. Vamathevan, H. Khouri, T. 
Utterback, C. Lee, G. Dimitrov, L. Jiang, H. Qin, J. Weidman, K. Tran, K. Kang, 
I. R. Hance, K. E. Nelson and C. M. Fraser, J Bacteriol, 2005, 187, 2426-2438. 
40. L. C. Xu and C. A. Siedlecki, Biomedical Materials, 2014, 9, 035003. 
41. P. G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai and A. J. Janczuk, Chemical 
Reviews, 2002, 102, 1091-1134. 
42. C.-E. Lin, S. K. Richardson, W. Wang, T. Wang and D. S. Garvey, Tetrahedron, 
2006, 62, 8410-8418. 
43. M. W. Vaughn, L. Kuo and J. C. Liao, Am J Physiol, 1998, 274, H2163-2176. 
44. J. D. Patel, M. Ebert, R. Ward and J. M. Anderson, Journal of Biomedical Materials 
Research Part A, 2007, 80A, 742-751. 
45. C. P. Xu, N. P. Boks, J. de Vries, H. J. Kaper, W. Norde, H. J. Busscher and H. C. 
van der Mei, Applied and Environmental Microbiology, 2008, 74, 7522-7528. 
46. O. M. Hartford, E. R. Wann, M. Hook and T. J. Foster, Journal of Biological 
Chemistry, 2001, 276, 2466-2473. 
47. A. Cassie and S. Baxter, Transactions of the Faraday Society, 1944, 40, 546-551. 
48. K. A. Poelstra, N. A. Barekzi, A. M. Rediske, A. G. Felts, J. B. Slunt and D. W. 
Grainger, Journal of Biomedical Materials Research, 2002, 60, 206-215. 
 
 220 
49. E. M. Hetrick and M. H. Schoenfisch, Chem Soc Rev, 2006, 35, 780-789. 
50. Y. Wo, E. J. Brisbois, R. H. Bartlett and M. E. Meyerhoff, Biomaterials Science, 






CHAPTER 6  
Dual Functioning Antibacterial Surface via Controlled 
Delivery of Nitric Oxide Combined with Submicron-Textured 
Surface Topography 
 
Wo, Y. †; Xu, L. †; Meyerhoff, M.E.; Siedlecki, C.A. Biomater Sci, submitted. 
† These authors have contributed equally to this work.* 
 
6.1 Introduction 
Bacterial attachment and biofilm formation play a substantial role in causing health-care 
related infections in the hospital, especially those associated with the use of implanted 
biomedical devices, such as intravascular (IV) catheters, urinary catheters, prosthetic heart 
valves, and orthopedic implants.1–3  Such biomaterial-associated infections are extremely 
difficult to treat by use of antibiotics alone due to formation of microbial biofilm that 
consists of an extracellular polymeric substance (EPS), also known as the “house of biofilm 
cells”.  EPS is known to be a physical barrier that protects bacteria in mature biofilm from
                                                
* The SNAP synthesis, polymer impregnation, NO release measurements and statistical analysis were 
conducted by the Ph.D. candidate, while the preparation of the textured materials, AFM characterization and 
antibacterial testing reported in this chapter were conducted by Dr. Lichong Xu. 
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 traditional antibiotic treatment.4,5  It has been suggested that the slow penetration rate of 
antibiotics can thus foster the expression of genes in the bacteria that mediate antibiotic 
resistance.6  Thus, surgical removal and replacement of an infected implanted devices often 
is the only option in this situation, causing significant morbidity and mortality, and this 
greatly influences patient outcome and  healthcarecost.7,8  Several bacteria are commonly 
found to be associated with catheter-related bloodstream infections (CRBSIs), including 
Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), 
Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli).9–12  Table 6.1 
summarizes the four bacteria’s characteristics based on their shape, gram staining, with or 








Staining With or without coagulase 
Virulence and % responsible for 
CRBSIs 
S. aureus grape positive coagulase positive 
40 % 9,10 
25 % in children 39,40  
22 % 41 
20 % is responsible for CLABSIs 42 ** 
MRSA accounts for >50 % of all S.aureus 
infection 43 
1 in 4 S.aureus colonization on IV 
catheters develop to bacteremia if not 
treated w/antibiotics 39,44 
S. epidermidis grape positive coagulase negative 
< 34 % in children 39,40 * 
< 37 % 41 * 
< 8 % 10 * 
< 31 % is responsible for CLABSIs 42 ** 
22 %, repsonsible for BSIs in ICU in US, 
causing 2 billion annually in US 12 
P. aeruginosa rod negative coagulase negative 16 % 
10 
5.5 % 41 
E. coli rod negative n/a 8 % 
10 
6 % is responsible for CLABSIs 42 ** 
 
* The data reported in the papers are for coagulase negative Staphylococci (CoNS) in general, in which one of the most important strain is  
S. epidermidis, therefore the % responsible for CRBSIs by S. epidermidis is reported as "< % for CoNS". 




The first step of biofilm formation on the surface of medical devices is bacteria attachment.  
For a successful long-term implant, the device should ideally be able to prevent bacterial 
colonization, especially in the most susceptible initial 6 h of post-implantation which is 
termed the “decisive period”.13  Therefore, developing biomaterial surfaces that can resist 
bacteria attachment represents one of the most straightforward solutions to this problem.8  
Bacteria can adhere to biomaterial surface via either nonspecific interactions or indirect 
binding to molecules adsorbed on the material.  Therefore, one strategy is to mediate 
bacterial adhesion by modifying the material’s surface property and reduce the initial 
bacterial attachment.  Surface texture manufacturing techniques can be applied to 
biomaterials as a means to obtain topographical features that mimic the skin of a shark.14,15  
This physical modification of the polymer surface can reduce the surface contact area and 
the availability of binding sites of bacteria cells.  Xu et al. have demonstrated that 
submicron-textured surface featuring patterns with pillars of diameter and spacing of 
400/400 nm and 500/500 nm can decrease the adhesion and bacterial colonization of S. 
aureus and S. epidermidis.8 Helbig et al. have also reported ordered surface structure with 
dimensions (holes, posts or lines) in similar range as bacterial cell size can decrease S. 
epidermidis and E. coli bacterial adhesion, regardless of contact time (minutes to hours) or 
surface hydrophobicity.16 
 
Antibacterial biomaterials that can release nitric oxide (NO), which mimics the NO release 
from nasal epithelial cells, macrophage anti-inflammatory cells and endothelial cells, 
etc.,3,17–21 have also gained great research interest over the past two decades. NO serves as 
an indispensable antimicrobial agent in our immune response system to combat infectious 
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diseases.21–23  NO possesses broad-spectrum antibacterial activity against both gram-
positive and gram-negative bacteria, including methicillin-resistant S. aureus (MRSA), 
without any known antibiotic resistance.24  Low levels of NO (picomolar to nanomolar in 
solution phase) are also an important signaling molecule in bacterial quorum sensing to 
minimize bacterial adhesion and disperse mature biofilm.25,26  Many NO releasing 
polymeric materials, where NO is released/generated via decomposition of various NO 
donors (e.g., N-diazeniumdiolates or S-nitrothiols, etc.) or reduction of nitrite through 
electrochemical modulation, have been evaluated for their antibacterial and antibiofilm 
efficacy in vitro.27–33  S-Nitroso-N-acetylpenicillamine (SNAP) is a particularly attractive 
S-nitrothiols for incorporation into biomedical grade polymers for NO release application 
because of its low cost, safety and potential for long-term NO release.6,30,34,35    SNAP also 
exhibits long term stability during 8 months storage in the dark at 37 °C when incorporated 
into CarboSil 20 80A, a low water uptake silicone-polycarbonate-urethane tri-block 
copolymer (see Chapter 2 of this dissertation).30  Polyurethane block copolymers have been 
widely used for blood-contacting medical devices due to their relatively good 
biocompatibility, that partly result from the micro-phase separation between the 
thermodynamic immiscibility of hard segments and soft segments.8,36,37  Specifically, 
SNAP-doped CarboSil IV catheters exhibited potent antibacterial effect in vitro against S. 
aureus with 5-log unit reduction of viable bacteria count on SNAP catheter surface than 
the corresponding controls, in a 7 d study using a drip-flow biofilm reactor.30  These results 
have demonstrated that NO releasing materials represent an attractive antibacterial 




Although either physical surface modification (topographical surface textures) and 
chemical modification (nitric oxide release) have both been proven to be effective approach 
to inhibit bacterial adhesion and biofilm formation in prior studies, a very promising 
approach would be to combine these two techniques to create enhanced dual functioning 
antibacterial polymer surfaces for clinical use.  Since both approaches can reduce bacterial 
attachment and thus prevent biofilm formation, the single cells either adhered onto catheter 
surface or in bulk of blood, are subject to antibiotic treatment without the physical barrier 
and protection from EPS, which would greatly reduce the possibility of CRBSIs.  
Therefore, a submicron textured surfaces with reduced surface area that would decrease 
bacteria adhesion coupled with long-term NO release can better inhibit biofilm formation 
than either of these two methods alone.   
 
Previously, we have reported our effort to prepare CarboSil films that bear ordered pillar 
topography at the top surface using a soft lithography two-stage replication process using 
by layer-by-layer spin-coating technique and formed a ”sandwich-like” film configuration 
with SNAP-doped CarboSil in middle layer and top thin layer textured with pattern (see 
Chapter 5).  Obviously such a process is time-consuming, often requiring 1-2 weeks to 
reach the desired thickness.  Furthermore, the repeated spin-coating of new SNAP-polymer 
solution onto the dried SNAP-polymer surface may lead to the re-dissolution and re-
crystallization of SNAP, causing undesired SNAP degradation during fabrication.   
 
Therefore, herein, a simple solvent impregnation approach to incorporate NO donor SNAP 
into the bulk of a surface textured polymer film is described.  Textured CarboSil films 
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without SNAP were first fabricated by spin-coating8 and dried.  Then the polymer film 
bearing the ordered pillar topography was immersed in an optimized SNAP/solvent 
solution for SNAP impregnation.  After thorough drying, the resulting material is shown 
to achieve long-term NO release.  StreamLine High Resolution (HR) Raman mapping 
characterization was utilized to elucidate the chemical constituent of crystals inside of the 
SNAP-impregnated CarboSil films in combination with the 2D representation of crystal 
distribution.  In vitro bacterial adhesion studies were conducted to examine the anti-
bacterial adhesion efficacy and analyze if there is any interaction between surface texturing 
and NO release and whether the antibacterial efficacy from SNAP-impregnated textured 
CarboSil films are additive or synergistic against the four microorganisms mentioned 
above.  
 
6.2 Experimental Section 
6.2.1 Materials 
N-Acetyl-D-penicillamine (NAP), sodium nitrite, L-cysteine, sodium chloride, potassium 
chloride, sodium phosphate dibasic, potassium phosphate monobasic, copper (II) chloride, 
ethylenediaminetetraacetic acid (EDTA), tetrahydrofuran (THF) and N,N-
dimethylacetamide (DMAc) were purchased from Sigma-Aldrich (St. Louis, MO).  
Methanol (MeOH), methyl ethyl ketone (MEK), hydrochloric acid, sulfuric acid were 
products of Fisher Scientific (Hampton, NH).  CarboSil 20 80A was obtained from DSM 
Biomedical Inc. (Berkeley, CA).  All aqueous solutions were prepared with 18.2 MΩ-
deionized water using a Milli-Q filter from EMD Millipore (Billerica, MA).  Phosphate 
buffered saline (PBS), pH 7.4, containing 138 mM NaCl, 2.7 mM KCl, 10 mM sodium 
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phosphate, and 100 µM EDTA was used for all in vitro experiments.  Textured silicon 
wafers were fabricated by RTI International (Research Triangle Park, NC) based on 
requirements.  S. epidermidis ATCC  35984, S. aureus ATCC 25904, P. aeruginosa ATCC 
27853 and E. coli ATCC 11775 were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA).   
 
6.2.2 Preparation of smooth and textured CarboSil film 
The CarboSil 2080A PU film surfaces were textured with ordered arrays of pillars using a 
modified soft lithography two-stage replication molding technique that has been described 
previously.8  Briefly, textured silicon wafers with different ordered array of pillars, either 
fabricated by RTI International (Research Triangle Park, NC) or Penn State 
Nanofabrication Lab (State College, PA), were used as the master patterns to prepare the 
master PDMS molds and the corresponding CarboSil films were then fabricated. CarboSil 
pellets were dissolved in N,N-dimethylacetamide (DMAc) at concentration of 15 w/v% 
(1.5 g PU in 10 ml DMAc) and was spin-coated onto the silicon mold to prepare the 
textured CarboSil films.  To obtain the highest replication efficiency of surface topography, 
the films were prepared by spin casting CarboSil onto a PDMS mold at 1200 rpm for 1 min 
in one thin layer first, followed by degassing and curing overnight at room temperature 
under vacuum.  Then, additional layers of CarboSil were added by spin casting at 600 rpm 
for 1 min, respectively, until reaching the desired thickness of 700 µm.  Each layer was 
degassed and cured at room temperature under vacuum.  The master silicon wafers with 
pillar geometries having diameter (d), separation (s) and height (h) values of 400/400/600 
nm, 500/500/600 nm and 700/700/300 nm were used as the masters for replicating CarboSil 
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textured films for AFM images, but only 700/700/300 nm textured films were used in all 
in vitro experiments. Smooth CarboSil films were also prepared by spin-coating against a 
smooth PDMS mold.8 
 
6.2.3 SNAP impregnation of textured CarboSil film 
Small disks of films (10 mm in diameter) were punched out from both the  smooth and 
textured CarboSil films. As described previously in Chapter 4, the films were impregnated 
in solutions (70 % MEK and 30 % MeOH) with different SNAP solution concentrations 
(35, 65 and 110 mg/mL) to achieve 5, 10 and 15 wt% SNAP loading, respectively.  After 
2 h of impregnation, the films were removed from the impregnation solution, quickly wash 
with methanol to remove any residual SNAP solution on the film surface, and allowed to 
dry thoroughly in an ambient environment protected from light exposure.  
 
6.2.4 Characterization of surface topography by atomic force microscopy (AFM) 
Multimode AFM with a Nanoscope IIIa control system (software version 5.12r3, Veeco, 
Santa Barbara, CA) was used to examine the surface textures of CarboSil films operated in 
tapping mode (intermittent contact) using Si probes having aspect ratio of ~ 4:1 (TETRA, 
K-Tek Nanotechnology, Wilsonville, OR) in air.  AFM was also used to image the bacterial 
adhesion on CarboSil PU surfaces.  AFM images were viewed and analyzed by off-line 




6.2.5 Surface water wettability measurement 
The water wettability of all CarboSil PU films was determined as the advancing water 
contact angle measured by the Sessile drop method using a Krüss contact angle goniometer.  
All measurements were made using water as a probe liquid and an ~ 8 µl of water droplet 
was used for the measurement.  Advancing contact angles were obtained by a minimum of 
eight independent measurements and are presented as mean ± standard deviation. 
 
6.2.6 NO release measurement by nitric oxide analyzer (NOA) 
Nitric oxide release from the CarboSil films was measured by a Nitric Oxide Analyzer 
(NOA) 280i (Boulder, CO) via chemiluminescence.  Briefly, films with diameter of ~10 
mm were placed in the sample vessel immersed in 4 mL PBS containing 100 µM EDTA 
at 37°C.  NO was continuously purged from the buffer and swept from the headspace using 
nitrogen gas and a bubbler into the chemiluminescence detection chamber of the NOA.  
When not being tested with the NOA, the SNAP-doped samples were incubated in PBS 
under same conditions, protected from light exposure. 
 
6.2.7 Characterization of SNAP-impregnated and SNAP-doped CarboSil films by Raman 
spectroscopy 
StreamLine High Resolution (HR) Raman mapping characterization was utilized to map 
the two-dimensional SNAP crystal distribution at the cross-section of a 5 wt% SNAP-
impregnated CarboSil film and a 5 wt% SNAP-doped CarboSil film.  The film was first 
cut to expose its cross-section and then embedded into optimal cutting temperature 
compound (OCT), allowed to harden at -20 °C, and then cut carefully into 30 µm thick 
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slices by a Leica CM3050S research cryostat.  StreamLine HR Raman Mapping 
experiments were conducted by using a Renishaw inVia Raman microscope equipped with 
a Leica microscope, a RenCam CCD detector and a 785nm laser employing a 1200 
lines/nm grating and a 50 µm slit.  The obtained spectrum of each spot was fitted with pure 
orthorhombic SNAP spectrum as the reference, and the green areas in the presented figures 
correspond to regions fitting the characteristic peaks of orthorhombic SNAP. 
 
6.2.8 Bacterial adhesion on the surface of CarboSil films with different configuration 
The methods used for culturing and collection of bacteria have been reported previously.8  
Bacterial colonies of four different strains were cultured in tryptic soy broth (TSB) at 37 
°C for 24 h and collected by centrifuge at 1360g for 10 min.  The collected bacteria were 
then re-suspended in PBS and diluted to a final concentration of 1×107 CFU/mL, as 
determined by turbidity measurement at 600 nm using a spectrophotometer.  All CarboSil 
films, both smooth or textured, with increasing SNAP concentration (0, 5, 10, 15 wt%), 
were pre-hydrated in Millipore water for 24 h and conditioned in PBS for 1 h before use.  
Bacterial adhesion studies were conducted by placing the CarboSil films in a 12-well 
home-made microwell containing 0.5 mL of bacteria suspended in PBS solution at 37°C 
for 1 h under static conditions.  After the experiment, the film was washed with PBS 3 
times, and then the bacteria remaining on the film surface were fixed in 2.5% 
glutaraldehyde for 2 h.   The bacteria on the films were washed with PBS again before 
being stained with Hoechst 33258 (Invitrogen) and analyzed under a fluorescence optical 
microscope (Nikon, Eclipse 80i).  Nine optical microscopy images of each film were taken 
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(50 µm × 50 µm) and the number of bacteria adhered on the surface was counted and 
average ± standard error or means were used for statistical analysis. 
 
6.2.9 Statistical Analysis 
Statistical analysis of the bacterial adhesion data was performed using IBM SPSS statistics 
22.  The data were analyzed using a univariate general linear model to determine the 
significance of SNAP, surface texturing, and the interaction of SNAP´texturing on the 
reduction of bacterial adhesion.  Briefly, the 700/700/300 texture topography property of 
the film was set as covariate X1 (depicted as 0 or 1), and the SNAP concentration in the 
film was set as fixed factors X2 (depicted as 0, 1, 2 or 3).  The number of bacteria adhered 
on the surface was the dependent variable, Y.  The analysis was conducted to determine if 
X1 or X2 have significant impact on the outcome, and also to determine if there is any 
significant interaction between X1 and X2.  The data analysis was always first conducted 
assuming there is interaction between the two factors, then if the significance p is <0.05, 
then there is interaction between the factors, suggesting that texturing and NO release have 
a synergistic effect on reducing bacteria adhesion.  If the significance p is > 0.05, then there 
is no interaction between surface topography and NO release and they have only an 
additive effect on reducing bacteria adhesion. 
 
6.3 Results and Discussion 
6.3.1 Characterization of SNAP-impregnated textured CarboSil films 
CarboSil films were textured with ordered arrays of pillars using a soft lithography two-
stage replication molding technique.  Initially, Carbosil films with different dimensions, 
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including 400/400/600 nm, 500/500/600 nm, 700/700/300 nm patterns, depicted by their 
diameter/separation/height, were prepared  Textured silicon wafers were used as the master 
patterns to prepare the master PDMS molds (Figure 6.1A) and the corresponding CarboSil 
films were then fabricated using the PDMS molds (Figure 6.1B).  Textured Carbosil film 
bearing different topographical patterns were punched out and impregnated with 5, 10 and 
15 wt% SNAP loading.  However, further topography images showed that the cylinder 
pillars with dimensions of 400 or 500 nm in diameter and 600 nm in height were collapsed 
due to the solvent during impregnation, while the shorter and larger pillars with 700 nm in 
size and 300 nm in height remain intact, which suggested that the solvent impregnation 
process is more suitable for the pillars with low aspect ratio of height to diameter.  As a 
result, 5 wt%, 10 wt% and 15 wt% SNAP-impregnated smooth and textured (700/700/300 
nm) CarboSil films were fabricated for further characterization and bacterial adhesion 
studies.   
 
Figure 6.1. Schematic diagrams of the steps in the soft lithography two-stage replication 
molding technique employed to prepare textured CarboSil films, followed by SNAP 





The topographical surface texture and pillars remain intact in all SNAP-impregnated 
textured CarboSil films (5, 10 and 15 wt%), as shown in the atomic force microscopy 
(AFM) images.  Representative AFM images of the textured film before and after 10 wt% 
SNAP impregnation are shown in Figure 6.2.  
 
Figure 6.2. 2D AFM images of textured PU surface (A) before and (B) after impregnation 
of SNAP.  Bearing analysis showing the overall height difference of pillars (C) before and 
(D) after impregnation of SNAP (scale bar = 5 µm).  The red cursors represent the height 
levels of surface features with maximum bearing area fraction.  The distance between two 




The bearing analysis of surface topography shows that the average height of pillars of films 
before impregnation is about 300 nm, while the height of pillars reduced to about 220 nm 
after impregnation.  The reduction in pillar height is believed to be due to the impregnation 
of SNAP that lifts the level of the base.  The regular smooth CarboSil films and CarboSil 
films with SNAP impregnation are hydrophobic, with the water contact angle of ~90.5°.  
Surface texturing increased the hydrophobicity of the polymer films to 122.5° due to air 
trapped in between pillars (Figure 6.3), but lower than the contact angle of regular textured 
films (~145°).  The results demonstrate that SNAP impregnation into polymer films 
decreased the hydrophobicity of the polymer surface. 
 
Figure 6.3. Water contact angle of smooth and textured (700/700/300 nm pattern) CarboSil 
films with different concentration (0, 5, 10 and 15 wt%) of SNAP impregnation. 
 
NO release varied with the concentration of SNAP incorporated into the PU films.  NO 
release of 5 wt%, 10 wt% and 15 wt% SNAP-impregnated textured CarboSil films were 
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measured by the nitric oxide analyzer (NOA) via chemiluminescence.   Briefly, the NO 
release from films in PBS buffer at 37°C was measured at various time points for 4 h each 
time, and the average NO flux over the 4 h period was used to represent the average NO 
flux of the film during that day.  The films were incubated in PBS buffer at 37 °C and 
protected from light when not being tested, and the buffer solution was changed daily.  NO 
release from SNAP-impregnated textured films can last up to 9, 19 and 38 d at 
physiological conditions (with flux > 0.5 x 10 -10 mol cm-2 min -1, the lower end of 
physiological NO level released by endothelial cells) for the 5 wt%, 10 wt% and 15 wt% 
films, respectively (see Figure 6.4).   
 
Figure 6.4. NO release profile at physiological conditions from 5 wt% (A), 10 wt% (B) 
and 15 wt% (C) SNAP-impregnated CarboSil films with 700/700/300 nm surface textures. 
  
The main advantage of SNAP impregnated textured CarboSil films is its preparation time 
efficiency, stability and extended NO release lifetime.  In the previous study, we have 
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prepared SNAP-textured CarboSil film by a layer-by-layer type spin-coating procedure 
where SNAP is doped in the middle layer of the sandwich like CarboSil film bearing 
textured pattern on the top (Chapter 5).  However, not only is that process extremely time-
consuming, but also the repeated dissolution of crystalized SNAP may lead to SNAP 
degradation during fabrication and shorten the NO release lifetime.  The solvent 
impregnation technique allows SNAP incorporation into the CarboSil polymer via a one 
step method following polymer solvent swelling, and the impregnated SNAP will 
crystallize in the bulk of the material as the solvents evaporate (see Chapter 4).  It is known 
that SNAP can partially dissolve in CarboSil polymer with a solubility limit of ~3.4-4 
wt%30 and SNAP exceeding this concentration will form a stable polymer-crystal 
composite that can lead to stable, long-term NO release from the polymer film.   
 
In order to compare the SNAP crystal distribution in textured CarboSil film prepared by 
the spin-coating and solvent impregnation methods, Raman mapping was conducted to 
compare the crystal distribution in 5 wt% SNAP-doped and 5 wt% SNAP-impregnated 
CarboSil films.  It was hypothesized that SNAP molecules were “inserted” into the 
interspace between the layers of the CarboSil 20 80A polymer (see Chapter 4), within a 
lamellae structure of the PDMS phase and the polycarbonate/polyurethane hard segment 
mixed phase,38 during solvent impregnation.  This process may result in a slightly less 
uniform crystals distribution in the 5 % SNAP-impregnated films when compared to the 5 
wt% SNAP-doped films that are prepared by the traditional spin coating technique 
employed in Chapter 4.  Two-dimensional Raman spectra of the cross-section of 5 wt% 
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SNAP-doped textured CarboSil film (A) and 5 wt% SNAP-impregnated film (Figure 6.5) 
indeed validate this hypothesis.  
 
Figure 6.5. StreamLine HR Raman mapping results for fitting of cross section of A) 5 wt% 
SNAP-doped CarboSil films and (B) 5 wt% SNAP-impregnated CarboSil films, under 50× 
objective.  Green areas represent the distribution of crystalline SNAP, which is less uniform 
in the 5 wt% SNAP-impregnated CarboSil films. 
 
6.3.2 Evaluation of the antibacterial adhesion properties of NO releasing textured films 
To evaluate the anti-bacterial adhesion properties of CarboSil films with respect to surface 
topography and SNAP concentration, all films with different configurations were 
incubated with different strains of bacteria in PBS buffer (with a concentration of 1×107 
CFU/mL) at 37°C for 1 h, respectively.  At the end of each experiment, the films were 
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observed under fluorescent optical microscope and the average of bacterial count on the 
surface of the films per unit area (104 µm2) were compared (see Figure 6.6).   
 
Figure 6.6.  Summary of bacterial adhesion on CarboSil films with different configurations 
under static conditions at 37°C for 1 h, represented as the number of adhered bacteria per 
104 µm2 of polymer film. 
 
Without any NO release from the polymer film (0 wt% SNAP), the 700/700/300 nm surface 
texture alone reduced the bacteria count by 28 %, 33 %, 49 % and 27 % for S. aureus, S. 
epidermidis, P. aeruginosa and E. coli, respectively.  However, with NO release from 
polymer film (15 wt% SNAP), the reduction rate of textured surface increased to 61 %, 86 
%, 88 % and 85 %, respectively.  Bacterial adhesion generally decreases with an increase 
of SNAP concentration and the concomitant increase of NO release rate.  A univariate 
general linear model was utilized to analyze the significance of surface texture and NO 
release (SNAP) on reduction of bacteria adhesion as well as to determine if there is any 
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interaction between surface texturing and NO release with respect to the observed bacteria 
count reduction.  The results are summarized in Table 6.2 and indicate that either surface 
texturing or NO release alone have a significant effect on reduced bacterial cell adhesion 
to the surface, regardless of bacteria strain tested.  There was significant interaction 
between the two factors for S. epidermidis (p=0.037) and P. aeruginosa (p<0.001), but a 
non-significant interaction for S. aureus (p=0.199) and E coli (p=0.089).  This means that 
surface texturing and NO release produced a synergistic effect on bacterial adhesion 
reduction for S. epidermidis and P. aeruginosa but the effect was only additive for reducing 
adhesion of S. aureus and E. coli.  But the mechanism of synergy between texturing and 
NO release on preventing bacterial adhesion in a short period of time is not entirely clear 
and the different effects of these two factors on different bacteria stains still need careful 
investigation in the future.  
Table 6.2. Statistical analysis of the bacterial adhesion result, in which X1 represents 
texture and X2 (0, 1, 2, 3) represents 0, 5, 10 and 15 wt% of SNAP in films. 
Significance 
Parameter S. aureus S. epidermidis P. aeruginosa E. coli 
X1*X2 0.199 0.037 <0.001 0.089 
X1 <0.001 0.031 <0.001 <0.001 
[X2=0] <0.001 <0.001 <0.001 <0.001 
[X2=1] <0.001 0.041 <0.001 0.001 
[X2=2] 0.013 0.101 0.108 0.492 
[X2=3] 0a 0a 0a 0a 




[X2=1] * X1 0.577 0.004 
[X2=2] * X1 0.527 0.136 
[X2=3] * X1 0a 0a 




AFM surface images of CarboSil films after bacterial adhesion were also taken in order to 
examine the distribution and orientation of adhered bacteria on polymer film surfaces. The 
representative images of S. epidermidis and P. aeruginosa adhesion on CarboSil films with 
different configurations are presented in Figure 6.7 A and B, respectively.  Similar to the 
optical microscopic images, the bacteria count on polymer surfaces visibly decrease with 
increasing SNAP concentration (0, 5, 10, 15 wt%), for both smooth and textured films.  For 
CarboSil films with the same SNAP concentration, bacteria attach less to the surfaces with 
a textured pattern than the smooth surfaces.  Of note, the grape shape S. epidermidis 
bacteria were mostly present in 2 or 3 or more cell clusters on the film surface and no cell 
clusters were trapped in the space between pillars, for films either with or without SNAP 
impregnation (see Figure 6.7A).  However, as shown in the enlarged AFM images (Figure 
6.7B), the larger rod shaped P. aeruginosa species on the film surfaces were mostly single 
microbes, and hence this bacteria can be trapped in between the grooves of the pillars on 
the surface of the textured films without NO release and their orientation is aligned with 
the pattern features.  Surprisingly, the P. aeruginosa were merely adhered on the surface 
but not trapped in between pillar spaces on the textured films when the films do not have 
NO release, and this indicates the importance of NO in reducing bacterial adhesion via its 
role as a signaling molecule.  In the future, it will be important to examine and compare 
the influence of different parameters of the pillar arrays in surface topographical designs, 








Figure 6.7. Representative AFM images of A) S. epidermidis and B) P. aeruginosa 
adhesion on CarboSil films with different configuration after 1 h incubation, scale bar is 
10 µm.  To better observe the bacterial orientation on the textured pattern surface, he 
magnified images for S.epidermidis (top-view) and P. aeruginosa (side-view) are provided 






In summary, a novel dual functioning CarboSil polymer surface with texturing and NO 
release have been prepared by fabricating polymeric films bearing ordered submicron 
(700/700/300 nm) pillars on top surface first and subsequently impregnating the films with 
the NO donor SNAP to achieve NO release.  This preparation approach is much more time-
efficient and produces more stable and longer-term NO release at physiological conditions, 
compared to sequential spin coating method described in Chapter 5.  Both surface texture 
and NO release alone can significantly reduce bacterial adhesion of S. aureus, S. 
epidermidis, P. aeruginosa and E. coli, respectively.  Moreover, synergy was observed 
between texturing and NO release against S. epidermidis and P. aeruginosa microbial 
adhesion.  Such a dual functionality surface should provide a promising approach to devise 
new biomaterials that can significantly reduce bacterial adhesion, and thus potentially 
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CHAPTER 7  
Conclusion and Future Directions 
 
7.1 Conclusion 
As demonstrated within this dissertation, nitric oxide (NO), an endogenously produced 
small gas molecule, has many favorable physiological functions that can be used for 
improving the biocompatibility of implanted medical devices, such as intravascular 
catheters, urinary catheters, etc.  The term “biocompatibility” is interpreted differently 
under different circumstances. The ideal biocompatible surface should prevent any protein 
adsorption, which is almost impossible to achieve.  Protein adsorption to device surfaces 
is considered the first critical step that occurs to promote platelet activation and also the 
colonization of the device surface with bacteria.  NO releasing materials cannot eliminate 
protein adsorption; however, they can directly inhibit platelet activation and thus disrupt 
the coagulation cascade which can ultimately prevent thrombus formation. Localized NO 
release can also kill microbes and prevent bacterial biofilm formation on surfaces.  Clearly, 
a stable and cost-effective polymeric matrix that can provide continuous, long-term NO 
release would significantly facilitate the applications of the NO release technology in 
various medical settings.  This thesis has focused on the study and applications of SNAP-




In Chapter 2, it was demonstrated that doping SNAP into CarboSil 20 80A polymer, a 
commercial tri-block copolymer of polydimethylsiloxane, polycarbonate and 
polyurethane, generates a very attractive material for biomedical application.  The 
mechanism of the long-term stability and NO release capability was elucidate using solid-
state analysis.  This work showed that most of the SNAP crystalizes via hydrogen bonding 
within the bulk of the CarboSil polymer phase that has very low water uptake and that slow 
dissolution of the crystals leads to the long-term NO release upon solution contact.  SNAP-
doped CarboSil catheters with a silicone rubber top-coating showed reduced clotting when 
implanted in blood vessels of rabbits 7 h and prevented the S. aureus bacterial biofilm 
formation on its surface during 7 d in vitro experiments using a drip-flow bioreactor.  
 
In Chapter 3, studies of the real-time crystallization process of SNAP within CarboSil 20 
80A were reported.  It was also demonstrated that the unique NO release mechanism from 
this polymer-crystal composite material is directly correlated with the surface area of the 
polymer that is exposed to aqueous solution, suggesting that a water rich layer within the 
outermost surfaces of the polymer is the likely site where most of the NO is liberated from 
soluble SNAP within the polymer.  SNAP-doped CarboSil catheters with CarboSil coating 
exhibited significant bactericidal effects against P. aeruginosa and P. mirabilis in 14 d 
anti-biofilm experiments in the CDC bioreactor, when compared to the controls of NAP-




Chapter 4 provided a significant follow-up report to a paper1 that was initially published 
that demonstrated, for the first time, that existing commercial urinary silicone Foley 
catheters can be impregnated with SNAP via a solvent swelling method.  In Chapter 4, the 
SNAP impregnation process was optimized for use with CarboSil 20 80A, a polymer that 
has better innate biocompatibility compared to silicone rubber and other common 
biomedical polyurethanes.  The SNAP impregnation process was optimized using using 
dip-coated CarboSil catheters that can be impregnated with a SNAP solution (120 mg/mL 
in 70 % MEK and 30 % methanol) to achieve 15 wt% SNAP loading within 2 h at room 
temperature.  After thorough drying to remove the impregnating solvent system, the 
resulting catheters impregnated with SNAP have were found to exhibit significant 
antimicrobial activity with respect to reducing mature biofilm formation by S. epidermidis 
and P. aeruginosa.  Testing these SNAP impregnated catheters within a rabbit model also 
demonstrated their greatly improved hemocompatibility when compared to the control 
catheters of the same material without NO release. 
 
Chapter 5 reported on a collaboration project between our group and Dr. Lichong Xu and 
Dr. Christopher A. Siedlecki at the Penn State Medical School.  We demonstrated, for the 
first time, on our effort to combine physical modification (topographical surface texture) 
and chemical modification (NO release) to create dual-functional antibacterial polymeric 
surfaces. A CarboSil polymer surface with ordered pillar topographies (400/400/600 nm 
and 500/500/600 nm patterns) at the top surface and a SNAP-doped layer in the middle 
was created by spin-coating via a soft lithography two-stage replication process.  The NO 
release from the underlying 15 wt% SNAP-doped CarboSil with 500/500/600 nm texture 
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on the top can last 10 d at or above the lower end of the physiological flux level.  Synergy 
was observed between surface texture and NO release for the inhibition of S. epidermidis 
bacterial adhesion on the pillared surface.  This new polymer surface can inhibit S. 
epidermidis biofilm formation for up to 28 d and provides an exciting approach to improve 
the antibacterial functionality of current biomimetic biomaterials. 
 
Chapter 6 provided a follow-up to Chapter 5 studies regarding the development of  dual-
functional biomaterial surfaces with enhanced antibacterial properties.  Spin-coating a tri-
layer film configuration with SNAP-doped CarboSil within the middle layer can be time-
consuming, and the repeated spin-coating of new polymer solution might lead to 
dissolution and decomposition of the previously dried SNAP layer.   Hence in Chapter 6, 
the combined NO release/textured CarboSil polymer film bearing 700/700/300 nm pillars 
was made first and then the NO release capability was incorporated to the material using 
the solvent impregnation technique described in Chapter 3.  Raman mapping demonstrated 
a slightly less uniform SNAP distribution in CarboSil films prepared by this impregnation 
approach (Chapter 6) compared to the spin-coating method (Chapter 5). The NO releasing 
textured surfaces displayed a synergistic effect in reducing bacterial adhesion by 
Staphylococcus epidermidis and Pseudomonas aeruginosa. 
 
Overall, this thesis work demonstrated that SNAP-incorporated within CarboSil has 
tremendous potential in improving the hemocompatibility and antibacterial properties of 
the blood contacting biomedical devices currently used in hospitals.  One of its biggest 
advantages is the stability of this composite material during long-term storage.  The lack 
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of need for precise temperature control during storage and shipping is very beneficial for 
any future commercialization of medical device products that would employ this 
technology.  
 
7.2 Future Directions 
7.2.1 The Cytotoxicity Test of SNAP on Mammalian Cells 
One important aspect that remains to be examined is whether SNAP-impregnated 
polymeric materials are safe in applications when they are not in contact with blood, such 
as when employed to create antimicrobial urinary catheters.1  In this application the NO 
release would occur in direct contact with urothelial cells that line the urethra, and unlike 
blood, such cells would not immediately scavenge the NO (via reaction with 
oxyhemoglobin).  Therefore, A follow-up study is needed to examine whether NO 
releasing SNAP-impregnated silicone Foley urinary catheters might potentially have 
cytotoxic effect on the urothelial cells. 
 
Very preliminary experiments toward this end were recently conducted by treating cells 
with SNAP solutions of different concentrations to evaluate their cytotoxicity.  Of note, 
AD-293 cells, a human embryonic kidney cell line, rather than urothelial cells were used 
as the subject cells in this preliminary study because of easy access.  
 
SNAP solution (7.5 mM) was prepared in PBS buffer first and then diluted by Dulbecco’s 
modified eagle medium (DMEM) cell culture media with 2 % BSA added to the desired 
SNAP concentrations of 0, 3.75, 7.5, 15, 150, 300, 500, 750 and 1500 µM.  The AD-293 
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cells were then plated (~10,000 cells/well) into the wells of the sterile 96-well cell culture 
plate in 200 µl of cell culture medium.  When the cells reached 90-95 % confluence, the 
cells were treated with the different dosages of SNAP solution.  Finally, at different time 
points (1, 2, 3, and 5 d), the cytotoxicity test was performed using the standard lactate 
dehydrogenase (LDH) assay kit2 and the results are shown in Figure 7.1. 
 
Figure 7.1. The cytotoxicity effect of SNAP solutions with different concentrations on 
AD-293 cells. 
 
The results indicated that SNAP has very minor cytotoxic effect on AD-293 cells within 5 
d culture period and that low doses of SNAP (<300 µM) could decrease cytotocixity and 
potentially protect the AD-293 cells.  Clearly, more cytotoxicity studies like this are needed 
in the future, especially using urothelial cells, and perhaps also using polymeric films with 




7.2.2 SNAP-Impregnated PDMS Microfluidic Device for Continuous Blood Analysis 
One potential application of SNAP-impregnated PDMS membranes/tubing is for the use 
in fabrication of hemocompatible microfluidic devices.  Dr. Shuichi Takayama’s research 
group in the Biomedical Engineering Department at U of M is interested in taking 
advantage of this material in order to pump whole blood at low flow rates through PDMS 
tubing and microchannels.3  This would be particularly useful in continuous monitoring of 
many important blood analytes, such as glucose, lactate, pH, etc.  For preliminary studies, 
in order to fabricate the NO releasing microfluidic devices, heat curable PDMS Sylgard® 
184 (Dow Corning Corporation) was spin-coated on microfluidic molds and cured to form 
thin membranes with embedded microchannels.4  These membranes were then 
impregnated in a solution of SNAP THF solution (50 mg/mL) for 24 h4 and the final 
membranes were allow to dry in ambient conditions for several days for complete removal 
of residual solvent.  Then one PDMS membrane with channels and one without channels 
were first treated with plasma oxidization,5 which can functionalize the PDMS surface and 
allow for bonding,  and then baked at 60 °C for 120 s.  After bonding, holes were punched 
out at the inlets/outlets, and SNAP-impregnated silicon tubing was connected in place to 
allow continuous flow of sample solution through the device.  The ultimate goal of this 
approach would be to use an integrated microfluidic pump6 to continuously withdraw 
patient blood at a constant low flow rate through an NO release SNAP doped catheter, 
which will then flow over different sensors for analyte detection (see Figure 7.2).  By 
minimizing sample volume, this device would minimize the impact of continuous blood 
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withdrawal and analysis on the patient.  A braille display based pump was first proposed 
as the peristaltic pump for continuous blow withdrawal (see Figure 7.3). 
 
Further studies are now needed to test this system for its ability to be coupled with a tiny 
SNAP impregnated catheter tubing for sampling blood continuously at very low flow rate 
without observing any clot formation in the tubing and pump.  Animal studies to pursue 
such testing will hopefully take place soon. 
 
Figure 7.2. The schematic of the integrated microfluidic pump for continuous blood 





Figure 7.3. The braille-based microcirculatory channels for peristaltic pump.  Upper 
images: braille display at ON and OFF mode; lower image: the connection between PDMS 
channels and the braille nodules. 
 
7.2.3 Development of Dual-functional Antibiotic and NO Releasing Catheters 
It is known that bacteria are sensitive to most broad spectrum antibiotics before they are 
protected by the extracellular polysaccharide matrix, also known as biofilm.  Cook Medical 
has manufactured catheters with the antibiotics rifampin and minocycline impregnated 
within peripherally inserted central line (PICC) catheters, with the aim of reducing the risk 
of catheter-related bloodstream infections.  However, after bacteria colonize the catheter 
surfaces, they can form biofilm that protect them from antibiotic penetration.  Therefore, it 
may be of interest to develop dual-functioning catheters that can release antibiotics as well 
as nitric oxide (NO), so we can utilize the function of NO as a signaling agent to prevent 
biofilm formation and the efficient bactericidal function of antibiotics against various 




So to pursue the preliminary feasibility of this conept an impregnation method for 
incorporation of two antibiotics, structures shown in Figure 7.4, rifampin (A) and 
minocycline (B) as well as NO donor SNAP, into commercial silicone tubing was pursued.  
 
Figure 7.4. The structures of antibiotics rifampin (A) and minocycline (B). 
 
Before screening the solvents system that can dissolve rifampin, minocycline and SNAP, 
and also be able to impregnate silicone rubber material, it is very important to optimize 
characterization method for accurate detection and quantification of the two antibiotics 
separately when the impregnated polymer is in contact with physiological solution.  The 
accurate qualification and separation of the antibiotics is essential for determination of the 
total loading of antibiotics within the silicone tubing.  UV-Vis spectra of rifampin and 






Figure 7.5. The UV-Vis absorbance spectra of rifampin and minocycline at 50 µg/mL.  
 
To avoid signal overlap in absorbance when both compounds are present in the soaking 
solution, 475 nm and 350 nm can be used as the characteristic wavelengths for 
identification and quantification of rifampin and minocycline, respectively.  Each antibiotic 
stock solution (50 µg/mL) was diluted with PBS buffer to the desired concentration for 
standard calibration.  Calibration curves for both rifampin (at 475 nm) and minocycline (at 
350 nm) were conducted by measuring the UV-Vis absorption of solutions containing 
different concentration of each antibiotic (see Figure 7.6 and Figure 7.7 for the absorbance 





Figure 7.6. The UV-Vis absorbance spectra of rifampin solutions with different 




Figure 7.7. The UV-Vis absorbance of minocycline solutions with different concentrations 
(A), and the resulting calibration curve of absorbance at 350 nm vs. concentration (B). 
 
Liquid chromatography-tandem mass spectrometry (6520 Accurate-Mass Q-TOF LC/MS, 
Agilent Technologies, CA) can also be optimized as a detection and qualification method 
for analyzing soaking solutions containing both antibiotics.  In preliminary studies toward 
use of this approach, the mass spectrometer used electrospray ionization in the positive ion 
mode, and the detected species were [M+H]+.  The m/z for rifampin ion is 823.4119, while 
the m/z for minocycline is 458.1922.  A reversed-phase column (ZORBAX RRHD Eclipse 
Plus C18, 1.8 µm, 2.1 x 50 mm) was used in order to separate the two antibiotics. The 
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gradient was obtained with eluent A (water with 0.1% formic acid) and eluent B (95% 
acetonitrile, 0.1% formic acid).  After sample injection (15 µL), a linear change of eluent 
mixtures from 95% A to 40% A over 7.5 min was carried out with a flow rate of 0.4 
mL/min.  Minocycline, log P = 0.20 (obtained by Marvin Sketch software) was separated 
from rifampin and eluted from the column first, between 2 to 2.2 min; rifampin, with log 







Figure 7.8. The total ion chromatography (TIC) of the separation result for a solution 
and rifampin, each at 6.25 µg/mL. The UV-Vis containing minocycline 
measurements using diode array detection (DAD) and the extracted ion 
chromatography results (EIC) of both antibiotics were also obtained. 
 
In order to eventually quantify the concentration of antibiotics in the solution using MS, 
calibration curves of concentration and peak area were plotted for samples detected by MS 





Figure 7.9. The calibration curves of peak area vs analytes concentration, for solutions 
containing 0.625, 3.125, 6.25, 12.5 and 25 µg/mL of both rifampin and minocycline. 
 
The ultimate goal of for future research would be to optimize the solvent system for 
impregnation of both of the antibiotics and SNAP into silicone tubing (and potentially other 
catheter tubing (e.g., CarboSil), and fabricate dual-functioning antibiotic and NO releasing 
polymeric tubing that might exhibit enhanced antibacterial efficiency.  After characterizing 
the NO and antibiotic release rates from such tubing, the device can then be tested in 
existing bioreactor models for antimicrobial activity, and compared to tubing that only 
release NO (via SNAP impregnation) or only both antibiotics only.  This would enable us 
to determine whether the combination of NO with the antibiotics significantly increases 
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